SANUWAVE Health (SNWV) S-15 Oct 20IPO registrationFinancial data

Company Profile

Document and Entity Information

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	0001417663
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	S-1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (FY) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 1,760,455	$ 364,549
Accounts receivable, net of allowance for doubtful accounts of $72,376 in 2019 and $33,045 in 2018	75,543	234,774
Due from related party	0	1,228
Inventory	542,955	357,820
Prepaid expenses and other current assets	125,405	125,111
TOTAL CURRENT ASSETS	2,504,358	1,083,482
PROPERTY AND EQUIPMENT, net	512,042	77,755
RIGHT OF USE ASSETS, net	323,661	0
OTHER ASSETS	41,931	16,491
TOTAL ASSETS	3,381,992	1,177,728
CURRENT LIABILITIES
Accounts payable	1,439,413	1,592,643
Accrued expenses	1,111,109	689,280
Accrued employee compensation	1,452,910	340,413
Contract liabilities	66,577	131,797
Operating lease liability	173,270	0
Finance lease liability	121,634	0
Advances from related parties	18,098	0
Line of credit, related parties	212,388	883,224
Accrued interest, related parties	1,859,977	1,171,782
Short term notes payable	587,233	1,883,163
Convertible promissory notes, net	0
SBA loans	0
Convertible promissory notes, net	0	2,652,377
Notes payable, related parties, net	5,372,743	5,372,743
Warrant liability	0	1,769,669
TOTAL CURRENT LIABILITIES	12,415,352	16,487,091
NON-CURRENT LIABILITIES
Contract liabilities	573,224	46,736
Operating lease liability	185,777	0
Finance lease liability	271,240	0
TOTAL NON-CURRENT LIABILITIES	1,030,241	46,736
TOTAL LIABILITIES	13,445,593	16,533,827
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	0	0
COMMON STOCK	293,781	155,665
ADDITIONAL PAID-IN CAPITAL	115,457,808	101,153,882
ACCUMULATED DEFICIT	(125,752,956)	(116,602,778)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(62,234)	(62,868)
TOTAL STOCKHOLDERS' DEFICIT	(10,063,601)	(15,356,099)
TOTAL LIABILITIES, MEZZANIE EQUITY AND STOCKHOLDERS' DEFICIT	3,381,992	1,177,728
Series A Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	0	0
Series B Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (FY) (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 12, 2016	Mar. 14, 2014
Accounts receivable, allowance for doubtful accounts		$ 72,376	$ 33,045
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000	350,000,000
Common stock, shares issued	302,119,428	293,780,400	155,665,138
Common stock, shares outstanding	302,119,428	293,780,400	155,665,138
Series A Convertible Preferred Stock
Preferred stock, par value		$ 0.001	$ 0.001		$ 1,000
Preferred stock, shares authorized		6,175	6,175
Preferred stock, shares issued		6,175	6,175
Preferred stock, shares outstanding		0	0
Series B Convertible Preferred Stock
Preferred stock, par value		$ 0.001	$ 0.001	$ 1,000
Preferred stock, shares authorized		293	293
Preferred stock, shares issued		293	293
Preferred stock, shares outstanding		0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (FY) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
REVENUES	$ 1,028,730	$ 1,850,060
COST OF REVENUES (exclusive of depreciation shown below)	538,923	693,664
GROSS MARGIN	489,807	1,156,396
OPERATING EXPENSES
Research and development	1,181,892	981,654
Selling and marketing	1,590,957	521,413
General and administrative	6,440,093	6,811,255
Depreciation	71,213	22,332
TOTAL OPERATING EXPENSES	9,284,155	8,336,654
OPERATING LOSS	(8,794,348)	(7,180,258)
OTHER INCOME (EXPENSE)
Gain on warrant valuation adjustment	227,669	55,376
Interest expense	(1,147,986)	(3,708,562)
Interest expense, related party	(688,195)	(787,586)
Other income, net	0	9,952
Loss on foreign currency exchange	(26,979)	(20,316)
TOTAL OTHER INCOME (EXPENSE), NET	(1,635,491)	(4,451,136)
NET LOSS	(10,429,839)	(11,631,394)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	19,844	(19,085)
TOTAL COMPREHENSIVE LOSS	$ (10,409,995)	$ (11,650,479)
LOSS PER SHARE:
Net loss - basic and diluted	$ (0.05)	$ (0.08)
Weighted average shares outstanding - basic and diluted	203,588,106	149,537,777
Product
REVENUES	$ 645,169	$ 949,601
COST OF REVENUES (exclusive of depreciation shown below)	454,862	525,216
License fees
REVENUES	315,557	819,696
COST OF REVENUES (exclusive of depreciation shown below)	0
Other
REVENUES	68,004	80,763
COST OF REVENUES (exclusive of depreciation shown below)	$ 84,061	$ 168,448

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (FY) - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance (in shares) at Dec. 31, 2017	0	139,300,122
Beginning balance at Dec. 31, 2017	$ 0	$ 139,300	$ 94,995,040	$ (104,971,384)	$ (43,783)	$ (9,880,827)
Net loss				(11,631,394)		(11,631,394)
Proceeds from warrant exercise (in shares)		422,939
Proceeds from warrant exercise		$ 423	40,305			40,728
Cashless warrant exercises with waived proceeds (in shares)		6,395,499
Cashless warrant exercises with waived proceeds		$ 6,396	(6,396)			0
Shares issued for services (in shares)		1,049,340
Shares issued for services		$ 1,049	180,451			181,500
Reclassification of warrant liability to equity due to adoption of ASU 2017-11, amount			118,838			118,838
Conversion of promissory notes (in shares)		8,497,238
Conversion of promissory notes		$ 8,497	926,199			934,696
Warrants issued for services			828,690			828,690
Stock-based compensation - options and warrants			2,480,970			2,480,970
Warrants issued with convertible promissory note			808,458			808,458
Beneficial conversion feature on convertible promissory notes			709,827			709,827
Warrants issued with promissory note			36,104			36,104
Beneficial conversion feature on promissory notes			35,396			35,396
Foreign currency translation adjustment					(19,085)	(19,085)
Ending balance (in shares) at Dec. 31, 2018	0	155,665,138
Ending balance at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	(15,356,099)
Cashless warrant exercises (in shares)		704,108
Cashless warrant exercises		$ 704	(704)			0
Cashless warrant exercises with waived proceeds (in shares)		3,333,334
Cashless warrant exercises with waived proceeds		$ 3,334	263,333			266,667
Foreign currency translation adjustment					(2,398)	(2,398)
Ending balance (in shares) at Mar. 31, 2019	0	160,322,580
Ending balance at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Beginning balance (in shares) at Dec. 31, 2018	0	155,665,138
Beginning balance at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	(15,356,099)
Net loss						(4,931,748)
Ending balance (in shares) at Jun. 30, 2019	0	188,650,891
Ending balance at Jun. 30, 2019	$ 0	$ 188,651	103,774,485	(120,254,865)	(63,777)	(16,355,506)
Beginning balance (in shares) at Dec. 31, 2018	0	155,665,138
Beginning balance at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	(15,356,099)
Net loss				(10,429,839)		(10,429,839)
Proceeds from warrant exercise (in shares)		40,284,422
Proceeds from warrant exercise		$ 40,285	3,581,674			1,758,142
Cashless warrant exercises (in shares)		4,962,157
Cashless warrant exercises		$ 4,962	(4,962)			0
Cashless warrant exercises with waived proceeds (in shares)	450,000	35,550
Cashless warrant exercises with waived proceeds	$ 450	$ 36,000
Shares issued for services (in shares)		150,000
Shares issued for services		$ 150	28,350			28,500
Conversion of short term notes payable and convertible notes payable, shares		65,247,517
Conversion of short term notes payable and convertible notes payable, amount		$ 65,248	6,427,607			6,492,855
Reclassification of warrant liability to equity due to adoption of ASU 2017-11, amount			262,339	1,279,661		$ 1,542,000
Conversion of promissory notes (in shares)		7,020,455				7,020,455
Conversion of promissory notes		$ 7,020	672,980			$ 680,000
Warrants issued for services			186,867			186,867
Stock-based compensation - options and warrants			333,422			333,422
Proceeds from PIPE offering, shares		20,000,711
Proceeds from PIPE offering, amount		$ 20,001	2,780,099			2,800,100
Foreign currency translation adjustment					634	634
Ending balance (in shares) at Dec. 31, 2019	0	293,780,400
Ending balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Beginning balance (in shares) at Mar. 31, 2019	0	160,322,580
Beginning balance at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Net loss						(2,734,431)
Cashless warrant exercises (in shares)		2,997,375
Cashless warrant exercises		$ 2,997	13,003			16,000
Cashless warrant exercises with waived proceeds (in shares)		2,475,000
Cashless warrant exercises with waived proceeds		$ 2,475	177,525			180,000
Warrants issued for services			36,067			36,067
Foreign currency translation adjustment					1,489	1,489
Ending balance (in shares) at Jun. 30, 2019	0	188,650,891
Ending balance at Jun. 30, 2019	$ 0	$ 188,651	103,774,485	(120,254,865)	(63,777)	(16,355,506)
Beginning balance (in shares) at Dec. 31, 2019	0	293,780,400
Beginning balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Cashless warrant exercises with waived proceeds (in shares)		1,820,461
Cashless warrant exercises with waived proceeds		$ 1,820	262,164			263,984
Shares issued for services (in shares)		1,000,000
Shares issued for services		$ 1,000	199,000			200,000
Foreign currency translation adjustment					4,826	4,826
Ending balance (in shares) at Mar. 31, 2020	0	297,663,672
Ending balance at Mar. 31, 2020	$ 0	$ 297,664	115,951,907	(128,754,104)	(57,408)	(12,561,941)
Beginning balance (in shares) at Dec. 31, 2019	0	293,780,400
Beginning balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Net loss						(6,634,168)
Cashless warrant exercises with waived proceeds						354,729
Ending balance (in shares) at Jun. 30, 2020	0	302,119,428
Ending balance at Jun. 30, 2020	$ 0	$ 302,119	117,326,629	(132,387,124)	(64,157)	(14,822,533)
Beginning balance (in shares) at Mar. 31, 2020	0	297,663,672
Beginning balance at Mar. 31, 2020	$ 0	$ 297,664	115,951,907	(128,754,104)	(57,408)	(12,561,941)
Net loss						(3,633,020)
Cashless warrant exercises with waived proceeds (in shares)		759,328
Cashless warrant exercises with waived proceeds		$ 759	89,986			90,745
Shares issued for services (in shares)		2,200,000
Shares issued for services		$ 2,200	515,300			517,500
Stock-based compensation - options and warrants		$ 225	44,025			44,250
Foreign currency translation adjustment					(6,749)	(6,749)
Ending balance (in shares) at Jun. 30, 2020	0	302,119,428
Ending balance at Jun. 30, 2020	$ 0	$ 302,119	$ 117,326,629	$ (132,387,124)	$ (64,157)	$ (14,822,533)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) (FY) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (10,429,839)	$ (11,631,394)
Adjustments to reconcile net loss to net cash used by operating activities
Depreciation	71,213	22,332
Bad debt expense (recovery)	39,331	(59,752)
Stock-based compensation	333,422	2,480,970
Warrants issued for consulting services	186,867	828,690
Stock issued for consulting services	28,500	181,500
Loss (gain) on warrant valuation adjustment	(227,669)	(55,376)
Amortization of operating lease	(9,236)	0
Amortization of debt issuance costs	0	2,767,361
Amortization of debt discount	0	150,484
Waived proceeds from warrant exercise	36,000	0
Accrued interest	1,159,713	410,289
Interest payable, related parties	688,195	485,875
Changes in operating assets and liabilities
Accounts receivable - trade	(8,600)	(22,502)
Inventory	(185,135)	(123,118)
Prepaid expenses	(294)	(34,823)
Due from related parties	1,228	0
Other assets	(25,440)	(3,802)
Operating leases	44,622	0
Accounts payable	(138,730)	276,120
Accrued expenses	421,829	188,708
Accrued employee compensation	1,134,497	338,733
Contract liabilities	468,768	178,533
NET CASH USED BY OPERATING ACTIVITIES	(6,410,758)	(3,621,172)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(53,939)	(42,888)
NET CASH USED BY INVESTING ACTIVITIES	(53,939)	(42,888)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from PIPE offering	2,800,100	0
Advances from related parties	2,055,414	0
Proceeds from warrant exercise	1,758,142	40,728
Proceeds from short term note	1,215,000	1,637,497
Proceeds from line of credit, related party	90,000	624,000
Proceeds from convertible promissory notes, net	0	1,159,785
Proceeds from note payable, product	0	96,708
Payment on line of credit, related party	0	(144,500)
Payments on note payable, product	0	(96,708)
Payments of principal on finance leases	(58,687)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	7,859,969	3,317,510
EFFECT OF EXCHANGE RATES ON CASH	634	(19,085)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,395,906	(365,635)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	364,549	730,184
CASH AND CASH EQUIVALENTS, END OF PERIOD	1,760,455	364,549
SUPPLEMENTAL INFORMATION
Cash paid for interest, related parties	0	151,227
NONCASH INVESTING ACTIVITIES
Other warrant exercise	1,863,815	0
Conversion of line of credit, related party to equity	680,000	0
Conversion of line of credit, related party to accounts receivable	121,000	0
Conversion of short term notes payable to equity	3,559,542	0
Conversion of convertible promissory notes to equity	2,933,313	0
Additions to right of use assets from new operating lease liabilities	476,029	0
Additions to right of use assets from new finance lease liabilities	451,561	0
Reclassification of warrant liability to equity	1,542,000	118,838
Advances payable converted to convertible promissory notes	0	310,000
Accounts payable converted to convertible promissory notes	36,500	120,000
Beneficial conversion feature on convertible debt	0	745,223
Warrants issued for debt	0	844,562
Conversion of 10% convertible promissory notes	$ 0	$ 934,696

Condensed Consolidated Balanc_3

Condensed Consolidated Balance Sheets (Q2) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 430,606	$ 1,760,455
Accounts receivable, net of allowance for doubtful of $255,503 in 2020 and $72,376 in 2019	110,501	75,543
Inventory	651,344	542,955
Prepaid expenses and other current assets	1,337,086	125,405
TOTAL CURRENT ASSETS	2,529,537	2,504,358
PROPERTY AND EQUIPMENT, net	591,064	512,042
RIGHT OF USE ASSETS, net	243,251	323,661
OTHER ASSETS	43,096	41,931
TOTAL ASSETS	3,406,948	3,381,992
CURRENT LIABILITIES
Accounts payable	1,799,630	1,439,413
Accrued expenses	1,071,214	1,111,109
Accrued employee compensation	2,160,610	1,452,910
Contract liabilities	551,755	66,577
Operating lease liability	179,524	173,270
Finance lease liability	181,371	121,634
Convertible promissory notes, net	705,980	0
SBA loans	614,335	0
Line of credit, related parties	222,164	212,388
Short term note payable	210,000	587,233
Advances from related parties	0	18,098
Notes payable, related parties, net	5,372,743	5,372,743
Accrued interest, related parties	2,229,713	1,859,977
TOTAL CURRENT LIABILITIES	15,299,039	12,415,352
NON-CURRENT LIABILITIES
Contract liabilities	53,782	573,224
Operating lease liability	92,889	185,777
Finance lease liability	333,771	271,240
TOTAL NON-CURRENT LIABILITIES	480,442	1,030,241
TOTAL LIABILITIES	15,779,481	13,445,593
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	0	0
COMMON STOCK, par value $0.001, 350,000,000 shares authorized; 302,119,428 and 293,780,400 issued and outstanding in 2020 and 2019, respectively	302,119	293,781
ADDITIONAL PAID-IN CAPITAL	117,326,629	115,457,808
ACCUMULATED DEFICIT	(132,386,958)	(125,752,956)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(64,323)	(62,234)
TOTAL STOCKHOLDERS' DEFICIT	(14,822,533)	(10,063,601)
TOTAL LIABILITIES, MEZZANIE EQUITY AND STOCKHOLDERS' DEFICIT	3,406,948	3,381,992
Series C Convertible Preferred Stock
NON-CURRENT LIABILITIES
REDEEMABLE PREFERRED STOCK, SERIES C CONVERTIBLE, par value $0.001, 90 designated; 90 shares issued and outstanding in 2020	2,250,000	0
Series D Convertible Preferred Stock
NON-CURRENT LIABILITIES
REDEEMABLE PREFERRED STOCK, SERIES D CONVERTIBLE, par value $0.001, 8 designater; 8 shares issued and outstanding in 2020	200,000	0
Series A Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	0	0
Series B Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
PREFERRED STOCK	$ 0	$ 0

Condensed Consolidated Balanc_4

Condensed Consolidated Balance Sheets (Q2) (Parenthetical) - USD ($)	Jun. 30, 2020	May 14, 2020	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 12, 2016	Mar. 14, 2014
Accounts receivable, allowance for doubtful accounts				$ 72,376	$ 33,045
Preferred stock, par value	$ 0.001			$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000			5,000,000	5,000,000
Preferred stock, shares issued	0			0	0
Preferred stock, shares outstanding	0			0	0
Common stock, par value	$ 0.001			$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000			350,000,000	350,000,000
Common stock, shares issued	302,119,428			293,780,400	155,665,138
Common stock, shares outstanding	302,119,428			293,780,400	155,665,138
Series C Convertible Preferred Stock
Preferred stock, par value	$ 0.001			$ 0.001
Preferred stock, shares authorized	90		90	90
Preferred stock, shares issued	90			90
Preferred stock, shares outstanding	90			90
Series D Convertible Preferred Stock
Preferred stock, par value	$ 0.001			$ 0.001
Preferred stock, shares authorized	8	8		8
Preferred stock, shares issued	8			8
Preferred stock, shares outstanding	8			8
Series A Convertible Preferred Stock
Preferred stock, shares authorized	6,175			6,175
Series B Convertible Preferred Stock
Preferred stock, shares authorized	293			293

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss (Q2) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
REVENUES	$ 83,301	$ 316,976	$ 231,893	$ 494,939	$ 1,028,730	$ 1,850,060
COST OF REVENUES	26,347	185,881	115,224	279,734	538,923	693,664
GROSS MARGIN	56,954	131,095	116,669	215,205	489,807	1,156,396
OPERATING EXPENSES
Research and development	264,907	307,273	551,661	567,922	1,181,892	981,654
Selling and marketing	433,151	407,477	1,041,001	565,559	1,590,957	521,413
General and administrative	2,566,793	1,426,405	4,474,710	2,943,860	6,440,093	6,811,255
Depreciation	64,766	9,455	117,789	17,812
TOTAL OPERATING EXPENSES	3,329,617	2,150,610	6,185,161	4,095,153	9,284,155	8,336,654
OPERATING LOSS	(3,272,663)	(2,019,515)	(6,068,492)	(3,879,948)	(8,794,348)	(7,180,258)
OTHER INCOME (EXPENSE)
Gain on warrant valuation adjustment	0	195,310	0	227,669	227,669	55,376
Interest expense	(168,941)	(790,178)	(187,673)	(938,439)	(1,147,986)	(3,708,562)
Interest expense, related party	(187,172)	(112,984)	(369,736)	(332,671)	(688,195)	(787,586)
Loss on foreign currency exchange	(4,244)	(7,064)	(8,267)	(8,359)	(26,979)	(20,316)
TOTAL OTHER INCOME (EXPENSE), NET	(360,357)	(714,916)	(565,676)	(1,051,800)	(1,635,491)	(4,451,136)
NET LOSS	(3,633,020)	(2,734,431)	(6,634,168)	(4,931,748)	(10,429,839)	(11,631,394)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	(6,551)	1,489	(1,923)	(909)	19,844	(19,085)
TOTAL COMPREHENSIVE LOSS	$ (3,639,571)	$ (2,732,942)	$ (6,636,091)	$ (4,932,657)	$ (10,409,995)	$ (11,650,479)
LOSS PER SHARE:
Net loss - basic and diluted	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.08)
Weighted average shares outstanding - basic and diluted	299,497,960	174,730,747	297,856,870	165,921,811	203,588,106	149,537,777
Product
REVENUES	$ 69,341	$ 220,667	$ 143,900	$ 285,232	$ 645,169	$ 949,601
COST OF REVENUES	24,825	178,458	103,740	243,570	454,862	525,216
License Fees
REVENUES	0	66,808	10,000	173,058	315,557	819,696
COST OF REVENUES					0
Other
REVENUES	13,960	29,501	77,993	36,649	68,004	80,763
COST OF REVENUES	$ 1,522	$ 7,423	$ 11,484	$ 36,164	$ 84,061	$ 168,448

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficit (Q2) - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance (in shares) at Dec. 31, 2017	0	139,300,122
Beginning balance at Dec. 31, 2017	$ 0	$ 139,300	$ 94,995,040	$ (104,971,384)	$ (43,783)	$ (9,880,827)
Proceeds from stock option exercise, shares						0
Proceeds from stock option exercised			2,480,970			$ 2,480,970
Shares issued for services (in shares)		1,049,340
Fair value of shares issued for services		$ 1,049	180,451			181,500
Conversion of short term notes and convertible notes payable (in shares)		6,395,499
Conversion of short term notes and convertible notes payable		$ 6,396	(6,396)			0
Warrants issued for consulting services			828,690			828,690
Foreign currency translation adjustment					(19,085)	(19,085)
Ending balance (in shares) at Dec. 31, 2018	0	155,665,138
Ending balance at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	(15,356,099)
Net loss				(2,197,317)		(2,197,317)
Cashless warrant exercises (in shares)		704,108
Cashless warrant exercises		$ 704	(704)			0
Stock Issued During Period, Shares, Warrants Exercised		620,000
Proceeds from warrant exercise		$ 620	52,580			53,200
Conversion of short term notes and convertible notes payable (in shares)		3,333,334
Conversion of short term notes and convertible notes payable		$ 3,334	263,333			266,667
Reclassification of warrant liability to equity due to adoption of ASU 2017-11			262,339	1,279,661		1,542,000
Foreign currency translation adjustment					(2,398)	(2,398)
Ending balance (in shares) at Mar. 31, 2019	0	160,322,580
Ending balance at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Beginning balance (in shares) at Dec. 31, 2018	0	155,665,138
Beginning balance at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	(15,356,099)
Net loss						(4,931,748)
Beneficial conversion feature on convertible debt						0
Conversion of advances from related parties						180,000
Ending balance (in shares) at Jun. 30, 2019	0	188,650,891
Ending balance at Jun. 30, 2019	$ 0	$ 188,651	103,774,485	(120,254,865)	(63,777)	(16,355,506)
Beginning balance (in shares) at Dec. 31, 2018	0	155,665,138
Beginning balance at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	$ (15,356,099)
Proceeds from stock option exercise, shares						0
Proceeds from stock option exercised			333,422			$ 333,422
Cashless warrant exercises (in shares)		4,962,157
Cashless warrant exercises		$ 4,962	(4,962)			0
Shares issued for services (in shares)		150,000
Fair value of shares issued for services		$ 150	28,350			28,500
Conversion of short term notes and convertible notes payable (in shares)	450,000	35,550
Conversion of short term notes and convertible notes payable	$ 450	$ 36,000
Warrants issued for consulting services			186,867			186,867
Foreign currency translation adjustment					634	634
Ending balance (in shares) at Dec. 31, 2019	0	293,780,400
Ending balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Beginning balance (in shares) at Mar. 31, 2019	0	160,322,580
Beginning balance at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Net loss				(2,734,431)		(2,734,431)
Cashless warrant exercises (in shares)		2,997,375
Cashless warrant exercises		$ 2,997	13,003			16,000
Stock Issued During Period, Shares, Warrants Exercised		17,051,769
Proceeds from warrant exercise		$ 17,052	1,333,005			1,350,057
Other warrant exercise, shares		5,804,167
Other warrant exercise, amount		$ 5,804	451,697			457,501
Stock-based compensation			31,758			31,758
Conversion of short term notes and convertible notes payable (in shares)		2,475,000
Conversion of short term notes and convertible notes payable		$ 2,475	177,525			180,000
Warrants issued for consulting services			36,067			36,067
Foreign currency translation adjustment					1,489	1,489
Ending balance (in shares) at Jun. 30, 2019	0	188,650,891
Ending balance at Jun. 30, 2019	$ 0	$ 188,651	103,774,485	(120,254,865)	(63,777)	(16,355,506)
Beginning balance (in shares) at Dec. 31, 2019	0	293,780,400
Beginning balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Net loss				(3,001,148)		(3,001,148)
Stock Issued During Period, Shares, Warrants Exercised		1,000,000
Proceeds from warrant exercise		$ 1,000	9,000			10,000
Shares issued for services (in shares)		1,000,000
Fair value of shares issued for services		$ 1,000	199,000			200,000
Stock-based compensation			21,900			21,900
Conversion of short term notes and convertible notes payable (in shares)		1,820,461
Conversion of short term notes and convertible notes payable		$ 1,820	262,164			263,984
Conversion of advances from related parties (in shares)		62,811
Conversion of advances from related parties		$ 63	2,035			2,098
Foreign currency translation adjustment					4,826	4,826
Ending balance (in shares) at Mar. 31, 2020	0	297,663,672
Ending balance at Mar. 31, 2020	$ 0	$ 297,664	115,951,907	(128,754,104)	(57,408)	(12,561,941)
Beginning balance (in shares) at Dec. 31, 2019	0	293,780,400
Beginning balance at Dec. 31, 2019	$ 0	$ 293,781	115,457,808	(125,752,956)	(62,234)	(10,063,601)
Net loss						$ (6,634,168)
Proceeds from stock option exercise, shares						225,000
Beneficial conversion feature on convertible debt						$ 560,682
Conversion of short term notes and convertible notes payable						354,729
Conversion of advances from related parties						18,098
Ending balance (in shares) at Jun. 30, 2020	0	302,119,428
Ending balance at Jun. 30, 2020	$ 0	$ 302,119	117,326,629	(132,387,124)	(64,157)	(14,822,533)
Beginning balance (in shares) at Mar. 31, 2020	0	297,663,672
Beginning balance at Mar. 31, 2020	$ 0	$ 297,664	115,951,907	(128,754,104)	(57,408)	(12,561,941)
Net loss				(3,633,020)		(3,633,020)
Proceeds from PIPE, shares		1,071,428
Proceeds from PIPE, amount		$ 1,071	148,929			150,000
Proceeds from stock option exercise, shares		225,000
Proceeds from stock option exercised		$ 225	44,025			44,250
Beneficial conversion feature on convertible debt			560,682			560,682
Shares issued for services (in shares)		2,200,000
Fair value of shares issued for services		$ 2,200	515,300			517,500
Conversion of short term notes and convertible notes payable (in shares)		759,328
Conversion of short term notes and convertible notes payable		$ 759	89,986			90,745
Conversion of advances from related parties (in shares)		200,000
Conversion of advances from related parties		$ 200	15,800			16,000
Foreign currency translation adjustment					(6,749)	(6,749)
Ending balance (in shares) at Jun. 30, 2020	0	302,119,428
Ending balance at Jun. 30, 2020	$ 0	$ 302,119	$ 117,326,629	$ (132,387,124)	$ (64,157)	$ (14,822,533)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Q2) (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,634,168)	$ (4,931,748)
Adjustments to reconcile net loss to net cash used by operating activities
Depreciation	117,789	17,812
Change in allowance for doubtful accounts	183,127	25,248
Share-based payment	739,400	67,825
Amortization of debt issuance costs	69,862	0
Accrued interest	84,072	936,658
Interest payable, related parties	369,736	332,671
Amortization of operating leases	(6,224)	(3,471)
Waived proceeds from warrant exercise	0	16,000
Gain on warrant valuation adjustment	0	(227,669)
Changes in operating assets and liabilities
Accounts receivable - trade	(218,085)	34,485
Inventory	(108,389)	(66,112)
Prepaid expenses	(101,681)	(126,505)
Due from related parties	0	1,228
Other assets	(1,165)	(7,070)
Operating leases	0	44,623
Accounts payable	360,217	(135,916)
Accrued expenses	110,105	106,178
Accrued employee compensation	557,700	525,487
Contract liabilities	(34,264)	3,642
NET CASH USED BY OPERATING ACTIVITIES	(4,511,968)	(3,386,634)
CASH FLOWS FROM INVESTING ACTIVITIES
Deposit paid towards acquisition	(1,110,000)	0
Purchases of property and equipment	(4,855)	(25,839)
NET CASH USED BY INVESTING ACTIVITIES	(1,114,855)	(25,839)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of convertible preferred stock	2,450,000	0
Proceeds from convertible promissory note	1,100,000	0
Proceeds from SBA loan	614,335	0
Proceeds from PIPE offering	150,000	0
Proceeds from stock option exercise	44,250	0
Proceeds from short term note	0	1,215,000
Proceeds from warrant exercise	10,000	1,403,257
Advances from related parties	0	585,022
Payments of principal on finance leases	(69,688)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,298,897	3,203,279
EFFECT OF EXCHANGE RATES ON CASH	(1,923)	(909)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(1,329,849)	(210,103)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,760,455	364,549
CASH AND CASH EQUIVALENTS, END OF PERIOD	430,606	154,446
NONCASH INVESTING ACTIVITIES
Conversion of short term notes payable to equity	354,729	724,168
Conversion of advances from related parties to equity	18,098	180,000
Additions to right of use assets from new finance lease liabilities	127,611	0
Beneficial conversion feature on convertible debt	560,682	0
Reclassification of warrant liability to equity	$ 0	$ 262,339

Description of the Business and

Description of the Business and Going Concern and Management's Plans (FY)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business and Going Concern and Management's Plans	2. Going Concern The Company does not currently generate significant recurring revenue and will require additional capital during 2020. As of June 30, 2020, the Company had cash and cash equivalents of $430,606. For the six months ended June 30, 2020, the net cash used by operating activities was $4,511,968. The Company incurred a net loss of $6,634,168 for the six months ended June 30, 2020. The operating losses and the events of default on the Company’s short term notes payable (see Note 6) and the notes payable, related parties (see Note 9) raised substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this report. Management is currently evaluating the impact on cash flows of the Company’s acquisition of certain assets of Celularity Inc., as more fully described in Note 18. The continuation of the Company’s business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.	1. SANUWAVE Health, Inc. and Subsidiaries (the “Company”) is a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. FDA granted the Company’s request to classify the dermaPACE System as a Class II device via the de novo The Company is marketing its dermaPACE System for treatment usage in the United States and is able to generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities. As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $10,429,839 and $11,631,394 during the years ended December 31, 2019 and 2018, respectively, and the net cash used by operating activities was $6,410,758 and $3,621,172, respectively. As of December 31, 2019, the Company had a net working capital deficit of $9,910,994, and cash and cash equivalents of $1,760,455. These factors and the events of default on the notes payable to HealthTronics, Inc. (see Note 11) and the Company’s short term notes payable (see Note 9) raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the financial statement issuance date. The Company does not currently generate significant recurring revenue and will require additional capital during 2020. Although no assurances can be given, management of the Company believes that existing capital resources should enable the Company to fund operations into the third quarter of 2020. The continuation of the Company’s business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital in 2020 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be required to significantly curtail or discontinue operations or obtain funds through financing transactions with unfavorable terms. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies (FY)	6 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (FY)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies The significant accounting policies followed by the Company are summarized below and should be read in conjunction with the 2019 Annual Report: Principles of consolidation Estimates Inventory Preferred stock Distinguishing Liabilities from Equity Sequencing policy	2. The significant accounting policies followed by the Company are summarized below: Foreign currency translation - Principles of consolidation - Estimates - Reclassifications – Cash and cash equivalents - Concentration of credit risk and limited suppliers - Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. Three distributors and partners accounted for 18%, 15% and 12% of revenues for the year ended December 31, 2019, and 0%, 0% and 22% of accounts receivable at December 31, 2019. Three distributors and partners accounted for 33%, 23% and 11% of revenues for the year ended December 31, 2018, and 24%, 60% and 7.7% of accounts receivable at December 31, 2018. The Company expects that actions taken in response to the COVID-19 pandemic will also negatively impact sales of dermaPACE and orthoPACE. Some hospitals are restricting procedures that are not deemed to be life-threatening at this time. Because dermaPACE and orthoPACE are not deemed to be life-threatening procedures, we expect that the number of procedures performed will decline. A decrease in the number of procedures performed will adversely affect our expected revenues and our financial results. The Company depends on suppliers for product component materials and other components that are subject to stringent regulatory requirements. The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may be difficult to arrange a replacement supplier because certain of these materials may only be available from one or a limited number of sources. In addition, our suppliers could be disrupted by conditions related to COVID-19, or other epidemics Establishing additional or replacement suppliers for these materials may take a substantial period of time, as certain of these suppliers must be approved by regulatory authorities. Accounts receivable - Inventory - Depreciation of property and equipment - Fair value of financial instruments - The Company has adopted ASC 820-10, Fair Value Measurements The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions. The Company recognizes all derivatives on the balance sheet at fair value. The fair value of the warrant liability is determined based on a lattice solution, binomial approach pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and risk-free interest rate, and therefore is classified within level 3 of the fair value hierarchy. (See Note 14). The Company’s notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace. Impairment of long-lived assets – Revenue recognition - Shipping and handling costs - Shipping charges billed to customers are included in revenues. Shipping and handling costs incurred have been recorded in cost of revenues. Income taxes - A provision of ASC 740, Income Taxes The Company will recognize in income tax expense, interest and penalties related to income tax matters. For the years ended December 31, 2019 and 2018, the Company did not have any amounts recorded for interest and penalties. Loss per share - 2019 2018 Stock options 34,303,385 31,703,385 Warrants 9,474,091 103,994,927 Convertible promissory notes 2,250,000 24,112,518 Anti-dilutive equity securities 46,027,476 159,810,830 Comprehensive income – Stock-based compensation - Research and development - Liabilities related to warrants issued – Warrants related to debt issued – Beneficial conversion feature on convertible debt - Recently issued or adopted accounting standards - Leases (Topic 842). In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19. The ASU introduces a new model for assessing impairment of most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. The ASU is effective for annual reporting periods beginning after January 2023 with early adoption permitted. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480): Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Inventory (FY)

Inventory (FY)	12 Months Ended
Inventory (FY)	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory	3. Inventory consists of the following at December 31, 2019 and 2018: 2019 2018 Inventory - finished goods $ 357,265 $ 188,116 Inventory – parts 185,690 169,704 Total inventory $ 542,955 $ 357,820

Property and Equipment (FY)

Property and Equipment (FY)	12 Months Ended
Property and Equipment (FY)	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	4. Property and equipment consists of the following at December 31, 2019 and 2018: 2019 2018 Finance lease right of use asset $ 451,561 $ — Machines and equipment 281,633 240,295 Office and computer equipment 201,841 196,150 Devices 81,059 81,059 Software 38,126 38,126 Furniture and fixtures 22,929 16,019 Other assets 2,259 2,259 Total 1,079,408 573,908 Accumulated depreciation (567,366 ) (496,153 ) Net property and equipment $ 512,042 $ 77,755 Depreciation expense was $71,213 and $22,332 for the years ended December 31, 2019 and 2018, respectively.

Accrued Expenses (FY)

Accrued Expenses (FY)	6 Months Ended	12 Months Ended
Accrued Expenses (FY)	Jun. 30, 2020	Dec. 31, 2019
Accrued Liabilities [Abstract]
Accrued Expenses	4. Accrued expenses Accrued expenses consist of the following: June 30, 2020 December 31, 2019 Accrued board of director’s fees $ 416,667 $ 400,000 Accrued legal and professional fees 200,000 134,970 Accrued executive severance 313,000 154,000 Accrued travel 120,000 120,000 Accrued outside services 106,233 108,033 Accrued inventory 50,275 167,050 Accrued clinical study expenses 13,650 13,650 Accrued other 1,389 13,406 $ 1,221,214 $ 1,111,109	5. Accrued expenses consist of the following at December 31, 2019 and 2018: 2019 2018 Accrued board of director's fees $ 400,000 $ 200,000 Accrued inventory 167,050 — Accrued executive severance 154,000 136,000 Accrued travel 120,000 58,993 Accrued outside services 108,033 115,118 Accrued legal and professional fees 134,970 — Accrued clinical study expenses 13,650 13,650 Accrued related party advance — 101,137 Deferred rent — 44,623 Accrued computer equipment — 8,752 Accrued other 13,406 11,007 $ 1,111,109 $ 689,280 The Company is a party to a Severance and Advisory Agreement (the “Severance Agreement”) with its former President and Chief Executive Officer, and a director of the Company. Pursuant to the Severance Agreement, the former executive will receive, as severance along with other non-cash items, six months of his base salary payable over the following six month period and bonus payments of $100,000 upon each of four bonus payment events tied to the Company’s clinical trial plan for the dermaPACE device, or December 31, 2016, whichever occurs first. The Company achieved three of the four bonus payment events in 2014 and paid $300,000 in accrued executive severance in 2014. The accrued executive severance at December 31, 2019 and 2018 represents the unpaid portion of the bonus payments plus accrued interest due to late payment. On October 10, 2018, the Company entered into accrued related party advance with Shri P. Parikh, the President of the Company, in the total principal amount of $100,000 with an interest rate of 5% per annum. The principal and accrued interest are due and payable on the earlier of (i) one day after receipt of payment from Johnfk Medical Inc., (ii) six months from the date of issuance and (iii) the acceleration of the maturity of the short term note by the holder upon the occurrence of an event of default. On May 13, 2019, the Company repaid in full the outstanding balance on short term notes payable with Shri P. Parikh, the President of the Company.

Contract Liabilities (FY)

Contract Liabilities (FY)	6 Months Ended	12 Months Ended
Contract Liabilities (FY)	Jun. 30, 2020	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Contract Liabilities [Text Block]	5. Contract liabilities As of June 30, 2020, the Company has contract assets and liabilities from contracts with customers (see Note 14). Contract liabilities consist of the following: June 30, 2020 December 31, 2019 Service agreement $ 91,746 $ 133,510 License fees 500,000 500,000 Other 13,791 6,291 Total Contract liabilities 605,537 639,801 Non-Current (551,755 ) (573,224 ) Total Current $ 53,782 $ 66,577 The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate contract liability balances as of June 30, 2020, the Company expects to satisfy its remaining performance obligations associated with $551,755 and $53,782 of contract liability balances within the next twelve months and following thirty-two months, respectively. Of the aggregate contract liability balances as of December 31, 2019, the Company expects to satisfy its remaining performance obligations associated with $66,577 and $573,224 of contract liability balances within the next twelve months and following thirty-eight months, respectively.	6. As of December 31, 2019, the Company has contract assets and liabilities from contracts with customers (Note 16). Contract liabilities consist of the following: December 31, 2019 December 31, 2018 Service agreement $ 133,510 $ 57,365 Deposit on product — 92,950 License fees 500,000 — Other 6,291 28,218 Total Contract liabilities 639,801 178,533 Non-Current (573,224 ) (46,736 ) Total Current $ 66,577 $ 131,797 The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A contract asset (receivable) is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate $639,801 of contract liability balances as of December 31, 2019, the Company expects to satisfy its remaining performance obligations associated with $66,577 of contract liability balances within the next twelve months.

Advances From Related Parties (

Advances From Related Parties (FY)	12 Months Ended
Advances From Related Parties (FY)	Dec. 31, 2019
Payables and Accruals [Abstract]
Advances From Related Parties [Text Block]	7. During the year ended December 31, 2019, the Company received $2,055,414 for warrant exercises and short term notes for which shares were not immediately issued. During the year ended December 31, 2019, the Company converted $1,827,316 of the advances from related parties to equity and $210,000 of the advances from related parties to short term notes. Advances from related parties totaled $18,098 at December 31, 2019. The Company has received cash advances to help fund the Company’s operations. On January 10, 2018, the outstanding balance of the $310,000 of advances payable was converted into two 10% Convertible Promissory Notes (see Note 10). On November 12, 2018, the advances payable balance was added to the outstanding balance line of credit, related parties.

Line of Credit, Related Parties

Line of Credit, Related Parties (FY)	12 Months Ended
Line of Credit, Related Parties (FY)	Dec. 31, 2019
Debt Disclosure [Abstract]
Line of Credit, Related Parties	8. The Company entered into a line of credit agreement with a member of the board of directors and an existing shareholder at December 29, 2017. The agreement established a line of credit in the amount of $370,000 with an annualized interest rate of 6%. On November 12, 2018, the Company entered into an amendment to the line of credit agreement that increased the line of credit to $1,000,000 with an annualized interest rate of 6%. During the year ended December 31, 2019, the amount of the line of credit was decreased by $680,000 through a conversion to 7,020,455 shares of common stock, by $121,000 through payment on purchase of dermaPACE Systems and was increased by $90,000 through a deposit on purchase of future dermaPACE Systems. The line of credit may be called for payment upon demand of the holder. The line of credit, related parties had an aggregate outstanding balance of $212,388 and $883,224 as of December 31, 2019 and 2018, respectively. As of December 31, 2019, the amount of credit available is $861,500. Interest expense on the line of credit, related parties totaled $40,164 and $33,724 for the years ended December 31, 2019 and 2018, respectively.

Short Term Notes Payable (FY)

Short Term Notes Payable (FY)	12 Months Ended
Short Term Notes Payable (FY)	Dec. 31, 2019
Debt Disclosure [Abstract]
Short Term Notes Payable	9. The Company entered into non-interest bearing short term notes payable agreements on December 13, 2019 in the total principal amount of $210,000. The principal amount will be due and payable six months from the date of issuance of the respective notes via issuance of 2,250,000 shares of common stock. The Company entered into short term notes payable between January 30, 2019 and April 10, 2019 in the total principal amount of $1,215,000 with an interest rate of 5% per annum. The principal and accrued interest are due and payable six months from the date of issuance of the respective notes. During 2019, the Company converted $3,559,542 of the short term notes payable to equity. The Company entered into short term notes payable between June 26, 2018 and December 31, 2018 in the total principal amount of $1,870,525 with an interest rate of 5% per annum. The principal and accrued interest are due and payable six months from the date of issuance of the respective notes, of which $233,028 are held by an officer and director of the Company. During the year ended December 31, 2019, the Company defaulted on all of the short term notes payable and began accruing interest at the default interest rate of 10% upon the date of default. On April 17, 2019, the Company offered an incentive to Class L and Class N Warrant holders in return for their funding the operations of the Company prior to an effective Registration Statement with the SEC for the Class L and Class N Warrant Agreements and certain Series A Warrants. As the incentive to Class L and Class N Warrant holders, the Company approved the issuance of a 10% bonus number of shares of the Company’s common stock to be calculated by multiplying the number of shares being issued upon the Class L Warrant, Class N Warrant and Series A Warrant exercise by 10% at a cost basis equal to the exercise price and recorded interest expense in the amount of $629,963. The short term notes payable had an aggregate outstanding principal balance of $587,233 and $1,883,163 at December 31, 2019, and 2018, respectively. Interest expense on the short term notes payable totaled $838,613 and $12,638 for the years ended December 31, 2019 and 2018, respectively.

Convertible Promissory Notes (F

Convertible Promissory Notes (FY)	12 Months Ended
Convertible Promissory Notes (FY)	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Promissory Notes	10. In 2017, the Company issued certain 10% Convertible Promissory Notes which have a six month term from the subscription date, accrue interest at 10% per annum and the note holders can convert the 10% Convertible Promissory Notes at any time during the term to the number of shares of Company common stock, equal to the amount obtained by dividing (i) the amount of the unpaid principal and interest on the note by (ii) $0.11. The 10% Convertible Promissory Notes include a warrant agreement (the “Class N Warrant”) to purchase Common Stock equal to the amount obtained by dividing the (i) sum of the principal amount by (ii) $0.11. The Class N Warrants expired on September 3, 2019, as amended. The 10% Convertible Promissory Notes include a warrant agreement (the “Class N Warrant”) to purchase Common Stock equal to the amount obtained by dividing the (i) sum of the principal amount by (ii) $0.11. During the years ended December 31, 2018, the Company issued 10,599,999 Class N Warrants in connection with the closings of 10% Convertible Promissory Notes. The calculated fair value of the Class N Warrants was determined using the Black-Scholes pricing model based on the following assumptions: December 31, 2018 Weighted average contractual term in years 1.13-1.19 Weighted average risk free interest rate 1.98% - 2.15 % Weighted average volatility 94% - 99 % Forfeiture rate 0.0 % Expected dividend yield 0.0 % Additional debt issuance costs will be incurred and amortized over the remaining lives of the 10% Convertible Promissory Notes when Class N Warrants are issued per the engagement letter with West Park Capital. On June 29, 2018, the Company issued 1,242,955 Class N Warrants to West Park Capital per the terms of a placement agent agreement and $417,633 was expensed as interest expense. On October 4, 2018, the Company issued 1,242,954 Class N Warrants to West Park Capital per the terms of a placement agent agreement and $91,233 was expensed as interest expense. As of August 2, 2018, the Company defaulted on all of the 10% Convertible Promissory Notes issued and began accruing interest at the default interest rate of 18%. The 10% Convertible Promissory Notes had an aggregate outstanding principal balance of $0 and $2,652,377, net of $0 beneficial conversion feature, warrant discount and debt issuance costs at December 31, 2019 and 2018, respectively. The common shares related to the conversion of the Convertible Promissory Notes were issued during the year ended December 31, 2019 (see Note 13). Interest expense on the 10% Convertible Promissory Notes totaled $280,936 and $3,565,198 for the years ended December 31, 2019 and 2018, respectively. Kevin A. Richardson II, CEO, chairperson of the Company’s board of directors and an existing shareholder of the Company, was a purchaser in the 10% Convertible Promissory Notes in the amount of $260,000 and was issued 2,363,636 Class N Warrants for the year ended December 31, 2018. A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company, was a purchaser in the 10% Convertible Promissory Notes in the amount of $170,000 and was issued 1,545,455 and Class N Warrants for the years ended December 31, 2018. On January 29, 2018, the Company entered into an additional 10% Convertible Promissory Note with an accredited investor in the amount of $71,500 and issued 650,000 Class N Warrants in connection with such 10% Convertible Promissory Note. The Company intends to use the proceeds from such 10% Convertible Promissory Note for payment of services to an investor relations company and the account of the attorney updating the Registration Statement on Form S-1 of the Company filed under the Securities Act of 1933, as amended, on January 3, 2017 (File No. 333-213774), which registration statement shall also register the shares issuable upon conversion of such 10% Convertible Promissory Note and issuable upon the exercise of a Class N Warrants issued concurrently with the issuance of such 10% Convertible Promissory Note. In 2018, the Company recorded $35,396 debt discount for the beneficial conversion feature of the 10% Convertible Promissory Note and $36,104 in debt discount for the discount on the Class N Warrant agreement to be amortized over the life of the 10% Convertible Promissory Note. December 31, 2018 Weighted average contractual term in years 1.14 Weighted average risk free interest rate 1.96 % Weighted average volatility 98.2 % Forfeiture rate 0.0 % Expected dividend yield 0.0 % The 10% Convertible Promissory Note was converted in full in August 2018 (See Note 13).

Notes Payable, Related Parties

Notes Payable, Related Parties (FY)	6 Months Ended	12 Months Ended
Notes Payable, Related Parties (FY)	Jun. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable, Related Parties	9. Notes payable, related parties The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal was due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because it is a shareholder in the Company and has a security agreement with the Company detailed below. The Company is a party to a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. During any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. An Event of Default under the notes payable, related parties occurred on December 31, 2016 (“Default”). As a result of the Default, the notes payable, related parties have been accruing interest at the rate of 10% per annum since January 2, 2017 and continue to accrue interest at such rate. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. For the three months ended June 30, 2020, additional mandatory prepayments of principal and interest on the notes payable, related parties were due on June 30, 2020. The Company has not made the mandatory prepayments of principal to HealthTronics, Inc. on the notes payable, related parties as amended from proceeds received through the issuance or sale of any equity securities in cash through June 30, 2020. The notes payable, related parties had an aggregate outstanding principal balance of $5,372,743 at June 30, 2020 and December 31, 2019. Accrued interest, related parties currently payable totaled $2,229,713 at June 30, 2020 and $1,859,977 at December 31, 2019. Interest expense on notes payable, related parties totaled $187,172 and $112,984 for the three months ended June 30, 2020 and 2019, respectively and $369,736 and $332,671 for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, we are in default under the notes, as amended, and as a result HealthTronics, Inc. could, among other rights and remedies, exercise its rights under its first priority security interest in our assets. The Company entered into a letter agreement with HealthTronics, Inc., pursuant to which the Company paid off all outstanding debt due and owed to HealthTronics (see Note 18).	11. The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal is due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because they are a shareholder in the Company and have a security agreement with the Company detailed below. The Company is a party to a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. During any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. Events of Default under the notes payable, related parties have occurred and are continuing on account of the failure of SANUWAVE, Inc., a Delaware corporation, a wholly owned subsidiary of the Company and the borrower under the notes payable, related parties, to make the required payments of interest which were due on December 31, 2016, March 31, 2017, June 30, 2017, September 30, 2017, December 31, 2017, June 30, 2018, September 30, 2018, December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 (collectively, the “Defaults”). As a result of the Defaults, the notes payable, related parties have been accruing interest at the rate of 10% per annum since January 2, 2017 and continue to accrue interest at such rate. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. The Company has not made the mandatory prepayments of principal to HealthTronics, Inc. on the notes payable, related parties from proceeds received through the issuance or sale of any equity securities in cash through December 31, 2019. The notes payable, related parties had an aggregate outstanding principal balance of $5,372,743, net of $0 debt discount at December 31, 2019, and 2018. Accrued interest currently payable totaled $1,859,977 and $1,171,782 at December 31, 2019 and 2018, respectively. Interest expense on notes payable, related parties totaled $688,195 and $787,586 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, we are in default under the notes, as amended by the Third Amendment, and as a result HealthTronics, Inc. could, among other rights and remedies, exercise its rights under its first priority security interest in our assets. We are in negotiations with HealthTronics, Inc. to address the event of default.

Preferred Stock (FY)

Preferred Stock (FY)	6 Months Ended	12 Months Ended
Preferred Stock (FY)	Jun. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Preferred Stock	10. Preferred Stock On February 6, 2020, the Company entered into a Series C Preferred Stock Purchase Agreement (the “Series C Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of 90 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series C Preferred Stock”), for an aggregate total purchase price of $2,250,000. On January 31, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series C Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate 90 shares of our preferred stock as Series C Convertible Preferred Stock. On May 14, 2020, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of eight shares of the Company’s Series D Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series D Preferred Stock”), for an aggregate total purchase price of $200,000. On May 14, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series D Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate eight shares of our preferred stock as Series D Convertible Preferred Stock. Subject to the terms of the Certificates of Designation, each share of Series C Preferred Stock and Series D Preferred Stock is convertible into shares of Common Stock of the Company at a rate equal to the stated value of such share of Series C Preferred Stock and Series D Preferred Stock of $25,000, divided by the conversion price of $0.14 per share (subject to adjustment from time to time upon the occurrence of certain events as described in the Certificate of Designation). The Certificates of Designation became effective upon filing with the Secretary of State of the State of Nevada. If all outstanding shares of Series C Preferred Stock and Series D Preferred Stock were converted into Common Stock at the original conversion rate, such shares would convert into an aggregate of 17,500,000 shares of Common Stock. Notwithstanding the foregoing, the Series C Preferred Stock and Series D Preferred Stock is not currently convertible into shares of Common Stock because the Company does not currently have sufficient authorized and unissued shares of its Common Stock to permit conversion in full of all issued and outstanding shares of Series C Preferred Stock and Series D Preferred Stock. Accordingly, the Certificate of Designation provides that the Series C Preferred Stock and Series D Preferred Stock is only convertible into Common Stock once the Company amends its Articles of Incorporation to increase its authorized and unissued Common Stock to an amount sufficient to permit such conversion of the Series C Preferred Stock and Series D Preferred Stock. Each investor has agreed in the Purchase Agreement that such investor will, within five business days following such amendment to the Articles of Incorporation, convert all of such investor’s shares of Series C Preferred Stock and Series D Preferred Stock into shares of Common Stock. The Certificate of Designation provides that if the Company has not obtained the approval of its shareholders to amend the Company’s Articles of Incorporation to increase the authorized shares of Common Stock sufficient to permit such conversion, or if such amendment has not otherwise been filed with the Nevada Secretary of State on or before December 31, 2020 (either such event, an “Authorization Failure”), then the Company shall be required to redeem all outstanding shares of Series C Preferred Stock and Series D Preferred Stock for a per-share redemption price, payable in cash in a single installment not later than thirty (30) days following the date of such Authorization Failure, equal to the greater of (a) two hundred percent (200%) of the stated value of such share, and (b)(i) the volume-weighted average sale price of a share of Common Stock reported on the trading market on which the Common Stock is then traded for the thirty (30) consecutive trading days immediately preceding the date of such Authorization Failure, multiplied by (ii) the number of shares of Common Stock such share of Series C Preferred Stock and Series D Preferred Stock would otherwise be convertible into as of such date had such Authorization Failure not occurred. The closing of the private placements occurred on February 6, 2020 and May 14, 2020, respectively, and the preferred stock was recorded in temporary equity on the related condensed consolidated balance sheet at an aggregate value of $2,250,000 and $200,000 respectively. Ninety shares of the Series C Preferred Stock and eight shares of Series D Preferred Stock have been issued as of June 30, 2020. The Company has obtained the approval of its shareholders to amend the Company’s Articles of Incorporation to increase the authorized shares of Common Stock and effected such increase subsequent to June 30, 2020 (see Note 18).	12. The Company’s Articles of Incorporation authorize the issuance of up to 5,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by the board of directors. On January 12, 2016, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series B Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 293 shares of preferred stock, par value $0.001 per share, as Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock has a stated value of $1,000 per share. Holders of Series B Convertible Preferred Stock are entitled to convert each share of Series A Convertible Preferred Stock into 2,000 shares of common stock, provided that after giving effect to such conversion, such holder, together with its affiliates, shall not beneficially own in excess of 9.99% of the number of shares of common stock outstanding (the “Beneficial Ownership Limitation”). On March 14, 2014, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series A Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 6,175 shares of preferred stock, par value $0.001 per share, as Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has a stated value of $1,000 per share.

Equity Transactions (FY)

Equity Transactions (FY)	6 Months Ended	12 Months Ended
Equity Transactions (FY)	Jun. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Equity Transactions	11. Equity transactions Warrant Exercises During the three and six months ended June 30, 2020, the Company issued 1,000,000 shares of Common Stock upon the exercise of 1,000,000 Class P Warrants to purchase shares of stock and an exercise price of $0.01 per share under the terms of the respective warrant agreement. Conversion of liabilities During the six months ended June 30, 2020, the Company issued 2,579,789 shares of Common Stock upon the conversion of short term notes payable in the principal and accrued interest amount of $354,729 with the receipt of notices of Class L warrant exercises, all pursuant to the terms of the short term notes payable. Conversion of advances from related parties During the six months ended June 30, 2020, the Company issued 262,811 shares of Common Stock upon the conversion of advances from related parties in the amount of $18,098 with the receipt of notice of Series A Warrant exercise to purchase shares of stock under the terms of the respective warrant agreement. Consulting Agreement In January 2020, the Company entered into a six month consulting agreement for which the fee for the services was to be paid with Common Stock. The number of shares to be paid with Common Stock was 1,000,000 earned upon signing and an additional 1,000,000 upon agreement by both consultant and the Company no later than May 1, 2020. The Company issued 1,000,000 shares in March 2020 and 1,000,000 shares in April 2020. The fair value of the shares of $380,000 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020. The consulting agreement was extended to November 30, 2020 with an additional 2,000,000 Common Stock shares to be issued for services. The Company issued 1,000,000 shares to the consultant in June 2020. The fair value of the shares of $287,500 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020. PIPE Offering On December 11, 2019, the Company entered into a Common Stock Purchase Agreement with certain investors for the sale by the Company in a private placement of an aggregate of up to 21,071,143 shares of its common stock at a purchase price of $0.14 per share. During the six months ended June 30, 2020, the Company issued 1,071,428 shares of Common Stock in conjunction with this offering and received $150,000 in cash proceeds. Stock Option Exercise During the six months ended June 30, 2020, the Company issued 225,000 shares of Common Stock upon the exercise of stock options resulting in net proceeds of $44,250. Litigation Settlement During the six months ended June 30, 2020, the Company issued 200,000 shares of restricted Common Stock upon the settlement of outstanding litigation. The fair value of the shares of $50,000 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020.	13. Warrant Exercises During the year ended December 31, 2019, the Company issued 19,116,934 shares of Common Stock upon the exercise of 19,116,934 Class L Warrants, Class O Warrants, Class N Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements, in exchange for $1,758,142 in cash proceeds. During the year ended December 31, 2019, the Company issued 21,167,488 shares of Common Stock upon the exercise of 21,167,488 Class L Warrants, Class O Warrants, Class N Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements, in exchange for $1,827,315 in customer deposits and $36,500 in accounts payable. For the year ended December 31, 2018, the Company issued 422,939 shares of common stock upon the exercise of 422,939 Class N Warrants, Series A Warrants and Class O Warrants to purchase shares of stock under the terms of the respective warrant agreements. Cashless Warrant Exercises During the year ended December 31, 2019, the Company issued 4,962,157 shares of Common Stock upon the cashless exercise of 10,423,886 Class N Warrants, Class L Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements. During the year ended December 31, 2019, the Company issued 450,000 shares of Common Stock on a cashless basis upon the exercise of 450,000 Class L Warrants to purchase shares of stock under the terms of the respective warrant agreements. The Common Stock was issued on a cashless basis as a result of email breach in March 2019. The warrant holder sent the funds to an incorrect bank account as a result of the email breach and the Company elected to waive the requirement to cash exercise and allowed the warrant holder to net exercise. For the year ended December 31, 2018, the Company issued 6,395,499 shares of common stock upon the exercise of 7,878,925 Class N Warrants, Series A Warrants and Class O Warrants to purchase shares of stock under the terms of the respective warrant agreements. Conversion of liabilities During the year ended December 31, 2019, the Company issued 38,581,030 shares of Common Stock upon the exercise of 35,677,272 Class L Warrants, Class N Warrants and Series A Warrants, under the terms of the respective warrant agreements and 2,903,758 upon the conversion of interest and bonus shares pursuant to the terms of the short term note payable. The other warrant exercise constituted the conversion of short term note payable in the outstanding amount of $3,559,542 with the receipt of notices of Class L, Class N and Series A warrant exercises, all pursuant to the terms of the short term note payable. During the year ended December 31, 2019, the Company issued 26,666,487 shares of Common Stock due upon exercise of the conversion of convertible promissory notes in the principal and interest amount of $2,933,313 with the receipt of notices of conversion, all pursuant to the terms of the convertible promissory notes. During the year ended December 31, 2019, the Company issued 7,020,455 shares of Common Stock due upon exercise of 6,795,455 Class L and Class N Warrants and 225,000 upon the conversion of bonus share pursuant to the terms of the conversion of line of credit, related parties in the principal amount of $680,000 with the receipt of notices of conversion. For the year ended December 31, 2018, the Company issued 8,497,238 shares of Common Stock upon the conversion of 10% Convertible Promissory Notes in the amount of $902,500 plus accrued interest of $32,197 at the conversion price of $0.11 per share per the terms of the 10% Convertible Promissory Notes agreement. Consulting Agreement In February 2019, the Company entered into a three month consulting agreement for which a portion of the fee for the services was to be paid with Common Stock. The number of shares to be paid with Common Stock was 75,000 earned upon signing and an additional 75,000 upon renewal of the agreement. The Company issued 150,000 shares in December 2019. The fair value of the shares of $28,500 was recorded as a non-cash general and administrative expense during the year ended December 31, 2019. In April 2018, the Company verbally entered into a month-to-month consulting agreement with a consultant for which a portion of the fee for the services was to be paid with Common Stock. The number of shares to be paid with Common Stock was calculated by dividing the amount of the fee to be paid with Common Stock of $4,000 by the Company stock price at the close of business on the eighth business day of each month. The Company issued 74,714 shares of Common Stock for services performed from January through June 2018. $20,000 was recorded as a non-cash general and administrative expense during the year ended December 31, 2018. In May 2017, the Company entered into an agreement with an investment company to provide business advisory and consulting services. The compensation for those services was to be paid in a combination of cash and Common Stock. At December 31, 2017, the Company accrued $120,000 of expense for the services provided. The Common Stock was issued in March and June 2018 in the amount of 533,450 and 15,000 shares, respectively. On October 17, 2018, this agreement was verbally amended to provide for the cash compensation of services performed to be paid with Common Stock. The Common Stock was issued in October 2018 in the amount of 426,176 shares. The $37,500 was recorded as a non-cash general and administrative expense during the year ended December 31, 2018. PIPE Offering On December 11, 2019, the Company entered into a Common Stock Purchase Agreement with certain investors for the sale by the Company in a private placement of an aggregate of up to 21,071,143 shares of its common stockat a purchase price of $0.14 per share. The Company has granted the purchasers indemnification rights with respect to its representations, warranties, covenants and agreements under the purchase agreement. In connection with the agreement, the Company also entered into a registration rights agreement with the purchasers, pursuant to which the Company has agreed to file a registration statement with the SEC by April 30, 2020. During the year ended December 31, 2019, the Company issued 20,000,711 shares of Common Stock in conjunction with this offering and received $2,800,100 in cash proceeds.

Warrants (FY)

Warrants (FY)	6 Months Ended	12 Months Ended
Warrants (FY)	Jun. 30, 2020	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Warrants	12. Warrants A summary of the warrant activity during the six months ended June 30, 2020 is presented as follows: Warrant class Outstanding as of December 31, 2019 Issued Exercised Expired Outstanding as of June 30, 2020 Class K Warrants 7,200,000 — — — 7,200,000 Class O Warrants 909,091 — — — 909,091 Class P Warrants 1,365,000 — (1,000,000 ) (100,000 ) 265,000 Common Stock Purchase Warrants — 1,000,000 — — 1,000,000 9,474,091 1,000,000 (1,000,000 ) (100,000 ) 9,374,091 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January2022 Class P Warrants $ 0.20 June 2024 Common Stock Purchase Warrants $ 0.35 June 2025 The fair value of the Common Stock Purchase Warrants is estimated on the date of grant using the Black-Scholes option pricing model which approximates the binomial model using the following weighted average assumptions for the six months ended June 30, 2020: June 30, 2020 Weighted average contractual terms in years 2.5 Weighted average risk free interest rate 0.47 % Weighted average volatility 107.12 %	14. A summary of warrants as of December 31, 2019 and 2018, is presented as follows: Warrant class Outstanding as of December 31, 2017 Issued Exercised Expired Outstanding as of December 31, 2018 Issued Exercised Expired Outstanding as of December 31, 2019 Class F Warrants 300,000 — — (300,000 ) — — — — — Class G Warrants 1,503,409 — — (1,503,409 ) — — — — — Class H Warrants 1,988,095 — — (1,988,095 ) — — — — — Class I Warrants 1,043,646 — — (1,043,646 ) — — — — — Class K Warrants 7,200,000 — — — 7,200,000 — — — 7,200,000 Class L Warrants 63,898,173 — (6,639,834 ) — 57,258,339 — (57,133,339 ) (125,000 ) — Class N Warrants 13,943,180 17,644,999 (1,136,364 ) — 30,451,815 — (29,951,815 ) (500,000 ) — Class O Warrants 6,540,000 1,509,091 (120,000 ) — 7,929,091 — (6,549,090 ) (470,910 ) 909,091 Class P Warrants — — — — — 1,365,000 — — 1,365,000 Series A Warrants 1,561,348 — (405,666 ) — 1,155,682 — (1,092,936 ) (62,746 ) — 97,977,851 19,154,090 (8,301,864 ) (4,835,150 ) 103,994,927 1,365,000 (94,727,180 ) (1,158,656 ) 9,474,091 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January 2022 Class P Warrants $ 0.01 June 2021 Class P Warrants $ 0.20 June 2024 On January 23, 2019, the Company extended the expiration date to May 1, 2019 for Series A Warrants, Class L Warrants and Class N Warrants. On March 1, 2019, the Company extended the expiration date to June 28, 2019 for Class N Warrants and Class O Warrants. On May 31, 2019, the Company amended the expiration date of the Class N warrants from June 28, 2019 to September 3, 2019. No consideration was given for the warrant extensions. The Company has 1,033,334 Class L Warrants and 62,811 Series A Warrants that have been exercised but the common stock has not yet been issued. The cash for these issuable shares was previously received and recorded in Advances from related parties and Short term notes payable. The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company. The Class K Warrants may be exercised on a physical settlement or on a cashless basis. On June 11, 2019, the Company issued Class P Warrant Agreements to vendors to purchase 265,000 shares of common stock at an exercise price of $0.20 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrants at the grant date was $36,067 and was recorded as selling and marketing expense. The warrants vested upon issuance and expire on June 11, 2024. On June 14, 2019, the Company issued Class P Warrant Agreement to a vendor to purchase up to 1,000,000 shares of common stock at an exercise price of $0.01 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrants at the grant date was $150,800 and was recorded as general and administrative expense. The warrants vested upon issuance and expire on June 14, 2021. On June 24, 2019, the Company issued Class P Warrant Agreement to a vendor to purchase up to 100,000 shares of common stock at an exercise price of $0.20 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrant will be recorded as selling and marketing expense as the warrants are earned per the milestones. The warrants have not yet vested based on milestones and expire on June 24, 2024. In March 2019, the Company entered into a three month consulting agreement for which a portion of the fee for the services was to be paid with a par value warrant for 1,000,000 shares of Common Stock. The Company issued the warrant agreement in June 2019. The $150,800 calculated fair value of the warrants was recorded as a non-cash general and administrative expense during the year ended December 31, 2019. On January 26, 2018, the Company issued Class O Warrant Agreements to a related party vendor to purchase 909,091 shares of common stock at an exercise price of $0.11 per share. Each Class O Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class O Warrants at the grant date was $160,455 and was recorded as general and administrative expense. The warrants vested upon issuance and expire on March 17, 2019. On March 1, 2019, the Company extended the expiration date to June 28, 2019. In 2018, the Company issued Class O Warrant Agreements to a vendor to purchase 600,000 shares of common stock at an exercise price of $0.11 per share. Each Class O Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class O Warrants at their respective grant dates was $159,370 and was recorded as general and administrative expense. The warrants vested upon issuance and expire on March 17, 2019. On March 1, 2019, the Company extended the expiration date to June 28, 2019. The Class K Warrants and the Series A Warrants were derivative financial instruments. The estimated fair value of the Class K Warrants at the date of grant was $36,989 and recorded as debt discount, which is accreted to interest expense through the maturity date of the related notes payable, related parties. The estimated fair values of the Series A Warrants and the Series B Warrants at the date of grant were $557,733 for the warrants issued in conjunction with the 2014 Private Placement and $47,974 for the warrants issued in conjunction with the 18% Convertible Promissory Notes. The fair value of the Series A Warrants and Series B Warrants were recorded as equity issuance costs in 2014, a reduction of additional paid-in capital. The Series B Warrants expired unexercised in March 2015. The estimated fair values were determined using a binomial option pricing model based on various assumptions. The Company’s derivative liabilities have been classified as Level 3 instruments and are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models the Company uses to value the warrants, including the Company’s current common stock price, the remaining life of the warrants of 0.085 years, the volatility of the Company’s common stock price of 102%, and the risk-free interest rate of 2.43% for the year ended December 31, 2019. The remaining life of the warrants which ranged from 0.21 to 8.6 years, the volatility of the Company’s common stock price which ranged from 112% to 134%, and the risk-free interest rate which ranged from 2.43% to 2.64% for the year ended December 31, 2018. In addition, as of the valuation dates, management assessed the probabilities of future financing and other re-pricing events in the binominal valuation models. A summary of the changes in the warrant liability during the years ended December 31, 2019 and 2018, is as follows: Class K Warrants Series A Warrants Total Warrant liability as of December 31, 2017 $ 1,616,000 $ 327,883 $ 1,943,883 Issued — — — Redeemed — (118,838 ) (118,838 ) Change in fair value (74,000 ) 18,624 (55,376 ) Warrant liability as of December 31, 2018 1,542,000 227,669 1,769,669 Change in fair value — (32,359 ) (32,359 ) Expired — (195,310 ) (195,310 ) Reclassification due to Adoption of ASU 2017-11 (see Note 2) (1,542,000 ) — (1,542,000 ) Warrant liability as of December 31, 2019 $ — $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (FY)	6 Months Ended	12 Months Ended
Commitments and Contingencies (FY)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies [Abstract]
Commitments and Contingencies	13. Commitments and contingencies Operating Leases The Company is a party to certain operating leases. The Company has entered into a lease agreement, as amended, for office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis. For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date (except we used the practical expedients and recorded the outstanding operating lease at January 1, 2019) based on the present value of lease payments over the lease term. As the Company’s lease did not provide an implicit interest rate, the Company used the equivalent borrowing rate for a secured financing with the term of that equal to the remaining life of the lease at inception. The lease terms used to calculate the ROU asset and related lease liability did not include options to extend or termination of the lease; there are none and there is no reasonable certainty that the Company would extend the lease at expiration. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as separate lease components. Non-leasing components are not included in the ROU asset. Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 243,251 June 30, 2020 Lease liability - right of use Current portion $ 179,524 Long term portion 92,889 $ 272,413 As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 97,041 2021 197,462 Total lease payments 294,503 Less: Present value adjustment (22,090 ) Lease liability - right of use $ 272,413 As of June 30, 2020, the Company’s operating lease had a weighted average remaining lease term of 1.5 years and a weighted average discount rate of 7%. Rent expense for the three months ended June 30, 2020 and 2019 was $52,346 and $54,698, respectively, and for the six months ended June 30, 2020 and 2019 was $117,876 and $107,536, respectively. Financing Lease For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The present value of the lease payment exceeds 90% of the sales price of the equipment, therefore this lease will be considered a financing lease is included in Property and equipment, net on our Condensed Consolidated Balance Sheets. Lease expense will be recognized as payment of financing lease, depreciation expense and interest expense. Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 515,551 June 30, 2020 Lease liability - right of use Current portion $ 181,371 Long term portion 333,771 $ 515,141 As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 117,297 2021 234,593 2022 199,793 2023 18,388 Total $ 570,071 As of June 30, 2020, the Company’s financing leases had a weighted average remaining lease term of 2.44 years based on annualized base payments expiring through 2023 and a weighted average discount rate of 13.2%. As of June 30, 2020, the Company did not have additional operating or financing leases that have yet commenced. Litigation From time to time, the Company is subject to various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The Company believes that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.	15. Operating Leases The Company is a party to certain operating leases. In August 2016, the Company entered into a lease agreement for 7,500 square feet of office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. On February 1, 2018, the Company entered into an amendment to the lease agreement for an additional 380 square feet of office space for storage which expires on December 31, 2021. On January 2, 2019, the Company entered into a second amendment to the lease agreement for an additional 2,297 square feet of office space for office space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis. For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date (except we used the practical expedients and recorded the outstanding operating lease at January 1, 2019) based on the present value of lease payments over the lease term. As the Company’s lease did not provide an implicit interest rate, the Company used the equivalent borrowing rate for a secured financing with the term of that equal to the remaining life of the lease at inception. The lease terms used to calculate the ROU asset and related lease liability did not include options to extend or termination of the lease; there are none and there is no reasonable certainty that the Company would extend the lease at expiration. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as a separate lease components. Non-leasing components are not included in the ROU asset. Right of use assets and Lease Liability – right of use consists of the following: December 31, 2019 Right of use assets $ 323,661 Lease liability - right of use December 31, 2019 Current portion $ 173,270 Long term portion 185,777 $ 359,047 As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 191,713 2021 197,462 Total lease payments 389,175 Less: Present value adjustment (30,128 ) Lease liability - right of use $ 359,047 As of December 31, 2019, the Company’s operating lease had a weighted average remaining lease term of 2 years and a weighted average discount rate of 7%. Rent expense for the years ended December 31, 2019 and 2018, was $225,274 and $157,395, respectively. Financing Lease For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The present value of the lease payment exceeds 90% of the sales price of the equipment, therefore this lease will be considered a financing lease and is included in Property and equipment, net on our Consolidated Balance Sheets (see Note 4). Lease expense will be recognized as payment of financing lease, depreciation expense and interest expense. Right of use assets and Lease Liability – right of use consists of the following: December 31 2019 Right of use assets $ 418,088 Lease liability - right of use December 31, 2019 Current portion $ 121,634 Long term portion 271,240 $ 392,874 As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 165,078 2021 165,078 2022 130,278 Total $ 460,434 As of December 31, 2019, the Company’s financing leases had a weighted average remaining lease term of 2.8 years based on annualized base payments expiring through 2022 and a weighted average discount rate of 13.2%. As of December 31, 2019, the Company did not have additional operating or financing leases that have yet commenced. Litigation The Company is a defendant in various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. We believe that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.

Revenue (FY)

Revenue (FY)	6 Months Ended	12 Months Ended
Revenue (FY)	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue	14. Revenue The Company accounts for revenue in accordance with ASC 606. Disaggregation of Revenue The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 United States International Total United States International Total Product $ 63,076 $ 6,265 $ 69,341 $ 120,488 $ 100,179 $ 220,667 License fees — — — 6,250 60,558 66,808 Other Revenue 711 13,249 13,960 — 29,501 29,501 $ 63,787 $ 19,514 $ 83,301 $ 126,738 $ 190,238 $ 316,976 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 United States International Total United States International Total Product $ 96,730 $ 47,170 $ 143,900 $ 138,167 $ 147,065 $ 285,232 License fees 10,000 — 10,000 12,500 160,558 173,058 Other Revenue 1,252 76,741 77,993 — 36,649 36,649 $ 107,982 $ 123,911 $ 231,893 $ 150,667 $ 344,272 $ 494,939 Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. One distributor accounted for 86% of revenue for the six months ended June 30, 2020 and 72% of accounts receivable at June 30, 2020. Three distributors accounted for 72% of revenues for the six months ended June 30, 2019 and 49%, 0% and 25% of accounts receivable at June 30, 2019.	16. The Company began accounting for revenue in accordance with ASC 606, which we adopted beginning January 1, 2018, using the modified retrospective method (see Note 2). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. Pursuant to ASC 606, we apply the following the five-step model: 1. Identify the contract(s) with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods to be transferred and identifies the payment terms related to these goods, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. 2. Identify the performance obligation(s) in the contract. If a contract promises to transfer more than one good or service to a customer, each good or service constitutes a separate performance obligation if the good or service is distinct or capable of being distinct. 3. Determine the transaction price. The transaction price is the amount of consideration to which the entity expects to be entitled in exchanging the promised goods or services to the customer. 4. Allocate the transaction price to the performance obligations in the contract. For a contract that has more than one performance obligation, an entity should allocate the transaction price to each performance obligation in an amount that depicts the amount of consideration to which an entity expects to be entitled in exchange for satisfying each performance obligation. 5. Recognize revenue when (or as) the Company satisfies a performance obligation. For each performance obligation, an entity should determine whether the entity satisfies the performance obligation at a point in time or over time. Appropriate methods of measuring progress include output methods and input methods. The Company recognizes revenue primarily from the following types of contracts: Product sales Product sales include devices and applicators (new and refurbished). Performance obligations are satisfied at the point in time when the customer obtains control of the goods, which is generally at the point in time that the product is shipped. Procedure revenue from the dermaPACE System is not material to the consolidated financial statements as of December 31, 2019. Licensing transactions Licensing transaction include distribution licenses and intellectual property licenses. Licensing revenue is recognized as the Company satisfies its performance obligations, which may vary with the terms of the licensing agreement. Other activities Other activities primarily include warranties, repairs and billed freight. Device product sales are bundled with an initial one-year warranty and the Company offers a separately priced second-year warranty. The Company allocates the device sales price to the product and the embedded warranty by reference to the stand-alone extended warranty price. Because the warranty represents a stand-ready obligation, revenue is recognized over the time period that the Company satisfies its performance obligations, which is generally the warranty term. Repairs (parts and labor) and billed freight revenue are recognized at the point in time that the service is performed, or the product is shipped, respectively. Disaggregation of Revenue The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the years ended December 31, 2019 and 2018: Year ended December 31, 2019 Year ended December 31, 2018 United States International Total United States International Total Product $ 277,527 $ 367,642 $ 645,169 $ 209,842 $ 739,759 $ 949,601 License fees 125,000 190,557 315,557 25,000 794,696 819,696 Other Revenue 2,450 65,554 68,004 — 80,763 80,763 $ 404,977 $ 623,753 $ 1,028,730 $ 234,842 $ 1,615,218 $ 1,850,060

Related Party Transactions (FY)

Related Party Transactions (FY)	6 Months Ended	12 Months Ended
Related Party Transactions (FY)	Jun. 30, 2020	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	15. Related party transactions During the three and six months ended June 30, 2020 and 2019, the Company recorded $13,105 and $17,678, respectively, and $26,210 and $138,167 respectively, in revenue from an entity owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. Contract liabilities includes a balance at June 30, 2020 and 2019 of $90,943 and $102,899, respectively from this related party.	17. On February 13, 2018, the Company entered into an Agreement for Purchase and Sale, Limited Exclusive Distribution and Royalties, and Servicing and Repairs with Premier Shockwave Wound Care, Inc., a Georgia Corporation (“PSWC”), and Premier Shockwave, Inc., a Georgia Corporation (“PS”). The agreement provides for the purchase by PSWC and PS of dermaPACE System and related equipment sold by the Company and includes a minimum purchase of 100 units over 3 years. The agreement grants PSWC and PS limited but exclusive distribution rights to provide dermaPACE Systems to certain governmental healthcare facilities in exchange for the payment of certain royalties to the Company. No royalties were earned during the year ended December 31, 2018. Under the agreement, the Company is responsible for the servicing and repairs of such dermaPACE Systems and equipment. The agreement also contains provisions whereby in the event of a change of control of the Company (as defined in the agreement), the stockholders of PSWC have the right and option to cause the Company to purchase all of the stock of PSWC, and whereby the Company has the right and option to purchase all issued and outstanding shares of PSWC, in each case based upon certain defined purchase price provisions and other terms. The agreement also contains certain transfer restrictions on the stock of PSWC. Each of PS and PSWC is owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. For the year ended December 31, 2019, the Company recorded $253,013 in product revenue from this related party. The Contract liabilities balance includes a balance of $117,152 from this related party. For the year ended December 31, 2018, the Company recorded $207,457 in product revenue from this related party. The Contract liabilities balance includes a balance of $156,565 from this related party.

Stock-Based Compensation (FY)

Stock-Based Compensation (FY)	6 Months Ended	12 Months Ended
Stock-Based Compensation (FY)	Jun. 30, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock-Based Compensation	16. Stock-based compensation During the six months ended June 30, 2020, an employee exercised stock options to buy 175,000 shares at an exercise price of $0.21 per share and 50,000 shares at an exercise price of $0.15 per share of the Company’s common stock totaling 225,000 shares. During the six months ended June 30, 2020, 10,000 stock options to purchase the Company’s common stock were forfeited due to termination. The range of exercise prices for options was $0.04 to $2.00 for options outstanding at June 30, 2020 and December 31, 2019, respectively. The aggregate intrinsic value for all vested and exercisable options was $3,034,841 and $981,088 at June 30, 2020 and December 31, 2019, respectively. The weighted average remaining contractual term for outstanding exercisable stock options was 6.1 and 6.6 years as of June 30, 2020 and December 31, 2019, respectively.	18. On November 1, 2010, the Company approved the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. effective as of January 1, 2010 (the “Stock Incentive Plan”). The Stock Incentive Plan permits grants of awards to selected employees, directors and advisors of the Company in the form of restricted stock or options to purchase shares of common stock. Options granted may include non-statutory options as well as qualified incentive stock options. The Stock Incentive Plan is currently administered by the board of directors of the Company. The Stock Incentive Plan gives broad powers to the board of directors of the Company to administer and interpret the particular form and conditions of each option. The stock options granted under the Stock Incentive Plan are non-statutory options which generally vest over a period of up to three years and have a ten year term. The options are granted at an exercise price determined by the board of directors of the Company to be the fair market value of the common stock on the date of the grant. As of December 31, 2019, and 2018, the Stock Incentive Plan reserved a total of 35,000,000 and 35,000,000, respectively, shares of common stock for grant. On December 31, 2019, there were 2,028,281 shares of common stock available for grant under the Stock Incentive Plan. During the year ended December 31, 2019, the Company granted to employees, members of the board of directors and members of the Company’s Medical Advisory Board options to purchase an aggregate of 2,700,000 shares of common stock under a previously issued incentive plan. The options have an exercise price between $0.14 and $0.18 per share for an aggregate grant date value of approximately $333,422. The options vested upon issuance and have a term of ten years. During the year ended December 31, 2018, the Company granted to employees, members of the board of directors and members of the Company’s Medical Advisory Board options to purchase an aggregate of 10,110,000 shares of common stock under a previously issued incentive plan. The options have an exercise price between $0.11 and $0.42 per share for an aggregate grant date value of approximately $2,500,000. The options vested upon issuance and have a term of ten years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the years ended December 31, 2019 and 2018: 2019 2018 Weighted average expected life in years 5.00 5.00 Weighted average risk free interest rate 1.54% - 2.15 % 2.84% - 3.21 % Weighted average volatility 131% - 189 % 134% - 144 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 % The expected life of options granted represent the period of time that options granted are expected to be outstanding and are derived from the contractual terms of the options granted. The risk-free rate for periods within the contractual life of the option is based on the United States Treasury yield curve in effect at the time of the grant. The expected volatility is based on the average volatility of the Company and that of peer group companies similar in size and value to us. We estimate pre-vesting forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The expected dividend yield is based on our historical dividend experience, however, since our inception, we have not declared dividends. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. Ultimately, the total expense recognized over the vesting period will equal the fair value of the awards that actually vest. For the years ended December 31, 2019 and 2018, the Company recognized $333,422 and $2,480,970, respectively, as compensation cost related to options granted. As of December 31, 2019, and 2018, there are no unamortized compensation costs related to options granted. A summary of option activity as of December 31, 2019 and 2018, and the changes during the years then ended, is presented as follows: Options Weighted Average Exercise Price per share Outstanding at December 31, 2017 221,593,385 $ 0.31 Granted 10,110,000 $ 0.25 Exercised — $ — Forfeited or expired — $ — Outstanding at December 31, 2018 31,703,385 $ 0.29 Granted 2,700,000 $ 0.15 Exercised — $ — Forfeited or expired (100,000 ) $ 0.11 Outstanding at December 31, 2019 34,303,385 $ 0.28 Vested and exercisable at December 31, 2019 33,928,385 $ 0.29 The range of exercise prices for options was $0.04 to $2.00 for options outstanding at December 31, 2019 and 2018, respectively. The aggregate intrinsic value for outstanding options was $981,088 and $2,085,866 at December 31, 2019 and 2018, respectively. The aggregate intrinsic value for all vested and exercisable options was $981,088 and $2,085,866 at December 31, 2019 and 2018, respectively. The weighted average remaining contractual term for outstanding exercisable stock options is 6.62 years and 7.4 years as of December 31, 2019 and 2018, respectively. A summary of the Company’s nonvested options as of December 31, 2019 and 2018, and changes during the years then ended, is presented as follows: Options Weighted Average Exercise Price per share Outstanding at December 31, 2017 — $ — Granted 10,110,000 $ 0.25 Vested (10,110,000 ) $ 0.25 Forfeited or expired — $ — Outstanding at December 31, 2018 — $ — Granted 2,700,000 $ 0.15 Vested (2,350,000 ) $ 0.15 Forfeited or expired — $ — Outstanding at December 31, 2019 350,000 $ 0.18

Joint Ventures (FY)

Joint Ventures (FY)	12 Months Ended
Joint Ventures (FY)	Dec. 31, 2019
Joint Venture [Abstract]
Joint Ventures	19. On June 26, 2018, the Company entered into an Agreement with FKS, effective as of June 14, 2018, pursuant to which the Company and FKS committed to enter into a joint venture for the manufacture, sale and distribution of the Company’s dermaPACE and orthoPACE devices. Under the Agreement, FKS paid the Company a fee of $500,000 for initial distribution rights in Taiwan on June 22, 2018, with an additional fee of $500,000 for initial distribution rights in Singapore, Malaysia, Brunei, Cambodia, Myanmar, Laos, Indonesia, Thailand, Philippines and Vietnam (the “SEA Region”) to be paid in the first quarter of 2019. On September 21, 2018, the Company entered into a joint venture agreement (the “JV Agreement”) with FKS setting forth the terms of the operation, management and control of a joint venture entity initially with the name of Holistic Health Institute Pte. Ltd., a private limited company to be incorporated in the Republic of Singapore, but with such company name subject to confirmation by Singapore Government. On November 9, 2018, the joint venture entity was incorporated in the Republic of Singapore with the name of HWA. HWA was formed as a joint venture of the Company and FKS for the manufacture, sale and distribution of the Company’s dermaPACE and orthoPACE devices. Under the JV Agreement, the Company and FKS each hold shares constituting fifty percent of the issued share capital of HWA. The Company provides to HWA FDA and CE approved products for an agreed cost, access to treatment protocols, training, marketing and sales materials and management expertise, and FKS provides to HWA capital, human capital and sales resources in Singapore, Malaysia, Brunei, Cambodia, Myanmar, Laos, Indonesia, Thailand, Philippines and Vietnam, certain reports and identification of new key opinion leaders as well as clinical trial and poster access availability. The JV Agreement also established the corporate governance of HWA, including a five-person board of directors consisting of two directors designated by the Company, two directors designated by FKS, and a third director appointed jointly by the parties. Initially, net profits under the JV Agreement shall be used to repay FKS for (i) the payment of $500,000 on June 22, 2018 to the Company for initial distribution rights in Taiwan and (ii) the cash advance to HWA per the terms of the JV Agreement. The JV Agreement includes other customary terms, including regarding the transfer of shares, indemnification and confidentiality. On June 4, 2019, we entered into an agreement with Johnfk Medical Inc. (“FKS”) and Holistic Wellness Alliance Pte. Ltd. (“HWA”) pursuant to which we and FKS terminated the joint venture agreement, dated as of September 21, 2018, that established HWA as a joint venture between us and FKS. Pursuant to the termination agreement, FKS will pay us the outstanding amount of $63,275 for equipment delivered to FKS and a penalty fee of $50,000 for early termination of the joint venture agreement, which was received in 2019. We credited the outstanding amount of $63,275 due for equipment upon the return of the equipment on September 6, 2019. On September 27, 2017, the Company entered into a binding term sheet with MundiMed Distribuidora Hospitalar LTDA (“MundiMed”), for a joint venture for the manufacture, sale and distribution of our dermaPACE device. Under the binding term sheet, MundiMed was to pay the Company an initial upfront distribution fee, with monthly upfront distribution fees payable thereafter over the following eighteen months. The initial upfront distribution fee was received on October 6, 2017. Monthly upfront distribution fee payments have been received aggregating $372,222. In August 2018, MundiMed advised the Company that it did not anticipate being able to make further payments under the binding term sheet due to operational and cash flow difficulties. On September 14, 2018, the Company sent a letter to MundiMed informing them of a breach in our agreement regarding payment of the upfront distribution fee. On September 28, 2018, the Company received a response letter stating that the Company was in default of the agreement. On October 9, 2018, the Company sent MundiMed a letter of termination of the agreement effective as of October 8, 2018. Accordingly, the Company derecognized the contract assets and contract liabilities associated with the MundiMed contract. On December 13, 2019, the Company entered into a joint venture agreement (the “Agreement”) with Universus Global Advisors LLC, a limited liability company organized under the laws of the State of Delaware (“Universus”), Versani Health Consulting Consultoria em Gestão de Negócios EIRELI, an empresa individual de responsabilidade limitada organized under the laws of Brazil (“Versani”), Curacus Limited, a private limited company organized under the laws of England and Whales (“Curacus”), and certain individual citizens of Brazil and the Czech Republic (the individuals together with Curacus, the “IDIC Group”). The principal purpose of the joint venture company will be to manufacture, import, use, sell, and distribute, on an exclusive basis in Brazil, dermaPACE devices and wound kits consisting of a standard ultrasound gel and custom size sterile sleeves used for the treatment of various acute and chronic wounds using extracorporeal shockwave therapy technology. The joint venture company will also provide treatments related to the dermaPACE devices. The IDIC Group has agreed to pay to the Company a partnership fee in the total amount of $600,000 for the granting of exclusive territorial rights to the joint venture company to distribute the dermaPACE devices and wound kits in Brazil. Of the $600,000 partnership fee, $500,000 was received in November and December of 2019 and recorded as contract liability, while the remaining $100,000 is contingent on receipt of required regulatory approvals from ANVISA (the Brazilian Health Regulatory Agency) and is expected to be received within the next twelve to eighteen months. As the remaining $100,000 fee is contingent it was not recorded in the financial statements at December 31, 2019. The parties executed a shareholders’ agreement, a trademark license agreement, a supply agreement and a technology license agreement on January 31, 2020. The IDIC Group will also have the right to receive prioritized dividends until full reimbursement of the partnership fee and expenses incurred in the formation of the joint venture company, which are required to be paid by the IDIC Group.

Income Taxes (FY)

Income Taxes (FY)	12 Months Ended
Income Taxes (FY)	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	20. The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is subject to United States federal and state income tax examinations by tax authorities for any years that have net operating losses open until the net operating losses are used. The components of net loss before provision for income taxes for the years ended December 31, 2019 and 2018 are as follows: 2019 2018 Domestic $ (10,595,457 ) $ (12,031,115 ) Foreign 165,618 399,721 Net loss before provision for income taxes $ (10,429,839 ) $ (11,631,394 ) Deferred income taxes are provided for temporary differences between the carrying amounts and tax basis of assets and liabilities. Deferred taxes are classified as current or noncurrent based on the financial statement classification of the related asset or liability giving rise to the temporary difference. For those deferred tax assets or liabilities (such as the tax effect of the net operating loss carryforwards) which do not relate to a financial statement asset or liability, the classification is based on the expected reversal date of the temporary difference. The income tax provision (benefit) from continuing operations consists of the following at December 31, 2019 and 2018: 2019 2018 Current: Federal $ — $ — State — — Foreign — — — — Deferred: Federal (2,300,997 ) (2,157,035 ) State (409,313 ) (383,705 ) Foreign (3,676 ) 2,673 Change in valuation allowance 2,713,986 2,538,067 $ — $ — At December 31, 2018 and 2017, the Company did not have any undistributed earnings of our foreign subsidiaries. As a result, no additional income or withholding taxes have been provided for. The Company does not anticipate any impacts of the global intangible low taxed income (“GILTI”) and base erosion anti-abuse tax (“BEAT”) and as such, the Company has not recorded any impact associated with either GILTI or BEAT. The income tax provision (benefit) amounts differ from the amounts computed by applying the United States federal statutory income tax rate of 21% for the years ended December 31, 2019 and 2018 to pretax loss from operations as a result of the following for the years ended December 31, 2019 and 2018: 2019 2018 Tax benefit at statutory rate $ (2,071,322 ) $ (2,442,593 ) Increase (reduction) in income taxes resulting from: State income benefit, net of federal benefit (291,082 ) (343,257 ) Non-deductible loss on warrant valuation adjustment (47,810 ) (11,629 ) Income (loss) from foreign subsidiaries (2,595 ) 6,699 Change in valuation allowance 2,713,986 2,538,067 Other (301,177 ) 252,713 Income tax expense (benefit) $ — $ — The tax effects of temporary differences that give rise to the deferred tax assets at December 31, 2019 and 2018 are as follows: 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 23,727,093 $ 21,320,935 Net operating loss carryforwards – foreign 20,227 16,551 Excess of tax basis over book value of property and equipment 4,240 (2,229 ) Excess of tax basis over book value of intangible assets 73,705 146,943 Stock-based compensation 1,607,841 1,520,209 Accrued employee compensation 357,869 83,393 Captialized equity costs 49,471 49,471 Inventory reserve 38,323 29,510 25,878,769 23,164,783 Valuation allowance (25,878,769 ) (23,164,783 ) Net deferred tax assets $ — $ — The Company’s ability to use its net operating loss carryforwards could be limited and subject to annual limitations. Since a full analysis under Section 382 of the Internal Revenue Code has not been performed, the Company may realize a “more than 50% change in ownership” which could limit its ability to use its net operating loss carryforwards accumulated to date to reduce future taxable income and tax liabilities. Additionally, because United States tax laws limit the time during which net operating loss carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take advantage of all or portions of its net operating loss carryforwards for federal income tax purposes. The federal and state net operating loss carryforwards of approximately $77.9M from years ending December 31, 2005 through December 31, 2017 will begin to expire in 2025. The federal and state net operating loss carryforward for the years ended December 31, 2019 and 2018 of $18M will not expire. The foreign net operating loss carryforward at December 31, 2019 of $0.1M will begin to expire in 2024.

Segment and Geographic Informat

Segment and Geographic Information (FY)	12 Months Ended
Segment and Geographic Information (FY)	Dec. 31, 2019
Segment Reporting [Abstract]
Segment and Geographic Information	21. The Company has one line of business with revenues being generated from sales in Europe, Canada, Asia and Asia/Pacific. All significant expenses are generated in the United States. All significant assets are located in the United States.

Subsequent Events (FY)

Subsequent Events (FY)	12 Months Ended
Subsequent Events (FY)	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	22. The Company evaluates events that occur after the year-end date through the date the financial statements are available to be issued. On January 31, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series C Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate 90 shares of our preferred stock as Series C Convertible Preferred Stock. Subsequent to December 31, 2019, the Company received $2,250,000 in proceeds for the purchase of 90 shares of Series C Convertible Preferred Stock. As of the date of this report, no shares of Series C Convertible Preferred Stock have been issued. Warrant Exercise Subsequent to December 31, 2019, the Company issued 1,062,811 shares of common stock upon the exercise of 1,062,811 Class P Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements. Conversion of liabilities Subsequent to December 31, 2019, the Company issued 1,496,989 shares of Common Stock upon the exercise of 416,667 Class L Warrants, under the terms of the respective warrant agreements and 1,080,322 upon the conversion of interest and bonus shares pursuant to the terms of the short term note payable. The other warrant exercise constituted the conversion of short term note payable in the outstanding amount of $208,109 with the receipt of notices of Class L warrant exercises, all pursuant to the terms of the short term note payable. Consulting Agreement Subsequent to December 31, 2019, the Company entered into a six month consulting agreement for which the services are to be paid with Common Stock. The number of shares to be paid with Common Stock was 1,000,000 earned upon signing and if agreed by both client and consultant an additional 1,000,000 No later than May 1, 2020. The Company issued 1,000,000 shares in March 2020. New agreements Subsequent to December 31, 2019, the Company entered into the sixth drawdown of the Master Equipment Lease with NFS Leasing, Inc. to provide financing for equipment purchase in the amount of $125,689. Issuance of stock options Subsequent to December 31, 2019, the Company granted to new employees fully-vested options to purchase an aggregate of 100,000 shares of the Company’s common stock.

Note 1 - Nature of the Business

Note 1 - Nature of the Business (Q2)	6 Months Ended
Note 1 - Nature of the Business (Q2)	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	1. Nature of the Business SANUWAVE Health, Inc. and Subsidiaries (the “Company”) is a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. FDA granted the Company’s request to classify the dermaPACE System as a Class II device via the de novo The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company is marketing its dermaPACE System for treatment usage in the United States and is able to generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities. In March 2020, the World Health Organization characterized COVID-19 as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. Since then, the COVID-19 pandemic has rapidly spread across the globe and has already resulted in significant volatility, uncertainty and economic disruption. The primary impact of the COVID-19 pandemic has been seen in our dermaPACE System placements in the United States as our treatment is not widely recognized as an “essential” service. In addition, stay-at-home policies deployed to combat the spread of COVID-19 has greatly constrained visits to wound care centers, doctor’s offices and hospitals since late March 2020 and continuing as of this filing and have therefore delayed placements of new devices that were included in our revenue forecast. The future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. It is difficult at this time to predict the impact that COVID-19 will have on the Company’s business, financial position and operating results in future periods due to numerous uncertainties. The Company is closely monitoring the impact of the pandemic on all aspects of its business and operations. On August 6, 2020 the Company entered into an asset purchase agreement with Celularity Inc.(“Celularity”) pursuant to which the Company acquired Celularity’s UltraMIST assets, as more fully described in Note 18 to the Company’s condensed consolidated financial statements. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The financial information as of June 30, 2020 and for the three and six months ended June 30, 2020 and 2019 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2020. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s annual financial statements, included elsewhere in this prospectus.

Note 2 - Going Concern (Q2)

Note 2 - Going Concern (Q2)	6 Months Ended	12 Months Ended
Note 2 - Going Concern (Q2)	Jun. 30, 2020	Dec. 31, 2019
Going Concern [Abstract]
Going Concern	2. Going Concern The Company does not currently generate significant recurring revenue and will require additional capital during 2020. As of June 30, 2020, the Company had cash and cash equivalents of $430,606. For the six months ended June 30, 2020, the net cash used by operating activities was $4,511,968. The Company incurred a net loss of $6,634,168 for the six months ended June 30, 2020. The operating losses and the events of default on the Company’s short term notes payable (see Note 6) and the notes payable, related parties (see Note 9) raised substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this report. Management is currently evaluating the impact on cash flows of the Company’s acquisition of certain assets of Celularity Inc., as more fully described in Note 18. The continuation of the Company’s business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.	1. SANUWAVE Health, Inc. and Subsidiaries (the “Company”) is a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. FDA granted the Company’s request to classify the dermaPACE System as a Class II device via the de novo The Company is marketing its dermaPACE System for treatment usage in the United States and is able to generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities. As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $10,429,839 and $11,631,394 during the years ended December 31, 2019 and 2018, respectively, and the net cash used by operating activities was $6,410,758 and $3,621,172, respectively. As of December 31, 2019, the Company had a net working capital deficit of $9,910,994, and cash and cash equivalents of $1,760,455. These factors and the events of default on the notes payable to HealthTronics, Inc. (see Note 11) and the Company’s short term notes payable (see Note 9) raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the financial statement issuance date. The Company does not currently generate significant recurring revenue and will require additional capital during 2020. Although no assurances can be given, management of the Company believes that existing capital resources should enable the Company to fund operations into the third quarter of 2020. The continuation of the Company’s business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital in 2020 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be required to significantly curtail or discontinue operations or obtain funds through financing transactions with unfavorable terms. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies (Q2)	6 Months Ended	12 Months Ended
Note 3 - Summary of Significant Accounting Policies (Q2)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies The significant accounting policies followed by the Company are summarized below and should be read in conjunction with the 2019 Annual Report: Principles of consolidation Estimates Inventory Preferred stock Distinguishing Liabilities from Equity Sequencing policy	2. The significant accounting policies followed by the Company are summarized below: Foreign currency translation - Principles of consolidation - Estimates - Reclassifications – Cash and cash equivalents - Concentration of credit risk and limited suppliers - Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. Three distributors and partners accounted for 18%, 15% and 12% of revenues for the year ended December 31, 2019, and 0%, 0% and 22% of accounts receivable at December 31, 2019. Three distributors and partners accounted for 33%, 23% and 11% of revenues for the year ended December 31, 2018, and 24%, 60% and 7.7% of accounts receivable at December 31, 2018. The Company expects that actions taken in response to the COVID-19 pandemic will also negatively impact sales of dermaPACE and orthoPACE. Some hospitals are restricting procedures that are not deemed to be life-threatening at this time. Because dermaPACE and orthoPACE are not deemed to be life-threatening procedures, we expect that the number of procedures performed will decline. A decrease in the number of procedures performed will adversely affect our expected revenues and our financial results. The Company depends on suppliers for product component materials and other components that are subject to stringent regulatory requirements. The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may be difficult to arrange a replacement supplier because certain of these materials may only be available from one or a limited number of sources. In addition, our suppliers could be disrupted by conditions related to COVID-19, or other epidemics Establishing additional or replacement suppliers for these materials may take a substantial period of time, as certain of these suppliers must be approved by regulatory authorities. Accounts receivable - Inventory - Depreciation of property and equipment - Fair value of financial instruments - The Company has adopted ASC 820-10, Fair Value Measurements The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions. The Company recognizes all derivatives on the balance sheet at fair value. The fair value of the warrant liability is determined based on a lattice solution, binomial approach pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and risk-free interest rate, and therefore is classified within level 3 of the fair value hierarchy. (See Note 14). The Company’s notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace. Impairment of long-lived assets – Revenue recognition - Shipping and handling costs - Shipping charges billed to customers are included in revenues. Shipping and handling costs incurred have been recorded in cost of revenues. Income taxes - A provision of ASC 740, Income Taxes The Company will recognize in income tax expense, interest and penalties related to income tax matters. For the years ended December 31, 2019 and 2018, the Company did not have any amounts recorded for interest and penalties. Loss per share - 2019 2018 Stock options 34,303,385 31,703,385 Warrants 9,474,091 103,994,927 Convertible promissory notes 2,250,000 24,112,518 Anti-dilutive equity securities 46,027,476 159,810,830 Comprehensive income – Stock-based compensation - Research and development - Liabilities related to warrants issued – Warrants related to debt issued – Beneficial conversion feature on convertible debt - Recently issued or adopted accounting standards - Leases (Topic 842). In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19. The ASU introduces a new model for assessing impairment of most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. The ASU is effective for annual reporting periods beginning after January 2023 with early adoption permitted. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480): Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Note 4 - Accrued Expenses (Q2)

Note 4 - Accrued Expenses (Q2)	6 Months Ended	12 Months Ended
Note 4 - Accrued Expenses (Q2)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued expenses Accrued expenses consist of the following: June 30, 2020 December 31, 2019 Accrued board of director’s fees $ 416,667 $ 400,000 Accrued legal and professional fees 200,000 134,970 Accrued executive severance 313,000 154,000 Accrued travel 120,000 120,000 Accrued outside services 106,233 108,033 Accrued inventory 50,275 167,050 Accrued clinical study expenses 13,650 13,650 Accrued other 1,389 13,406 $ 1,221,214 $ 1,111,109	5. Accrued expenses consist of the following at December 31, 2019 and 2018: 2019 2018 Accrued board of director's fees $ 400,000 $ 200,000 Accrued inventory 167,050 — Accrued executive severance 154,000 136,000 Accrued travel 120,000 58,993 Accrued outside services 108,033 115,118 Accrued legal and professional fees 134,970 — Accrued clinical study expenses 13,650 13,650 Accrued related party advance — 101,137 Deferred rent — 44,623 Accrued computer equipment — 8,752 Accrued other 13,406 11,007 $ 1,111,109 $ 689,280 The Company is a party to a Severance and Advisory Agreement (the “Severance Agreement”) with its former President and Chief Executive Officer, and a director of the Company. Pursuant to the Severance Agreement, the former executive will receive, as severance along with other non-cash items, six months of his base salary payable over the following six month period and bonus payments of $100,000 upon each of four bonus payment events tied to the Company’s clinical trial plan for the dermaPACE device, or December 31, 2016, whichever occurs first. The Company achieved three of the four bonus payment events in 2014 and paid $300,000 in accrued executive severance in 2014. The accrued executive severance at December 31, 2019 and 2018 represents the unpaid portion of the bonus payments plus accrued interest due to late payment. On October 10, 2018, the Company entered into accrued related party advance with Shri P. Parikh, the President of the Company, in the total principal amount of $100,000 with an interest rate of 5% per annum. The principal and accrued interest are due and payable on the earlier of (i) one day after receipt of payment from Johnfk Medical Inc., (ii) six months from the date of issuance and (iii) the acceleration of the maturity of the short term note by the holder upon the occurrence of an event of default. On May 13, 2019, the Company repaid in full the outstanding balance on short term notes payable with Shri P. Parikh, the President of the Company.

Note 5 - Contract Liabilities (

Note 5 - Contract Liabilities (Q2)	6 Months Ended	12 Months Ended
Note 5 - Contract Liabilities (Q2)	Jun. 30, 2020	Dec. 31, 2019
Contract with Customer, Liability [Abstract]
Contract liabilities	5. Contract liabilities As of June 30, 2020, the Company has contract assets and liabilities from contracts with customers (see Note 14). Contract liabilities consist of the following: June 30, 2020 December 31, 2019 Service agreement $ 91,746 $ 133,510 License fees 500,000 500,000 Other 13,791 6,291 Total Contract liabilities 605,537 639,801 Non-Current (551,755 ) (573,224 ) Total Current $ 53,782 $ 66,577 The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate contract liability balances as of June 30, 2020, the Company expects to satisfy its remaining performance obligations associated with $551,755 and $53,782 of contract liability balances within the next twelve months and following thirty-two months, respectively. Of the aggregate contract liability balances as of December 31, 2019, the Company expects to satisfy its remaining performance obligations associated with $66,577 and $573,224 of contract liability balances within the next twelve months and following thirty-eight months, respectively.	6. As of December 31, 2019, the Company has contract assets and liabilities from contracts with customers (Note 16). Contract liabilities consist of the following: December 31, 2019 December 31, 2018 Service agreement $ 133,510 $ 57,365 Deposit on product — 92,950 License fees 500,000 — Other 6,291 28,218 Total Contract liabilities 639,801 178,533 Non-Current (573,224 ) (46,736 ) Total Current $ 66,577 $ 131,797 The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A contract asset (receivable) is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate $639,801 of contract liability balances as of December 31, 2019, the Company expects to satisfy its remaining performance obligations associated with $66,577 of contract liability balances within the next twelve months.

Note 6 - Short Term Notes Payab

Note 6 - Short Term Notes Payable (Q2)	6 Months Ended
Note 6 - Short Term Notes Payable (Q2)	Jun. 30, 2020
Notes Payable [Abstract]
Short Term Notes Payable	6. Short term notes payable During the six months ended June 30, 2020, the Company converted $354,729 of the short-term notes payable into 2,579,789 shares of Company common stock, $0.001 par value (the “Common Stock”).

Note 7 - Convertible Promissory

Note 7 - Convertible Promissory Note (Q2)	6 Months Ended
Note 7 - Convertible Promissory Note (Q2)	Jun. 30, 2020
Convertible Notes Payable [Abstract]
Convertible Promissory Note [Text Block]	7. Convertible promissory note On June 5, 2020, the Company entered into a Securities Purchase Agreement with investor LGH Investments LLC (the “Investor”) for (i) a Promissory Note (the “Convertible Promissory Note”) in the original principal amount of $1,210,000, convertible into shares of Common Stock, (ii) warrants entitling the Investor to acquire 1,000,000 shares of Common Stock (the “Warrants”) and (iii) 200,000 restricted common shares in the Company as an inducement grant (the “Inducement Shares”). Such note contained certain default provisions, as defined. As part of the Securities Purchase Agreement, the Company established a reserve of shares of its authorized but unissued and unreserved Common Stock in the amount of 11,000,000 shares for purposes of exercise of the Warrant or conversion of the Convertible Promissory Note. The Convertible Promissory Note matures on February 5, 2021 and includes a one-time interest charge of 8% to be applied on the issuance date to the original principal amount. The Investor can convert the Convertible Promissory Note and interest at any time prior to maturity to the number of shares of Common Stock, equal to the amount obtained by dividing (i) the amount of the unpaid principal and interest on the note by (ii) $0.25. The Warrants have an exercise price of $0.35 per share and have a term of five years. The exercise price and number of shares subject to purchase under the Warrants are subject to full-ratchet adjustment upon the occurrence o certain dilutive issuances as set forth in the Warrants. With respect to the Inducement Shares, in the event the Company’s share price has declined on the date on which the Investor seeks to have the restricted legend removed on such shares, the Company agrees to issue the Investor additional shares such that the aggregate value of the Inducement Shares equals the aggregate value of the Inducement Shares as of June 5, 2020. As of the date of filing the Inducement Shares have not yet been issued. The Company recorded a debt discount and original issuance discount aggregating $670,682 to be amortized over the life of the Convertible Promissory Note. The Convertible Promissory Note had an aggregate outstanding principal balance of $705,980, net of $600,820 beneficial conversion feature, warrant discount and original issuance discount costs at June 30, 2020. As of the date of this report, the note was repaid in full (See Note 18). Interest expense on the Convertible Promissory Note totaled $166,663 for the six months ended June 30, 2020.

Note 8 - SBA Loans (Q2)

Note 8 - SBA Loans (Q2)	6 Months Ended
Note 8 - SBA Loans (Q2)	Jun. 30, 2020
Loans Payable [Abstract]
SBA Loans [Text Block]	8. SBA Loans On May 28, 2020, the Company received proceeds from a loan in the approximate amount of $460,000 (the “PPP Loan”) from Truist Bank, as lender, pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (15 U.S.C. 636(a)(36)) (the “CARES Act”). The PPP Loan matures on May 28, 2022 and bears interest at a rate of 1% per annum. Commencing December 12, 2020, the Company is required to pay the lender equal monthly payments of principal and interest. The PPP Loan is evidenced by a promissory note dated May 28, 2020 (the “Note”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties and covenants. The PPP Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties. All or a portion of the PPP Loan may be forgiven by the U.S. Small Business Administration (“SBA”) upon application by the Company beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. The ultimate forgiveness of the PPP Loan is also predicated upon regulatory authorities concurring with management’s good faith assessment that the current economic uncertainty made the loan request necessary to support ongoing operations. If, despite the Company’s good-faith belief that given the circumstances the Company satisfied all eligibility requirements for the PPP Loan, the Company is later determined to have violated any applicable laws or regulations or it is otherwise determined that the Company was ineligible to receive the PPP Loan, the Company may be required to repay the PPP Loan in its entirety and/or be subject to additional penalties. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. Under the terms of the PPP Loan, the Company may be eligible for full or partial loan forgiveness in the third quarter of 2020, however, no assurance is provided that the Company will apply for, or obtain forgiveness for, any portion of the PPP Loan. As of June 30, 2020, $132,514 is classified as current and $321,821 as non-current. On June 10, 2020, the Company secured a loan offered by the U.S. Small Business Administration (SBA) under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of COVID-19 pandemic on the Company’s business. The principal amount of this loan of $150,000. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning June 10, 2021. The balance of principal and interest is payable 30 years from the date of the EIDL. The EIDL is secured by a security interest on all of the Company’s assets (See Note 9). As of June 30, 2020, $150,000 is classified as non-current.

Note 9 - Notes Payable, Related

Note 9 - Notes Payable, Related Parties (Q2)	6 Months Ended	12 Months Ended
Note 9 - Notes Payable, Related Parties (Q2)	Jun. 30, 2020	Dec. 31, 2019
Notes Payable [Abstract]
Notes Payable, Related Parties	9. Notes payable, related parties The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal was due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because it is a shareholder in the Company and has a security agreement with the Company detailed below. The Company is a party to a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. During any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. An Event of Default under the notes payable, related parties occurred on December 31, 2016 (“Default”). As a result of the Default, the notes payable, related parties have been accruing interest at the rate of 10% per annum since January 2, 2017 and continue to accrue interest at such rate. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. For the three months ended June 30, 2020, additional mandatory prepayments of principal and interest on the notes payable, related parties were due on June 30, 2020. The Company has not made the mandatory prepayments of principal to HealthTronics, Inc. on the notes payable, related parties as amended from proceeds received through the issuance or sale of any equity securities in cash through June 30, 2020. The notes payable, related parties had an aggregate outstanding principal balance of $5,372,743 at June 30, 2020 and December 31, 2019. Accrued interest, related parties currently payable totaled $2,229,713 at June 30, 2020 and $1,859,977 at December 31, 2019. Interest expense on notes payable, related parties totaled $187,172 and $112,984 for the three months ended June 30, 2020 and 2019, respectively and $369,736 and $332,671 for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, we are in default under the notes, as amended, and as a result HealthTronics, Inc. could, among other rights and remedies, exercise its rights under its first priority security interest in our assets. The Company entered into a letter agreement with HealthTronics, Inc., pursuant to which the Company paid off all outstanding debt due and owed to HealthTronics (see Note 18).	11. The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal is due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because they are a shareholder in the Company and have a security agreement with the Company detailed below. The Company is a party to a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. During any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. Events of Default under the notes payable, related parties have occurred and are continuing on account of the failure of SANUWAVE, Inc., a Delaware corporation, a wholly owned subsidiary of the Company and the borrower under the notes payable, related parties, to make the required payments of interest which were due on December 31, 2016, March 31, 2017, June 30, 2017, September 30, 2017, December 31, 2017, June 30, 2018, September 30, 2018, December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 (collectively, the “Defaults”). As a result of the Defaults, the notes payable, related parties have been accruing interest at the rate of 10% per annum since January 2, 2017 and continue to accrue interest at such rate. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. The Company has not made the mandatory prepayments of principal to HealthTronics, Inc. on the notes payable, related parties from proceeds received through the issuance or sale of any equity securities in cash through December 31, 2019. The notes payable, related parties had an aggregate outstanding principal balance of $5,372,743, net of $0 debt discount at December 31, 2019, and 2018. Accrued interest currently payable totaled $1,859,977 and $1,171,782 at December 31, 2019 and 2018, respectively. Interest expense on notes payable, related parties totaled $688,195 and $787,586 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, we are in default under the notes, as amended by the Third Amendment, and as a result HealthTronics, Inc. could, among other rights and remedies, exercise its rights under its first priority security interest in our assets. We are in negotiations with HealthTronics, Inc. to address the event of default.

Note 10 - Preferred Stock (Q2)

Note 10 - Preferred Stock (Q2)	6 Months Ended	12 Months Ended
Note 10 - Preferred Stock (Q2)	Jun. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Preferred Stock	10. Preferred Stock On February 6, 2020, the Company entered into a Series C Preferred Stock Purchase Agreement (the “Series C Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of 90 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series C Preferred Stock”), for an aggregate total purchase price of $2,250,000. On January 31, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series C Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate 90 shares of our preferred stock as Series C Convertible Preferred Stock. On May 14, 2020, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Purchase Agreement”) with certain accredited investors for the sale by the Company in a private placement of an aggregate of eight shares of the Company’s Series D Convertible Preferred Stock, par value $0.001 per share at a stated value equal to $25,000 per share (the “Series D Preferred Stock”), for an aggregate total purchase price of $200,000. On May 14, 2020, the Company filed a Certificate of Designation of Preferences, Right and Limitations of Series D Convertible Preferred Stock of the Company with the Nevada Secretary of State which amended our Articles of Incorporation to designate eight shares of our preferred stock as Series D Convertible Preferred Stock. Subject to the terms of the Certificates of Designation, each share of Series C Preferred Stock and Series D Preferred Stock is convertible into shares of Common Stock of the Company at a rate equal to the stated value of such share of Series C Preferred Stock and Series D Preferred Stock of $25,000, divided by the conversion price of $0.14 per share (subject to adjustment from time to time upon the occurrence of certain events as described in the Certificate of Designation). The Certificates of Designation became effective upon filing with the Secretary of State of the State of Nevada. If all outstanding shares of Series C Preferred Stock and Series D Preferred Stock were converted into Common Stock at the original conversion rate, such shares would convert into an aggregate of 17,500,000 shares of Common Stock. Notwithstanding the foregoing, the Series C Preferred Stock and Series D Preferred Stock is not currently convertible into shares of Common Stock because the Company does not currently have sufficient authorized and unissued shares of its Common Stock to permit conversion in full of all issued and outstanding shares of Series C Preferred Stock and Series D Preferred Stock. Accordingly, the Certificate of Designation provides that the Series C Preferred Stock and Series D Preferred Stock is only convertible into Common Stock once the Company amends its Articles of Incorporation to increase its authorized and unissued Common Stock to an amount sufficient to permit such conversion of the Series C Preferred Stock and Series D Preferred Stock. Each investor has agreed in the Purchase Agreement that such investor will, within five business days following such amendment to the Articles of Incorporation, convert all of such investor’s shares of Series C Preferred Stock and Series D Preferred Stock into shares of Common Stock. The Certificate of Designation provides that if the Company has not obtained the approval of its shareholders to amend the Company’s Articles of Incorporation to increase the authorized shares of Common Stock sufficient to permit such conversion, or if such amendment has not otherwise been filed with the Nevada Secretary of State on or before December 31, 2020 (either such event, an “Authorization Failure”), then the Company shall be required to redeem all outstanding shares of Series C Preferred Stock and Series D Preferred Stock for a per-share redemption price, payable in cash in a single installment not later than thirty (30) days following the date of such Authorization Failure, equal to the greater of (a) two hundred percent (200%) of the stated value of such share, and (b)(i) the volume-weighted average sale price of a share of Common Stock reported on the trading market on which the Common Stock is then traded for the thirty (30) consecutive trading days immediately preceding the date of such Authorization Failure, multiplied by (ii) the number of shares of Common Stock such share of Series C Preferred Stock and Series D Preferred Stock would otherwise be convertible into as of such date had such Authorization Failure not occurred. The closing of the private placements occurred on February 6, 2020 and May 14, 2020, respectively, and the preferred stock was recorded in temporary equity on the related condensed consolidated balance sheet at an aggregate value of $2,250,000 and $200,000 respectively. Ninety shares of the Series C Preferred Stock and eight shares of Series D Preferred Stock have been issued as of June 30, 2020. The Company has obtained the approval of its shareholders to amend the Company’s Articles of Incorporation to increase the authorized shares of Common Stock and effected such increase subsequent to June 30, 2020 (see Note 18).	12. The Company’s Articles of Incorporation authorize the issuance of up to 5,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by the board of directors. On January 12, 2016, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series B Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 293 shares of preferred stock, par value $0.001 per share, as Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock has a stated value of $1,000 per share. Holders of Series B Convertible Preferred Stock are entitled to convert each share of Series A Convertible Preferred Stock into 2,000 shares of common stock, provided that after giving effect to such conversion, such holder, together with its affiliates, shall not beneficially own in excess of 9.99% of the number of shares of common stock outstanding (the “Beneficial Ownership Limitation”). On March 14, 2014, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series A Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 6,175 shares of preferred stock, par value $0.001 per share, as Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has a stated value of $1,000 per share.

Note 11 - Equity Transactions (

Note 11 - Equity Transactions (Q2)	6 Months Ended	12 Months Ended
Note 11 - Equity Transactions (Q2)	Jun. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Equity Transactions	11. Equity transactions Warrant Exercises During the three and six months ended June 30, 2020, the Company issued 1,000,000 shares of Common Stock upon the exercise of 1,000,000 Class P Warrants to purchase shares of stock and an exercise price of $0.01 per share under the terms of the respective warrant agreement. Conversion of liabilities During the six months ended June 30, 2020, the Company issued 2,579,789 shares of Common Stock upon the conversion of short term notes payable in the principal and accrued interest amount of $354,729 with the receipt of notices of Class L warrant exercises, all pursuant to the terms of the short term notes payable. Conversion of advances from related parties During the six months ended June 30, 2020, the Company issued 262,811 shares of Common Stock upon the conversion of advances from related parties in the amount of $18,098 with the receipt of notice of Series A Warrant exercise to purchase shares of stock under the terms of the respective warrant agreement. Consulting Agreement In January 2020, the Company entered into a six month consulting agreement for which the fee for the services was to be paid with Common Stock. The number of shares to be paid with Common Stock was 1,000,000 earned upon signing and an additional 1,000,000 upon agreement by both consultant and the Company no later than May 1, 2020. The Company issued 1,000,000 shares in March 2020 and 1,000,000 shares in April 2020. The fair value of the shares of $380,000 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020. The consulting agreement was extended to November 30, 2020 with an additional 2,000,000 Common Stock shares to be issued for services. The Company issued 1,000,000 shares to the consultant in June 2020. The fair value of the shares of $287,500 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020. PIPE Offering On December 11, 2019, the Company entered into a Common Stock Purchase Agreement with certain investors for the sale by the Company in a private placement of an aggregate of up to 21,071,143 shares of its common stock at a purchase price of $0.14 per share. During the six months ended June 30, 2020, the Company issued 1,071,428 shares of Common Stock in conjunction with this offering and received $150,000 in cash proceeds. Stock Option Exercise During the six months ended June 30, 2020, the Company issued 225,000 shares of Common Stock upon the exercise of stock options resulting in net proceeds of $44,250. Litigation Settlement During the six months ended June 30, 2020, the Company issued 200,000 shares of restricted Common Stock upon the settlement of outstanding litigation. The fair value of the shares of $50,000 was recorded as a non-cash general and administrative expense during the six months ended June 30, 2020.	13. Warrant Exercises During the year ended December 31, 2019, the Company issued 19,116,934 shares of Common Stock upon the exercise of 19,116,934 Class L Warrants, Class O Warrants, Class N Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements, in exchange for $1,758,142 in cash proceeds. During the year ended December 31, 2019, the Company issued 21,167,488 shares of Common Stock upon the exercise of 21,167,488 Class L Warrants, Class O Warrants, Class N Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements, in exchange for $1,827,315 in customer deposits and $36,500 in accounts payable. For the year ended December 31, 2018, the Company issued 422,939 shares of common stock upon the exercise of 422,939 Class N Warrants, Series A Warrants and Class O Warrants to purchase shares of stock under the terms of the respective warrant agreements. Cashless Warrant Exercises During the year ended December 31, 2019, the Company issued 4,962,157 shares of Common Stock upon the cashless exercise of 10,423,886 Class N Warrants, Class L Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements. During the year ended December 31, 2019, the Company issued 450,000 shares of Common Stock on a cashless basis upon the exercise of 450,000 Class L Warrants to purchase shares of stock under the terms of the respective warrant agreements. The Common Stock was issued on a cashless basis as a result of email breach in March 2019. The warrant holder sent the funds to an incorrect bank account as a result of the email breach and the Company elected to waive the requirement to cash exercise and allowed the warrant holder to net exercise. For the year ended December 31, 2018, the Company issued 6,395,499 shares of common stock upon the exercise of 7,878,925 Class N Warrants, Series A Warrants and Class O Warrants to purchase shares of stock under the terms of the respective warrant agreements. Conversion of liabilities During the year ended December 31, 2019, the Company issued 38,581,030 shares of Common Stock upon the exercise of 35,677,272 Class L Warrants, Class N Warrants and Series A Warrants, under the terms of the respective warrant agreements and 2,903,758 upon the conversion of interest and bonus shares pursuant to the terms of the short term note payable. The other warrant exercise constituted the conversion of short term note payable in the outstanding amount of $3,559,542 with the receipt of notices of Class L, Class N and Series A warrant exercises, all pursuant to the terms of the short term note payable. During the year ended December 31, 2019, the Company issued 26,666,487 shares of Common Stock due upon exercise of the conversion of convertible promissory notes in the principal and interest amount of $2,933,313 with the receipt of notices of conversion, all pursuant to the terms of the convertible promissory notes. During the year ended December 31, 2019, the Company issued 7,020,455 shares of Common Stock due upon exercise of 6,795,455 Class L and Class N Warrants and 225,000 upon the conversion of bonus share pursuant to the terms of the conversion of line of credit, related parties in the principal amount of $680,000 with the receipt of notices of conversion. For the year ended December 31, 2018, the Company issued 8,497,238 shares of Common Stock upon the conversion of 10% Convertible Promissory Notes in the amount of $902,500 plus accrued interest of $32,197 at the conversion price of $0.11 per share per the terms of the 10% Convertible Promissory Notes agreement. Consulting Agreement In February 2019, the Company entered into a three month consulting agreement for which a portion of the fee for the services was to be paid with Common Stock. The number of shares to be paid with Common Stock was 75,000 earned upon signing and an additional 75,000 upon renewal of the agreement. The Company issued 150,000 shares in December 2019. The fair value of the shares of $28,500 was recorded as a non-cash general and administrative expense during the year ended December 31, 2019. In April 2018, the Company verbally entered into a month-to-month consulting agreement with a consultant for which a portion of the fee for the services was to be paid with Common Stock. The number of shares to be paid with Common Stock was calculated by dividing the amount of the fee to be paid with Common Stock of $4,000 by the Company stock price at the close of business on the eighth business day of each month. The Company issued 74,714 shares of Common Stock for services performed from January through June 2018. $20,000 was recorded as a non-cash general and administrative expense during the year ended December 31, 2018. In May 2017, the Company entered into an agreement with an investment company to provide business advisory and consulting services. The compensation for those services was to be paid in a combination of cash and Common Stock. At December 31, 2017, the Company accrued $120,000 of expense for the services provided. The Common Stock was issued in March and June 2018 in the amount of 533,450 and 15,000 shares, respectively. On October 17, 2018, this agreement was verbally amended to provide for the cash compensation of services performed to be paid with Common Stock. The Common Stock was issued in October 2018 in the amount of 426,176 shares. The $37,500 was recorded as a non-cash general and administrative expense during the year ended December 31, 2018. PIPE Offering On December 11, 2019, the Company entered into a Common Stock Purchase Agreement with certain investors for the sale by the Company in a private placement of an aggregate of up to 21,071,143 shares of its common stockat a purchase price of $0.14 per share. The Company has granted the purchasers indemnification rights with respect to its representations, warranties, covenants and agreements under the purchase agreement. In connection with the agreement, the Company also entered into a registration rights agreement with the purchasers, pursuant to which the Company has agreed to file a registration statement with the SEC by April 30, 2020. During the year ended December 31, 2019, the Company issued 20,000,711 shares of Common Stock in conjunction with this offering and received $2,800,100 in cash proceeds.

Note 12 - Warrants (Q2)

Note 12 - Warrants (Q2)	6 Months Ended	12 Months Ended
Note 12 - Warrants (Q2)	Jun. 30, 2020	Dec. 31, 2019
Warrants [Abstract]
Warrants	12. Warrants A summary of the warrant activity during the six months ended June 30, 2020 is presented as follows: Warrant class Outstanding as of December 31, 2019 Issued Exercised Expired Outstanding as of June 30, 2020 Class K Warrants 7,200,000 — — — 7,200,000 Class O Warrants 909,091 — — — 909,091 Class P Warrants 1,365,000 — (1,000,000 ) (100,000 ) 265,000 Common Stock Purchase Warrants — 1,000,000 — — 1,000,000 9,474,091 1,000,000 (1,000,000 ) (100,000 ) 9,374,091 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January2022 Class P Warrants $ 0.20 June 2024 Common Stock Purchase Warrants $ 0.35 June 2025 The fair value of the Common Stock Purchase Warrants is estimated on the date of grant using the Black-Scholes option pricing model which approximates the binomial model using the following weighted average assumptions for the six months ended June 30, 2020: June 30, 2020 Weighted average contractual terms in years 2.5 Weighted average risk free interest rate 0.47 % Weighted average volatility 107.12 %	14. A summary of warrants as of December 31, 2019 and 2018, is presented as follows: Warrant class Outstanding as of December 31, 2017 Issued Exercised Expired Outstanding as of December 31, 2018 Issued Exercised Expired Outstanding as of December 31, 2019 Class F Warrants 300,000 — — (300,000 ) — — — — — Class G Warrants 1,503,409 — — (1,503,409 ) — — — — — Class H Warrants 1,988,095 — — (1,988,095 ) — — — — — Class I Warrants 1,043,646 — — (1,043,646 ) — — — — — Class K Warrants 7,200,000 — — — 7,200,000 — — — 7,200,000 Class L Warrants 63,898,173 — (6,639,834 ) — 57,258,339 — (57,133,339 ) (125,000 ) — Class N Warrants 13,943,180 17,644,999 (1,136,364 ) — 30,451,815 — (29,951,815 ) (500,000 ) — Class O Warrants 6,540,000 1,509,091 (120,000 ) — 7,929,091 — (6,549,090 ) (470,910 ) 909,091 Class P Warrants — — — — — 1,365,000 — — 1,365,000 Series A Warrants 1,561,348 — (405,666 ) — 1,155,682 — (1,092,936 ) (62,746 ) — 97,977,851 19,154,090 (8,301,864 ) (4,835,150 ) 103,994,927 1,365,000 (94,727,180 ) (1,158,656 ) 9,474,091 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January 2022 Class P Warrants $ 0.01 June 2021 Class P Warrants $ 0.20 June 2024 On January 23, 2019, the Company extended the expiration date to May 1, 2019 for Series A Warrants, Class L Warrants and Class N Warrants. On March 1, 2019, the Company extended the expiration date to June 28, 2019 for Class N Warrants and Class O Warrants. On May 31, 2019, the Company amended the expiration date of the Class N warrants from June 28, 2019 to September 3, 2019. No consideration was given for the warrant extensions. The Company has 1,033,334 Class L Warrants and 62,811 Series A Warrants that have been exercised but the common stock has not yet been issued. The cash for these issuable shares was previously received and recorded in Advances from related parties and Short term notes payable. The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company. The Class K Warrants may be exercised on a physical settlement or on a cashless basis. On June 11, 2019, the Company issued Class P Warrant Agreements to vendors to purchase 265,000 shares of common stock at an exercise price of $0.20 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrants at the grant date was $36,067 and was recorded as selling and marketing expense. The warrants vested upon issuance and expire on June 11, 2024. On June 14, 2019, the Company issued Class P Warrant Agreement to a vendor to purchase up to 1,000,000 shares of common stock at an exercise price of $0.01 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrants at the grant date was $150,800 and was recorded as general and administrative expense. The warrants vested upon issuance and expire on June 14, 2021. On June 24, 2019, the Company issued Class P Warrant Agreement to a vendor to purchase up to 100,000 shares of common stock at an exercise price of $0.20 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrant will be recorded as selling and marketing expense as the warrants are earned per the milestones. The warrants have not yet vested based on milestones and expire on June 24, 2024. In March 2019, the Company entered into a three month consulting agreement for which a portion of the fee for the services was to be paid with a par value warrant for 1,000,000 shares of Common Stock. The Company issued the warrant agreement in June 2019. The $150,800 calculated fair value of the warrants was recorded as a non-cash general and administrative expense during the year ended December 31, 2019. On January 26, 2018, the Company issued Class O Warrant Agreements to a related party vendor to purchase 909,091 shares of common stock at an exercise price of $0.11 per share. Each Class O Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class O Warrants at the grant date was $160,455 and was recorded as general and administrative expense. The warrants vested upon issuance and expire on March 17, 2019. On March 1, 2019, the Company extended the expiration date to June 28, 2019. In 2018, the Company issued Class O Warrant Agreements to a vendor to purchase 600,000 shares of common stock at an exercise price of $0.11 per share. Each Class O Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class O Warrants at their respective grant dates was $159,370 and was recorded as general and administrative expense. The warrants vested upon issuance and expire on March 17, 2019. On March 1, 2019, the Company extended the expiration date to June 28, 2019. The Class K Warrants and the Series A Warrants were derivative financial instruments. The estimated fair value of the Class K Warrants at the date of grant was $36,989 and recorded as debt discount, which is accreted to interest expense through the maturity date of the related notes payable, related parties. The estimated fair values of the Series A Warrants and the Series B Warrants at the date of grant were $557,733 for the warrants issued in conjunction with the 2014 Private Placement and $47,974 for the warrants issued in conjunction with the 18% Convertible Promissory Notes. The fair value of the Series A Warrants and Series B Warrants were recorded as equity issuance costs in 2014, a reduction of additional paid-in capital. The Series B Warrants expired unexercised in March 2015. The estimated fair values were determined using a binomial option pricing model based on various assumptions. The Company’s derivative liabilities have been classified as Level 3 instruments and are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models the Company uses to value the warrants, including the Company’s current common stock price, the remaining life of the warrants of 0.085 years, the volatility of the Company’s common stock price of 102%, and the risk-free interest rate of 2.43% for the year ended December 31, 2019. The remaining life of the warrants which ranged from 0.21 to 8.6 years, the volatility of the Company’s common stock price which ranged from 112% to 134%, and the risk-free interest rate which ranged from 2.43% to 2.64% for the year ended December 31, 2018. In addition, as of the valuation dates, management assessed the probabilities of future financing and other re-pricing events in the binominal valuation models. A summary of the changes in the warrant liability during the years ended December 31, 2019 and 2018, is as follows: Class K Warrants Series A Warrants Total Warrant liability as of December 31, 2017 $ 1,616,000 $ 327,883 $ 1,943,883 Issued — — — Redeemed — (118,838 ) (118,838 ) Change in fair value (74,000 ) 18,624 (55,376 ) Warrant liability as of December 31, 2018 1,542,000 227,669 1,769,669 Change in fair value — (32,359 ) (32,359 ) Expired — (195,310 ) (195,310 ) Reclassification due to Adoption of ASU 2017-11 (see Note 2) (1,542,000 ) — (1,542,000 ) Warrant liability as of December 31, 2019 $ — $ — $ —

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies (Q2)	6 Months Ended	12 Months Ended
Note 13 - Commitments and Contingencies (Q2)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies [Abstract]
Commitments and Contingencies	13. Commitments and contingencies Operating Leases The Company is a party to certain operating leases. The Company has entered into a lease agreement, as amended, for office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis. For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date (except we used the practical expedients and recorded the outstanding operating lease at January 1, 2019) based on the present value of lease payments over the lease term. As the Company’s lease did not provide an implicit interest rate, the Company used the equivalent borrowing rate for a secured financing with the term of that equal to the remaining life of the lease at inception. The lease terms used to calculate the ROU asset and related lease liability did not include options to extend or termination of the lease; there are none and there is no reasonable certainty that the Company would extend the lease at expiration. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as separate lease components. Non-leasing components are not included in the ROU asset. Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 243,251 June 30, 2020 Lease liability - right of use Current portion $ 179,524 Long term portion 92,889 $ 272,413 As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 97,041 2021 197,462 Total lease payments 294,503 Less: Present value adjustment (22,090 ) Lease liability - right of use $ 272,413 As of June 30, 2020, the Company’s operating lease had a weighted average remaining lease term of 1.5 years and a weighted average discount rate of 7%. Rent expense for the three months ended June 30, 2020 and 2019 was $52,346 and $54,698, respectively, and for the six months ended June 30, 2020 and 2019 was $117,876 and $107,536, respectively. Financing Lease For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The present value of the lease payment exceeds 90% of the sales price of the equipment, therefore this lease will be considered a financing lease is included in Property and equipment, net on our Condensed Consolidated Balance Sheets. Lease expense will be recognized as payment of financing lease, depreciation expense and interest expense. Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 515,551 June 30, 2020 Lease liability - right of use Current portion $ 181,371 Long term portion 333,771 $ 515,141 As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 117,297 2021 234,593 2022 199,793 2023 18,388 Total $ 570,071 As of June 30, 2020, the Company’s financing leases had a weighted average remaining lease term of 2.44 years based on annualized base payments expiring through 2023 and a weighted average discount rate of 13.2%. As of June 30, 2020, the Company did not have additional operating or financing leases that have yet commenced. Litigation From time to time, the Company is subject to various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The Company believes that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.	15. Operating Leases The Company is a party to certain operating leases. In August 2016, the Company entered into a lease agreement for 7,500 square feet of office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. On February 1, 2018, the Company entered into an amendment to the lease agreement for an additional 380 square feet of office space for storage which expires on December 31, 2021. On January 2, 2019, the Company entered into a second amendment to the lease agreement for an additional 2,297 square feet of office space for office space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis. For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date (except we used the practical expedients and recorded the outstanding operating lease at January 1, 2019) based on the present value of lease payments over the lease term. As the Company’s lease did not provide an implicit interest rate, the Company used the equivalent borrowing rate for a secured financing with the term of that equal to the remaining life of the lease at inception. The lease terms used to calculate the ROU asset and related lease liability did not include options to extend or termination of the lease; there are none and there is no reasonable certainty that the Company would extend the lease at expiration. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense. The Company has lease agreements which require payments for lease and non-lease components and has elected to account for these as a separate lease components. Non-leasing components are not included in the ROU asset. Right of use assets and Lease Liability – right of use consists of the following: December 31, 2019 Right of use assets $ 323,661 Lease liability - right of use December 31, 2019 Current portion $ 173,270 Long term portion 185,777 $ 359,047 As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 191,713 2021 197,462 Total lease payments 389,175 Less: Present value adjustment (30,128 ) Lease liability - right of use $ 359,047 As of December 31, 2019, the Company’s operating lease had a weighted average remaining lease term of 2 years and a weighted average discount rate of 7%. Rent expense for the years ended December 31, 2019 and 2018, was $225,274 and $157,395, respectively. Financing Lease For leases where the Company is the lessee, ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The present value of the lease payment exceeds 90% of the sales price of the equipment, therefore this lease will be considered a financing lease and is included in Property and equipment, net on our Consolidated Balance Sheets (see Note 4). Lease expense will be recognized as payment of financing lease, depreciation expense and interest expense. Right of use assets and Lease Liability – right of use consists of the following: December 31 2019 Right of use assets $ 418,088 Lease liability - right of use December 31, 2019 Current portion $ 121,634 Long term portion 271,240 $ 392,874 As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 165,078 2021 165,078 2022 130,278 Total $ 460,434 As of December 31, 2019, the Company’s financing leases had a weighted average remaining lease term of 2.8 years based on annualized base payments expiring through 2022 and a weighted average discount rate of 13.2%. As of December 31, 2019, the Company did not have additional operating or financing leases that have yet commenced. Litigation The Company is a defendant in various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. We believe that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.

Note 14 - Revenue (Q2)

Note 14 - Revenue (Q2)	6 Months Ended	12 Months Ended
Note 14 - Revenue (Q2)	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue	14. Revenue The Company accounts for revenue in accordance with ASC 606. Disaggregation of Revenue The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 United States International Total United States International Total Product $ 63,076 $ 6,265 $ 69,341 $ 120,488 $ 100,179 $ 220,667 License fees — — — 6,250 60,558 66,808 Other Revenue 711 13,249 13,960 — 29,501 29,501 $ 63,787 $ 19,514 $ 83,301 $ 126,738 $ 190,238 $ 316,976 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 United States International Total United States International Total Product $ 96,730 $ 47,170 $ 143,900 $ 138,167 $ 147,065 $ 285,232 License fees 10,000 — 10,000 12,500 160,558 173,058 Other Revenue 1,252 76,741 77,993 — 36,649 36,649 $ 107,982 $ 123,911 $ 231,893 $ 150,667 $ 344,272 $ 494,939 Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. One distributor accounted for 86% of revenue for the six months ended June 30, 2020 and 72% of accounts receivable at June 30, 2020. Three distributors accounted for 72% of revenues for the six months ended June 30, 2019 and 49%, 0% and 25% of accounts receivable at June 30, 2019.	16. The Company began accounting for revenue in accordance with ASC 606, which we adopted beginning January 1, 2018, using the modified retrospective method (see Note 2). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. Pursuant to ASC 606, we apply the following the five-step model: 1. Identify the contract(s) with a customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods to be transferred and identifies the payment terms related to these goods, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. 2. Identify the performance obligation(s) in the contract. If a contract promises to transfer more than one good or service to a customer, each good or service constitutes a separate performance obligation if the good or service is distinct or capable of being distinct. 3. Determine the transaction price. The transaction price is the amount of consideration to which the entity expects to be entitled in exchanging the promised goods or services to the customer. 4. Allocate the transaction price to the performance obligations in the contract. For a contract that has more than one performance obligation, an entity should allocate the transaction price to each performance obligation in an amount that depicts the amount of consideration to which an entity expects to be entitled in exchange for satisfying each performance obligation. 5. Recognize revenue when (or as) the Company satisfies a performance obligation. For each performance obligation, an entity should determine whether the entity satisfies the performance obligation at a point in time or over time. Appropriate methods of measuring progress include output methods and input methods. The Company recognizes revenue primarily from the following types of contracts: Product sales Product sales include devices and applicators (new and refurbished). Performance obligations are satisfied at the point in time when the customer obtains control of the goods, which is generally at the point in time that the product is shipped. Procedure revenue from the dermaPACE System is not material to the consolidated financial statements as of December 31, 2019. Licensing transactions Licensing transaction include distribution licenses and intellectual property licenses. Licensing revenue is recognized as the Company satisfies its performance obligations, which may vary with the terms of the licensing agreement. Other activities Other activities primarily include warranties, repairs and billed freight. Device product sales are bundled with an initial one-year warranty and the Company offers a separately priced second-year warranty. The Company allocates the device sales price to the product and the embedded warranty by reference to the stand-alone extended warranty price. Because the warranty represents a stand-ready obligation, revenue is recognized over the time period that the Company satisfies its performance obligations, which is generally the warranty term. Repairs (parts and labor) and billed freight revenue are recognized at the point in time that the service is performed, or the product is shipped, respectively. Disaggregation of Revenue The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the years ended December 31, 2019 and 2018: Year ended December 31, 2019 Year ended December 31, 2018 United States International Total United States International Total Product $ 277,527 $ 367,642 $ 645,169 $ 209,842 $ 739,759 $ 949,601 License fees 125,000 190,557 315,557 25,000 794,696 819,696 Other Revenue 2,450 65,554 68,004 — 80,763 80,763 $ 404,977 $ 623,753 $ 1,028,730 $ 234,842 $ 1,615,218 $ 1,850,060

Note 15 - Related Party Transac

Note 15 - Related Party Transactions (Q2)	6 Months Ended	12 Months Ended
Note 15 - Related Party Transactions (Q2)	Jun. 30, 2020	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	15. Related party transactions During the three and six months ended June 30, 2020 and 2019, the Company recorded $13,105 and $17,678, respectively, and $26,210 and $138,167 respectively, in revenue from an entity owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. Contract liabilities includes a balance at June 30, 2020 and 2019 of $90,943 and $102,899, respectively from this related party.	17. On February 13, 2018, the Company entered into an Agreement for Purchase and Sale, Limited Exclusive Distribution and Royalties, and Servicing and Repairs with Premier Shockwave Wound Care, Inc., a Georgia Corporation (“PSWC”), and Premier Shockwave, Inc., a Georgia Corporation (“PS”). The agreement provides for the purchase by PSWC and PS of dermaPACE System and related equipment sold by the Company and includes a minimum purchase of 100 units over 3 years. The agreement grants PSWC and PS limited but exclusive distribution rights to provide dermaPACE Systems to certain governmental healthcare facilities in exchange for the payment of certain royalties to the Company. No royalties were earned during the year ended December 31, 2018. Under the agreement, the Company is responsible for the servicing and repairs of such dermaPACE Systems and equipment. The agreement also contains provisions whereby in the event of a change of control of the Company (as defined in the agreement), the stockholders of PSWC have the right and option to cause the Company to purchase all of the stock of PSWC, and whereby the Company has the right and option to purchase all issued and outstanding shares of PSWC, in each case based upon certain defined purchase price provisions and other terms. The agreement also contains certain transfer restrictions on the stock of PSWC. Each of PS and PSWC is owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. For the year ended December 31, 2019, the Company recorded $253,013 in product revenue from this related party. The Contract liabilities balance includes a balance of $117,152 from this related party. For the year ended December 31, 2018, the Company recorded $207,457 in product revenue from this related party. The Contract liabilities balance includes a balance of $156,565 from this related party.

Note 16 - Stock-based Compensat

Note 16 - Stock-based Compensation (Q2)	6 Months Ended	12 Months Ended
Note 16 - Stock-based Compensation (Q2)	Jun. 30, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock-Based Compensation	16. Stock-based compensation During the six months ended June 30, 2020, an employee exercised stock options to buy 175,000 shares at an exercise price of $0.21 per share and 50,000 shares at an exercise price of $0.15 per share of the Company’s common stock totaling 225,000 shares. During the six months ended June 30, 2020, 10,000 stock options to purchase the Company’s common stock were forfeited due to termination. The range of exercise prices for options was $0.04 to $2.00 for options outstanding at June 30, 2020 and December 31, 2019, respectively. The aggregate intrinsic value for all vested and exercisable options was $3,034,841 and $981,088 at June 30, 2020 and December 31, 2019, respectively. The weighted average remaining contractual term for outstanding exercisable stock options was 6.1 and 6.6 years as of June 30, 2020 and December 31, 2019, respectively.	18. On November 1, 2010, the Company approved the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. effective as of January 1, 2010 (the “Stock Incentive Plan”). The Stock Incentive Plan permits grants of awards to selected employees, directors and advisors of the Company in the form of restricted stock or options to purchase shares of common stock. Options granted may include non-statutory options as well as qualified incentive stock options. The Stock Incentive Plan is currently administered by the board of directors of the Company. The Stock Incentive Plan gives broad powers to the board of directors of the Company to administer and interpret the particular form and conditions of each option. The stock options granted under the Stock Incentive Plan are non-statutory options which generally vest over a period of up to three years and have a ten year term. The options are granted at an exercise price determined by the board of directors of the Company to be the fair market value of the common stock on the date of the grant. As of December 31, 2019, and 2018, the Stock Incentive Plan reserved a total of 35,000,000 and 35,000,000, respectively, shares of common stock for grant. On December 31, 2019, there were 2,028,281 shares of common stock available for grant under the Stock Incentive Plan. During the year ended December 31, 2019, the Company granted to employees, members of the board of directors and members of the Company’s Medical Advisory Board options to purchase an aggregate of 2,700,000 shares of common stock under a previously issued incentive plan. The options have an exercise price between $0.14 and $0.18 per share for an aggregate grant date value of approximately $333,422. The options vested upon issuance and have a term of ten years. During the year ended December 31, 2018, the Company granted to employees, members of the board of directors and members of the Company’s Medical Advisory Board options to purchase an aggregate of 10,110,000 shares of common stock under a previously issued incentive plan. The options have an exercise price between $0.11 and $0.42 per share for an aggregate grant date value of approximately $2,500,000. The options vested upon issuance and have a term of ten years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the years ended December 31, 2019 and 2018: 2019 2018 Weighted average expected life in years 5.00 5.00 Weighted average risk free interest rate 1.54% - 2.15 % 2.84% - 3.21 % Weighted average volatility 131% - 189 % 134% - 144 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 % The expected life of options granted represent the period of time that options granted are expected to be outstanding and are derived from the contractual terms of the options granted. The risk-free rate for periods within the contractual life of the option is based on the United States Treasury yield curve in effect at the time of the grant. The expected volatility is based on the average volatility of the Company and that of peer group companies similar in size and value to us. We estimate pre-vesting forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The expected dividend yield is based on our historical dividend experience, however, since our inception, we have not declared dividends. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. Ultimately, the total expense recognized over the vesting period will equal the fair value of the awards that actually vest. For the years ended December 31, 2019 and 2018, the Company recognized $333,422 and $2,480,970, respectively, as compensation cost related to options granted. As of December 31, 2019, and 2018, there are no unamortized compensation costs related to options granted. A summary of option activity as of December 31, 2019 and 2018, and the changes during the years then ended, is presented as follows: Options Weighted Average Exercise Price per share Outstanding at December 31, 2017 221,593,385 $ 0.31 Granted 10,110,000 $ 0.25 Exercised — $ — Forfeited or expired — $ — Outstanding at December 31, 2018 31,703,385 $ 0.29 Granted 2,700,000 $ 0.15 Exercised — $ — Forfeited or expired (100,000 ) $ 0.11 Outstanding at December 31, 2019 34,303,385 $ 0.28 Vested and exercisable at December 31, 2019 33,928,385 $ 0.29 The range of exercise prices for options was $0.04 to $2.00 for options outstanding at December 31, 2019 and 2018, respectively. The aggregate intrinsic value for outstanding options was $981,088 and $2,085,866 at December 31, 2019 and 2018, respectively. The aggregate intrinsic value for all vested and exercisable options was $981,088 and $2,085,866 at December 31, 2019 and 2018, respectively. The weighted average remaining contractual term for outstanding exercisable stock options is 6.62 years and 7.4 years as of December 31, 2019 and 2018, respectively. A summary of the Company’s nonvested options as of December 31, 2019 and 2018, and changes during the years then ended, is presented as follows: Options Weighted Average Exercise Price per share Outstanding at December 31, 2017 — $ — Granted 10,110,000 $ 0.25 Vested (10,110,000 ) $ 0.25 Forfeited or expired — $ — Outstanding at December 31, 2018 — $ — Granted 2,700,000 $ 0.15 Vested (2,350,000 ) $ 0.15 Forfeited or expired — $ — Outstanding at December 31, 2019 350,000 $ 0.18

Note 17 - Earnings (Loss) Per S

Note 17 - Earnings (Loss) Per Share (Q2)	6 Months Ended
Note 17 - Earnings (Loss) Per Share (Q2)	Jun. 30, 2020
LOSS PER SHARE:
Earnings (Loss) Per Share	17. Earnings (loss) per share Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following: June 30, 2020 June 30, 2019 Stock options 34,168,385 32,183,385 Preferred stock conversion 17,500,000 — Warrants 9,374,091 68,357,635 Convertible promissory notes 5,227,200 26,004,347 Short term notes payable 2,250,000 — Anti-dilutive equity securities 68,519,676 126,545,367

Note 18 - Subsequent Events (Q2

Note 18 - Subsequent Events (Q2)	6 Months Ended
Note 18 - Subsequent Events (Q2)	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent events On July 23, 2020, in connection with the Company’s 2020 Annual Meeting of Stockholders, the Company’s stockholders approved, among other matters, the following; • An amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of Common Stock from 355,000,000 to 605,000,000; and • To grant the board of directors the authority to effect a reverse split of the Company’s outstanding Common Stock at an exchange rate of between 1-for-10 and 1-for-50, with the exact ratio to be determined by the board of directors in its sole discretion. The amendment to the Company’s Articles of Incorporation to effect the increase in the number of authorized shares of Common Stock was filed with the Secretary of State of Nevada on August 3, 2020. An amendment to the Company’s Articles of Incorporation to effect the reverse stock split have not yet been filed with the Secretary of State of Nevada. On August 6, 2020, the Company entered into an asset purchase agreement with Celularity Inc. pursuant to which the Company acquired Celularity’s UltraMIST assets. The aggregate consideration paid for the assets was $24,000,000, which consisted of (i) a cash payment of $18,890,000, (ii) the issuance of a promissory note to Celularity in the principal amount of $4,000,000, and (iii) a credit of $1,110,000 for the previous payment made by the Company to Celularity pursuant to that certain letter of intent between the Company and Celularity dated June 7, 2020. The closing of the transaction occurred on August 6, 2020. In connection with the asset purchase agreement, on August 6, 2020, the Company entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance® and Interfyl®. The license agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance® in the Field (as defined in the License Agreement) in the Territory (as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl® in the Field in the Territory. The License Agreement has an initial five year term, after which it automatically renews for additional one year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term. On August 6, 2020, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale by the Company in a private placement of an aggregate of 123,550,000 shares of Common Stock and accompanying Class E Warrants to purchase up to an additional 123,550,000 shares of Common Stock, at a purchase price of $0.20 per share and accompanying warrant. The warrants have an exercise price of $0.25 per share and a three year term. The closing of the private placement occurred on August 6, 2020. On August 13, 2020, 24,500,000 shares of Common Stock were issued for net cash proceeds of $4,900,000. On August 15, 2020, 93,425,000 shares of Common Stock were issued for net cash proceeds of $18,685,000. On August 26, 2020, 5,625,000 shares of Common Stock were issued for net cash proceeds of $1,125,000. In connection with the Private Placement, H.C. Wainwright & Co., LLC, as exclusive placement agent for the Private Placement, received warrants to purchase up to 8,934,375 shares of Common Stock on the same terms as the Warrants, a cash fee and certain expenses. On August 6, 2020, the Company entered into a Note and Warrant Purchase and Security Agreement (the “NWPSA”), with the noteholder party thereto and NH Expansion Credit Fund Holdings LP, as agent. The NWPSA provides for (i) the sale and purchase of secured notes in an aggregate original principal amount of $15 million and (ii) the issuance of warrants equal to 2.0% of the fully-diluted Common Stock of the Company as of the issue date. The warrant has an exercise price of $0.01 per share and a 10 year term. On August 6, 2020, the Company entered into a letter agreement (the “HealthTronics Agreement”) with HealthTronics, Inc. (“HealthTronics”), pursuant to which the Company paid off all outstanding debt due and owed to HealthTronics. Pursuant to the HealthTronics Agreement, as consideration for the extinguishment of the debt due and owed to HealthTronics, (i) the Company paid to HealthTronics an amount in cash equal to $4,000,000, (ii) HealthTronics exercised all of its outstanding Class K Warrants to purchase 7,200,000 shares of Common Stock, (iii) the Company issued to HealthTronics a convertible promissory note in the principal amount of $1,372,743, and (iv) the Company and HealthTronics entered into a Securities Purchase Agreement dated August 6, 2020 pursuant to which the Company issued to HealthTronics an aggregate of 8,275,235 shares of Common Stock and an accompanying warrant to purchase up to an additional 8,275,235 shares of Common Stock. The warrant has an exercise price of $0.25 per share and a three year term. On August 26, 2020, 8,275,235 shares of Common Stock were issued pursuant to the Securities Purchase Agreement. On September 11, 2020, 7,200,000 shares of Common Stock were issued per the exercise of outstanding Class K Warrants. On August 6, 2020, the Company repaid all amounts owing to LGH Investments, LLC pursuant to that certain promissory note issued by the Company to LGH Investments, LLC dated June 5, 2020 in the original principal amount of $1,210,000 (the “LGH Note”). As a result, all obligations of the Company under the LGH Note have been terminated. The Warrants issued to LGH Investments, as more fully described in Note 7 to our condensed consolidated financial statements, contain certain anti-dilution adjustment provisions with respect to subsequent issuances of securities by the Company at a price below the exercise price of such warrants. As a result of certain dilutive issuances of securities by the Company during the third quarter of 2020, the exercise price of the Warrants decreased to $0.20 per share and the number of shares subject to the Warrants increased to 1,750,000 shares as of September 30, 2020. On September 11, 2020, 200,000 shares of Common Stock were issued as a part of the Securities Purchase Agreement. On August 6, 2020, the Company terminated that certain line of credit agreement with A. Michael Stolarski, a member of the Company’s board of directors, dated December 29, 2017 and as amended November 12, 2018, in the amount of $1,000,000 (the “Stolarski Line of Credit”). As consideration for the termination of the Stolarski Line of Credit, the Company issued to A. Michael Stolarski a convertible promissory note in the principal amount of $223,511 (the “Stolarski Note”). The Stolarski Note has a maturity date of August 6, 2021 and accrues interest at a rate equal to 12.0% per annum. In the event that the Stolarski Note has not been repaid prior to January 1, 2021, the holder may elect to convert the outstanding principal amount plus any accrued by unpaid interest thereon into shares of Common Stock at a conversion price of $0.10 per share. On August 26, 2020, 2,250,000 shares of Common Stock were issued in payment of Short Term Notes Payable. On August 26, 2020 and September 28, 2020 5,000,000 shares of Common Stock were issued for services rendered for consulting. On September 20, 2020, 17,499,958 shares of Common Stock were issued as a result of the conversion of outstanding Series C and Series D Preferred Stock. The Company has evaluated its subsequent events from June 30, 2020 through the date these condensed consolidated financial statements were issued, and has determined that there are no additional subsequent events required to be disclosed.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (FY) (Policies)	6 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (FY) (Policies)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Foreign currency translation		Foreign currency translation -
Principles of consolidation	Principles of consolidation	Principles of consolidation -
Estimates	Estimates	Estimates -
Reclassifications		Reclassifications –
Cash and cash equivalents		Cash and cash equivalents -
Concentration of credit risk and limited suppliers		Concentration of credit risk and limited suppliers - Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. Three distributors and partners accounted for 18%, 15% and 12% of revenues for the year ended December 31, 2019, and 0%, 0% and 22% of accounts receivable at December 31, 2019. Three distributors and partners accounted for 33%, 23% and 11% of revenues for the year ended December 31, 2018, and 24%, 60% and 7.7% of accounts receivable at December 31, 2018. The Company expects that actions taken in response to the COVID-19 pandemic will also negatively impact sales of dermaPACE and orthoPACE. Some hospitals are restricting procedures that are not deemed to be life-threatening at this time. Because dermaPACE and orthoPACE are not deemed to be life-threatening procedures, we expect that the number of procedures performed will decline. A decrease in the number of procedures performed will adversely affect our expected revenues and our financial results. The Company depends on suppliers for product component materials and other components that are subject to stringent regulatory requirements. The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may be difficult to arrange a replacement supplier because certain of these materials may only be available from one or a limited number of sources. In addition, our suppliers could be disrupted by conditions related to COVID-19, or other epidemics Establishing additional or replacement suppliers for these materials may take a substantial period of time, as certain of these suppliers must be approved by regulatory authorities.
Accounts receivable		Accounts receivable -
Inventory	Inventory	Inventory -
Depreciation of property and equipment		Depreciation of property and equipment -
Fair value of financial instruments		Fair value of financial instruments - The Company has adopted ASC 820-10, Fair Value Measurements The ASC 820-10 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 - Unobservable inputs that are not corroborated by market data, therefore requiring the Company to develop its own assumptions. The Company recognizes all derivatives on the balance sheet at fair value. The fair value of the warrant liability is determined based on a lattice solution, binomial approach pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and risk-free interest rate, and therefore is classified within level 3 of the fair value hierarchy. (See Note 14). The Company’s notes payable approximate fair value because the terms are substantially similar to comparable debt in the marketplace.
Impairment of long-lived assets		Impairment of long-lived assets –
Revenue recognition		Revenue recognition - Shipping and handling costs - Shipping charges billed to customers are included in revenues. Shipping and handling costs incurred have been recorded in cost of revenues.
Income taxes		Income taxes - A provision of ASC 740, Income Taxes The Company will recognize in income tax expense, interest and penalties related to income tax matters. For the years ended December 31, 2019 and 2018, the Company did not have any amounts recorded for interest and penalties.
Loss per share		Loss per share - 2019 2018 Stock options 34,303,385 31,703,385 Warrants 9,474,091 103,994,927 Convertible promissory notes 2,250,000 24,112,518 Anti-dilutive equity securities 46,027,476 159,810,830
Comprehensive income		Comprehensive income –
Stock-based compensation		Stock-based compensation -
Research and development		Research and development -
Liabilities related to warrants issued [Text Block]		Liabilities related to warrants issued –
Warrants related to debt issued [Text Block]		Warrants related to debt issued –
Beneficial conversion feature on convertible debt		Beneficial conversion feature on convertible debt -
Recently issued or adopted accounting standards		Recently issued or adopted accounting standards - Leases (Topic 842). In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which was subsequently revised by ASU 2018-19. The ASU introduces a new model for assessing impairment of most financial assets. Entities will be required to use a forward-looking expected loss model, which will replace the current incurred loss model, which will result in earlier recognition of allowance for losses. The ASU is effective for annual reporting periods beginning after January 2023 with early adoption permitted. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480): Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Q2) (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of consolidation	Principles of consolidation -
Estimates	Estimates	Estimates -
Inventory	Inventory	Inventory -
Preferred Stock	Preferred stock Distinguishing Liabilities from Equity
Sequencing Policy	Sequencing policy

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (FY) (Tables)	6 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (FY) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of antidilutive securities	Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following: June 30, 2020 June 30, 2019 Stock options 34,168,385 32,183,385 Preferred stock conversion 17,500,000 — Warrants 9,374,091 68,357,635 Convertible promissory notes 5,227,200 26,004,347 Short term notes payable 2,250,000 — Anti-dilutive equity securities 68,519,676 126,545,367	Anti-dilutive equity securities consist of the following at December 31, 2019 and 2018, respectively: 2019 2018 Stock options 34,303,385 31,703,385 Warrants 9,474,091 103,994,927 Convertible promissory notes 2,250,000 24,112,518 Anti-dilutive equity securities 46,027,476 159,810,830

Inventory (FY) (Tables)

Inventory (FY) (Tables)	12 Months Ended
Inventory (FY) (Tables)	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory	Inventory consists of the following at December 31, 2019 and 2018: 2019 2018 Inventory - finished goods $ 357,265 $ 188,116 Inventory – parts 185,690 169,704 Total inventory $ 542,955 $ 357,820

Property and Equipment (FY) (Ta

Property and Equipment (FY) (Tables)	12 Months Ended
Property and Equipment (FY) (Tables)	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment consists of the following at December 31, 2019 and 2018: 2019 2018 Finance lease right of use asset $ 451,561 $ — Machines and equipment 281,633 240,295 Office and computer equipment 201,841 196,150 Devices 81,059 81,059 Software 38,126 38,126 Furniture and fixtures 22,929 16,019 Other assets 2,259 2,259 Total 1,079,408 573,908 Accumulated depreciation (567,366 ) (496,153 ) Net property and equipment $ 512,042 $ 77,755

Accrued Expenses (FY) (Tables)

Accrued Expenses (FY) (Tables)	6 Months Ended	12 Months Ended
Accrued Expenses (FY) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Accrued Liabilities [Abstract]
Accrued expenses	Accrued expenses consist of the following: June 30, 2020 December 31, 2019 Accrued board of director’s fees $ 416,667 $ 400,000 Accrued legal and professional fees 200,000 134,970 Accrued executive severance 313,000 154,000 Accrued travel 120,000 120,000 Accrued outside services 106,233 108,033 Accrued inventory 50,275 167,050 Accrued clinical study expenses 13,650 13,650 Accrued other 1,389 13,406 $ 1,221,214 $ 1,111,109	Accrued expenses consist of the following at December 31, 2019 and 2018: 2019 2018 Accrued board of director's fees $ 400,000 $ 200,000 Accrued inventory 167,050 — Accrued executive severance 154,000 136,000 Accrued travel 120,000 58,993 Accrued outside services 108,033 115,118 Accrued legal and professional fees 134,970 — Accrued clinical study expenses 13,650 13,650 Accrued related party advance — 101,137 Deferred rent — 44,623 Accrued computer equipment — 8,752 Accrued other 13,406 11,007 $ 1,111,109 $ 689,280

Contract Liabilities (FY) (Tabl

Contract Liabilities (FY) (Tables)	6 Months Ended	12 Months Ended
Contract Liabilities (FY) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Contract liabilities	Contract liabilities consist of the following: June 30, 2020 December 31, 2019 Service agreement $ 91,746 $ 133,510 License fees 500,000 500,000 Other 13,791 6,291 Total Contract liabilities 605,537 639,801 Non-Current (551,755 ) (573,224 ) Total Current $ 53,782 $ 66,577	Contract liabilities consist of the following: December 31, 2019 December 31, 2018 Service agreement $ 133,510 $ 57,365 Deposit on product — 92,950 License fees 500,000 — Other 6,291 28,218 Total Contract liabilities 639,801 178,533 Non-Current (573,224 ) (46,736 ) Total Current $ 66,577 $ 131,797

Convertible Promissory Notes _2

Convertible Promissory Notes (FY) (Tables)	12 Months Ended
Convertible Promissory Notes (FY) (Tables)	Dec. 31, 2019
Debt Disclosure [Abstract]
Fair value of Class N warrants	The calculated fair value of the Class N Warrants was determined using the Black-Scholes pricing model based on the following assumptions: December 31, 2018 Weighted average contractual term in years 1.13-1.19 Weighted average risk free interest rate 1.98% - 2.15 % Weighted average volatility 94% - 99 % Forfeiture rate 0.0 % Expected dividend yield 0.0 %
Warrant agreement assumptions [Text Block]	In 2018, the Company recorded $35,396 debt discount for the beneficial conversion feature of the 10% Convertible Promissory Note and $36,104 in debt discount for the discount on the Class N Warrant agreement to be amortized over the life of the 10% Convertible Promissory Note. December 31, 2018 Weighted average contractual term in years 1.14 Weighted average risk free interest rate 1.96 % Weighted average volatility 98.2 % Forfeiture rate 0.0 % Expected dividend yield 0.0 %

Warrants (FY) (Tables)

Warrants (FY) (Tables)	6 Months Ended	12 Months Ended
Warrants (FY) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Summary of the warrant activity	A summary of the warrant activity during the six months ended June 30, 2020 is presented as follows: Warrant class Outstanding as of December 31, 2019 Issued Exercised Expired Outstanding as of June 30, 2020 Class K Warrants 7,200,000 — — — 7,200,000 Class O Warrants 909,091 — — — 909,091 Class P Warrants 1,365,000 — (1,000,000 ) (100,000 ) 265,000 Common Stock Purchase Warrants — 1,000,000 — — 1,000,000 9,474,091 1,000,000 (1,000,000 ) (100,000 ) 9,374,091	A summary of warrants as of December 31, 2019 and 2018, is presented as follows: Warrant class Outstanding as of December 31, 2017 Issued Exercised Expired Outstanding as of December 31, 2018 Issued Exercised Expired Outstanding as of December 31, 2019 Class F Warrants 300,000 — — (300,000 ) — — — — — Class G Warrants 1,503,409 — — (1,503,409 ) — — — — — Class H Warrants 1,988,095 — — (1,988,095 ) — — — — — Class I Warrants 1,043,646 — — (1,043,646 ) — — — — — Class K Warrants 7,200,000 — — — 7,200,000 — — — 7,200,000 Class L Warrants 63,898,173 — (6,639,834 ) — 57,258,339 — (57,133,339 ) (125,000 ) — Class N Warrants 13,943,180 17,644,999 (1,136,364 ) — 30,451,815 — (29,951,815 ) (500,000 ) — Class O Warrants 6,540,000 1,509,091 (120,000 ) — 7,929,091 — (6,549,090 ) (470,910 ) 909,091 Class P Warrants — — — — — 1,365,000 — — 1,365,000 Series A Warrants 1,561,348 — (405,666 ) — 1,155,682 — (1,092,936 ) (62,746 ) — 97,977,851 19,154,090 (8,301,864 ) (4,835,150 ) 103,994,927 1,365,000 (94,727,180 ) (1,158,656 ) 9,474,091
Summary of the warrant exercise price per share [Text Block]		A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January 2022 Class P Warrants $ 0.01 June 2021 Class P Warrants $ 0.20 June 2024
Summary of changes in warrant liability		A summary of the changes in the warrant liability during the years ended December 31, 2019 and 2018, is as follows: Class K Warrants Series A Warrants Total Warrant liability as of December 31, 2017 $ 1,616,000 $ 327,883 $ 1,943,883 Issued — — — Redeemed — (118,838 ) (118,838 ) Change in fair value (74,000 ) 18,624 (55,376 ) Warrant liability as of December 31, 2018 1,542,000 227,669 1,769,669 Change in fair value — (32,359 ) (32,359 ) Expired — (195,310 ) (195,310 ) Reclassification due to Adoption of ASU 2017-11 (see Note 2) (1,542,000 ) — (1,542,000 ) Warrant liability as of December 31, 2019 $ — $ — $ —

Commitments and Contingencies_2

Commitments and Contingencies (FY) (Tables)	6 Months Ended	12 Months Ended
Commitments and Contingencies (FY) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies [Abstract]
Right of use assets and lease liability	Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 243,251 June 30, 2020 Lease liability - right of use Current portion $ 179,524 Long term portion 92,889 $ 272,413	Right of use assets and Lease Liability – right of use consists of the following: December 31, 2019 Right of use assets $ 323,661 Lease liability - right of use December 31, 2019 Current portion $ 173,270 Long term portion 185,777 $ 359,047 Financing Lease Right of use assets and Lease Liability – right of use consists of the following: December 31 2019 Right of use assets $ 418,088 Lease liability - right of use December 31, 2019 Current portion $ 121,634 Long term portion 271,240 $ 392,874
Lease liability maturities	As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 97,041 2021 197,462 Total lease payments 294,503 Less: Present value adjustment (22,090 ) Lease liability - right of use $ 272,413	As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 191,713 2021 197,462 Total lease payments 389,175 Less: Present value adjustment (30,128 ) Lease liability - right of use $ 359,047
Finance Lease, Liability, Maturity	As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 117,297 2021 234,593 2022 199,793 2023 18,388 Total $ 570,071	As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 165,078 2021 165,078 2022 130,278 Total $ 460,434

Revenue (FY) (Tables)

Revenue (FY) (Tables)	6 Months Ended	12 Months Ended
Revenue (FY) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	The following table presents revenue from contracts with customers for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 United States International Total United States International Total Product $ 63,076 $ 6,265 $ 69,341 $ 120,488 $ 100,179 $ 220,667 License fees — — — 6,250 60,558 66,808 Other Revenue 711 13,249 13,960 — 29,501 29,501 $ 63,787 $ 19,514 $ 83,301 $ 126,738 $ 190,238 $ 316,976 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 United States International Total United States International Total Product $ 96,730 $ 47,170 $ 143,900 $ 138,167 $ 147,065 $ 285,232 License fees 10,000 — 10,000 12,500 160,558 173,058 Other Revenue 1,252 76,741 77,993 — 36,649 36,649 $ 107,982 $ 123,911 $ 231,893 $ 150,667 $ 344,272 $ 494,939	The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the years ended December 31, 2019 and 2018: Year ended December 31, 2019 Year ended December 31, 2018 United States International Total United States International Total Product $ 277,527 $ 367,642 $ 645,169 $ 209,842 $ 739,759 $ 949,601 License fees 125,000 190,557 315,557 25,000 794,696 819,696 Other Revenue 2,450 65,554 68,004 — 80,763 80,763 $ 404,977 $ 623,753 $ 1,028,730 $ 234,842 $ 1,615,218 $ 1,850,060

Stock-Based Compensation (FY) (

Stock-Based Compensation (FY) (Tables)	12 Months Ended
Stock-Based Compensation (FY) (Tables)	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Schedule of assumptions	The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the years ended December 31, 2019 and 2018: 2019 2018 Weighted average expected life in years 5.00 5.00 Weighted average risk free interest rate 1.54% - 2.15 % 2.84% - 3.21 % Weighted average volatility 131% - 189 % 134% - 144 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 %
Summary of option activity	A summary of option activity as of December 31, 2019 and 2018, and the changes during the years then ended, is presented as follows: Options Weighted Average Exercise Price per share Outstanding at December 31, 2017 221,593,385 $ 0.31 Granted 10,110,000 $ 0.25 Exercised — $ — Forfeited or expired — $ — Outstanding at December 31, 2018 31,703,385 $ 0.29 Granted 2,700,000 $ 0.15 Exercised — $ — Forfeited or expired (100,000 ) $ 0.11 Outstanding at December 31, 2019 34,303,385 $ 0.28 Vested and exercisable at December 31, 2019 33,928,385 $ 0.29
Schedule of other share-based compensation, activity	A summary of the Company’s nonvested options as of December 31, 2019 and 2018, and changes during the years then ended, is presented as follows: Options Weighted Average Exercise Price per share Outstanding at December 31, 2017 — $ — Granted 10,110,000 $ 0.25 Vested (10,110,000 ) $ 0.25 Forfeited or expired — $ — Outstanding at December 31, 2018 — $ — Granted 2,700,000 $ 0.15 Vested (2,350,000 ) $ 0.15 Forfeited or expired — $ — Outstanding at December 31, 2019 350,000 $ 0.18

Income Taxes (FY) (Tables)

Income Taxes (FY) (Tables)	12 Months Ended
Income Taxes (FY) (Tables)	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense (benefit)	The components of net loss before provision for income taxes for the years ended December 31, 2019 and 2018 are as follows: 2019 2018 Domestic $ (10,595,457 ) $ (12,031,115 ) Foreign 165,618 399,721 Net loss before provision for income taxes $ (10,429,839 ) $ (11,631,394 ) The income tax provision (benefit) from continuing operations consists of the following at December 31, 2019 and 2018: 2019 2018 Current: Federal $ — $ — State — — Foreign — — — — Deferred: Federal (2,300,997 ) (2,157,035 ) State (409,313 ) (383,705 ) Foreign (3,676 ) 2,673 Change in valuation allowance 2,713,986 2,538,067 $ — $ —
Effective income tax reconciliation	The income tax provision (benefit) amounts differ from the amounts computed by applying the United States federal statutory income tax rate of 21% for the years ended December 31, 2019 and 2018 to pretax loss from operations as a result of the following for the years ended December 31, 2019 and 2018: 2019 2018 Tax benefit at statutory rate $ (2,071,322 ) $ (2,442,593 ) Increase (reduction) in income taxes resulting from: State income benefit, net of federal benefit (291,082 ) (343,257 ) Non-deductible loss on warrant valuation adjustment (47,810 ) (11,629 ) Income (loss) from foreign subsidiaries (2,595 ) 6,699 Change in valuation allowance 2,713,986 2,538,067 Other (301,177 ) 252,713 Income tax expense (benefit) $ — $ —
Schedule of deferred tax assets and liabilities	The tax effects of temporary differences that give rise to the deferred tax assets at December 31, 2019 and 2018 are as follows: 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 23,727,093 $ 21,320,935 Net operating loss carryforwards – foreign 20,227 16,551 Excess of tax basis over book value of property and equipment 4,240 (2,229 ) Excess of tax basis over book value of intangible assets 73,705 146,943 Stock-based compensation 1,607,841 1,520,209 Accrued employee compensation 357,869 83,393 Captialized equity costs 49,471 49,471 Inventory reserve 38,323 29,510 25,878,769 23,164,783 Valuation allowance (25,878,769 ) (23,164,783 ) Net deferred tax assets $ — $ —

Note 4 - Accrued Expenses (Q2)

Note 4 - Accrued Expenses (Q2) (Tables)	6 Months Ended	12 Months Ended
Note 4 - Accrued Expenses (Q2) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued expenses	Accrued expenses consist of the following: June 30, 2020 December 31, 2019 Accrued board of director’s fees $ 416,667 $ 400,000 Accrued legal and professional fees 200,000 134,970 Accrued executive severance 313,000 154,000 Accrued travel 120,000 120,000 Accrued outside services 106,233 108,033 Accrued inventory 50,275 167,050 Accrued clinical study expenses 13,650 13,650 Accrued other 1,389 13,406 $ 1,221,214 $ 1,111,109	Accrued expenses consist of the following at December 31, 2019 and 2018: 2019 2018 Accrued board of director's fees $ 400,000 $ 200,000 Accrued inventory 167,050 — Accrued executive severance 154,000 136,000 Accrued travel 120,000 58,993 Accrued outside services 108,033 115,118 Accrued legal and professional fees 134,970 — Accrued clinical study expenses 13,650 13,650 Accrued related party advance — 101,137 Deferred rent — 44,623 Accrued computer equipment — 8,752 Accrued other 13,406 11,007 $ 1,111,109 $ 689,280

Note 5 - Contract Liabilities_2

Note 5 - Contract Liabilities (Q2) (Tables)	6 Months Ended	12 Months Ended
Note 5 - Contract Liabilities (Q2) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Contract with Customer, Liability [Abstract]
Contract liabilities	Contract liabilities consist of the following: June 30, 2020 December 31, 2019 Service agreement $ 91,746 $ 133,510 License fees 500,000 500,000 Other 13,791 6,291 Total Contract liabilities 605,537 639,801 Non-Current (551,755 ) (573,224 ) Total Current $ 53,782 $ 66,577	Contract liabilities consist of the following: December 31, 2019 December 31, 2018 Service agreement $ 133,510 $ 57,365 Deposit on product — 92,950 License fees 500,000 — Other 6,291 28,218 Total Contract liabilities 639,801 178,533 Non-Current (573,224 ) (46,736 ) Total Current $ 66,577 $ 131,797

Note 12 - Warrants (Q2) (Tables

Note 12 - Warrants (Q2) (Tables)	6 Months Ended	12 Months Ended
Note 12 - Warrants (Q2) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Warrants [Abstract]
Warrant activity	A summary of the warrant activity during the six months ended June 30, 2020 is presented as follows: Warrant class Outstanding as of December 31, 2019 Issued Exercised Expired Outstanding as of June 30, 2020 Class K Warrants 7,200,000 — — — 7,200,000 Class O Warrants 909,091 — — — 909,091 Class P Warrants 1,365,000 — (1,000,000 ) (100,000 ) 265,000 Common Stock Purchase Warrants — 1,000,000 — — 1,000,000 9,474,091 1,000,000 (1,000,000 ) (100,000 ) 9,374,091	A summary of warrants as of December 31, 2019 and 2018, is presented as follows: Warrant class Outstanding as of December 31, 2017 Issued Exercised Expired Outstanding as of December 31, 2018 Issued Exercised Expired Outstanding as of December 31, 2019 Class F Warrants 300,000 — — (300,000 ) — — — — — Class G Warrants 1,503,409 — — (1,503,409 ) — — — — — Class H Warrants 1,988,095 — — (1,988,095 ) — — — — — Class I Warrants 1,043,646 — — (1,043,646 ) — — — — — Class K Warrants 7,200,000 — — — 7,200,000 — — — 7,200,000 Class L Warrants 63,898,173 — (6,639,834 ) — 57,258,339 — (57,133,339 ) (125,000 ) — Class N Warrants 13,943,180 17,644,999 (1,136,364 ) — 30,451,815 — (29,951,815 ) (500,000 ) — Class O Warrants 6,540,000 1,509,091 (120,000 ) — 7,929,091 — (6,549,090 ) (470,910 ) 909,091 Class P Warrants — — — — — 1,365,000 — — 1,365,000 Series A Warrants 1,561,348 — (405,666 ) — 1,155,682 — (1,092,936 ) (62,746 ) — 97,977,851 19,154,090 (8,301,864 ) (4,835,150 ) 103,994,927 1,365,000 (94,727,180 ) (1,158,656 ) 9,474,091
Warrant exercise price per share	A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise price/share Expiration date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class O Warrants $ 0.11 January2022 Class P Warrants $ 0.20 June 2024 Common Stock Purchase Warrants $ 0.35 June 2025
Fair Value of Common Stock Purchase Warrants	The fair value of the Common Stock Purchase Warrants is estimated on the date of grant using the Black-Scholes option pricing model which approximates the binomial model using the following weighted average assumptions for the six months ended June 30, 2020: June 30, 2020 Weighted average contractual terms in years 2.5 Weighted average risk free interest rate 0.47 % Weighted average volatility 107.12 %

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Q2) (Tables)	6 Months Ended	12 Months Ended
Note 13 - Commitments and Contingencies (Q2) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies [Abstract]
Operating right of use assets and lease liabilities	Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 243,251 June 30, 2020 Lease liability - right of use Current portion $ 179,524 Long term portion 92,889 $ 272,413	Right of use assets and Lease Liability – right of use consists of the following: December 31, 2019 Right of use assets $ 323,661 Lease liability - right of use December 31, 2019 Current portion $ 173,270 Long term portion 185,777 $ 359,047 Financing Lease Right of use assets and Lease Liability – right of use consists of the following: December 31 2019 Right of use assets $ 418,088 Lease liability - right of use December 31, 2019 Current portion $ 121,634 Long term portion 271,240 $ 392,874
Operating lease liability maturities	As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 97,041 2021 197,462 Total lease payments 294,503 Less: Present value adjustment (22,090 ) Lease liability - right of use $ 272,413	As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 191,713 2021 197,462 Total lease payments 389,175 Less: Present value adjustment (30,128 ) Lease liability - right of use $ 359,047
Finance right of use assets and lease liabilities	Right of use assets and Lease liability – right of use consist of the following: June 30, 2020 Right of use assets $ 515,551 June 30, 2020 Lease liability - right of use Current portion $ 181,371 Long term portion 333,771 $ 515,141
Finance lease liability maturities	As of June 30, 2020, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 (remainder) $ 117,297 2021 234,593 2022 199,793 2023 18,388 Total $ 570,071	As of December 31, 2019, the maturities of the Company’s lease liability – right of use which have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2020 $ 165,078 2021 165,078 2022 130,278 Total $ 460,434

Note 14 - Revenue (Q2) (Tables)

Note 14 - Revenue (Q2) (Tables)	6 Months Ended	12 Months Ended
Note 14 - Revenue (Q2) (Tables)	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	The following table presents revenue from contracts with customers for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 United States International Total United States International Total Product $ 63,076 $ 6,265 $ 69,341 $ 120,488 $ 100,179 $ 220,667 License fees — — — 6,250 60,558 66,808 Other Revenue 711 13,249 13,960 — 29,501 29,501 $ 63,787 $ 19,514 $ 83,301 $ 126,738 $ 190,238 $ 316,976 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019 United States International Total United States International Total Product $ 96,730 $ 47,170 $ 143,900 $ 138,167 $ 147,065 $ 285,232 License fees 10,000 — 10,000 12,500 160,558 173,058 Other Revenue 1,252 76,741 77,993 — 36,649 36,649 $ 107,982 $ 123,911 $ 231,893 $ 150,667 $ 344,272 $ 494,939	The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the years ended December 31, 2019 and 2018: Year ended December 31, 2019 Year ended December 31, 2018 United States International Total United States International Total Product $ 277,527 $ 367,642 $ 645,169 $ 209,842 $ 739,759 $ 949,601 License fees 125,000 190,557 315,557 25,000 794,696 819,696 Other Revenue 2,450 65,554 68,004 — 80,763 80,763 $ 404,977 $ 623,753 $ 1,028,730 $ 234,842 $ 1,615,218 $ 1,850,060

Note 17 - Earnings (Loss) Per_2

Note 17 - Earnings (Loss) Per Share (Q2) (Tables)	6 Months Ended	12 Months Ended
Note 17 - Earnings (Loss) Per Share (Q2) (Tables)	Jun. 30, 2020	Dec. 31, 2019
LOSS PER SHARE:
Antidilutive shares	Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following: June 30, 2020 June 30, 2019 Stock options 34,168,385 32,183,385 Preferred stock conversion 17,500,000 — Warrants 9,374,091 68,357,635 Convertible promissory notes 5,227,200 26,004,347 Short term notes payable 2,250,000 — Anti-dilutive equity securities 68,519,676 126,545,367	Anti-dilutive equity securities consist of the following at December 31, 2019 and 2018, respectively: 2019 2018 Stock options 34,303,385 31,703,385 Warrants 9,474,091 103,994,927 Convertible promissory notes 2,250,000 24,112,518 Anti-dilutive equity securities 46,027,476 159,810,830

Description of the Business a_2

Description of the Business and Going Concern and Management's Plans (Narrative) (FY) (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)Study	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of double-blinded randomized clinical studies \| Study					2
Net loss	$ (3,633,020)	$ (2,734,431)	$ (6,634,168)	$ (4,931,748)	$ (10,429,839)	$ (11,631,394)
Net cash used in operating activities			(4,511,968)	$ (3,386,634)	(6,410,758)	(3,621,172)
Working capital deficit					(9,910,994)
Cash and cash equivalents	$ 430,606		$ 430,606		$ 1,760,455	$ 364,549	$ 730,184

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (FY) (Details) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Anti-dilutive equity securities	68,519,676	126,545,367	46,027,476	159,810,830
Stock Options
Anti-dilutive equity securities	34,168,385	32,183,385	34,303,385	31,703,385
Warrant
Anti-dilutive equity securities	9,374,091	68,357,635	9,474,091	103,994,927
Convertible Promissory Notes
Anti-dilutive equity securities			2,250,000	24,112,518

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Narrative) (FY) (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)Distributor	Dec. 31, 2018USD ($)Distributor
Number of distributors and partners \| Distributor					3	3
Income taxes [Abstract]
Interest and penalties					$ 0	$ 0
Recently issued or adopted accounting standards [Abstract]
Right of use assets	$ 243,251		$ 243,251		323,661	0
Operating Lease liability - right of use	272,413		272,413		359,047
Additional paid-in capital	117,326,629		117,326,629		115,457,808	101,153,882
Retained earnings	(132,386,958)		(132,386,958)		(125,752,956)	(116,602,778)
Warrant liability	$ 0	$ (195,310)	$ 0	$ (227,669)	$ (227,669)	(55,376)
ASU No. 2016-02
Recently issued or adopted accounting standards [Abstract]
Right of use assets						520,000
Operating Lease liability - right of use						520,000
ASU No. 2017-11
Recently issued or adopted accounting standards [Abstract]
Additional paid-in capital						262,339
Retained earnings						1,279,661
Warrant liability						$ (1,542,000)
Machines and equipment
Depreciation of property and equipment [Abstract]
Estimated useful lives					3 years
Devices \| Minimum
Depreciation of property and equipment [Abstract]
Estimated useful lives					5 years
Devices \| Maximum
Depreciation of property and equipment [Abstract]
Estimated useful lives					15 years
Office and computer equipment
Depreciation of property and equipment [Abstract]
Estimated useful lives					3 years
Furniture and fixtures
Depreciation of property and equipment [Abstract]
Estimated useful lives					3 years
Software
Depreciation of property and equipment [Abstract]
Estimated useful lives					2 years
Distributor 1 \| Revenues
Concentration risk			86.00%		18.00%	33.00%
Distributor 1 \| Accounts Receivable
Concentration risk			72.00%	49.00%	0.00%	24.00%
Distributor 2 \| Revenues
Concentration risk					15.00%	23.00%
Distributor 2 \| Accounts Receivable
Concentration risk				0.00%	0.00%	60.00%
Distributor 3 \| Revenues
Concentration risk					12.00%	11.00%
Distributor 3 \| Accounts Receivable
Concentration risk				25.00%	22.00%	7.70%

Inventory (FY) (Details)

Inventory (FY) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory - finished goods	$ 367,988	$ 357,265	$ 188,116
Inventory - parts	283,356	185,690	169,704
Net inventory	$ 651,344	$ 542,955	$ 357,820

Property and Equipment (FY) (De

Property and Equipment (FY) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross		$ 1,079,408	$ 573,908
Accumulated depreciation		(567,366)	(496,153)
Property and equipment, net	$ 591,064	512,042	77,755
Finance lease right of use asset
Property and equipment, gross		451,561	0
Machinery and Equipment
Property and equipment, gross		281,633	240,295
Office Equipment
Property and equipment, gross		201,841	196,150
Devices
Property and equipment, gross		81,059	81,059
Software
Property and equipment, gross		38,126	38,126
Furniture and Fixtures Gross
Property and equipment, gross		22,929	16,019
Other Assets
Property and equipment, gross		$ 2,259	$ 2,259

Property and Equipment (Narrati

Property and Equipment (Narrative) (FY) (Details) - USD ($)	6 Months Ended		12 Months Ended
Property and Equipment (Narrative) (FY) (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 117,789	$ 17,812	$ 71,213	$ 22,332

Accrued Expenses (FY) (Details)

Accrued Expenses (FY) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities [Abstract]
Accrued board of directors' fees	$ 416,667	$ 400,000	$ 200,000
Accrued inventory	50,275	167,050	0
Accrued executive severance	163,000	154,000	136,000
Accrued travel	120,000	120,000	58,993
Accrued outside services	106,233	108,033	115,118
Accrued legal and professional fees	200,000	134,970	0
Accrued clinical study expenses	13,650	13,650	13,650
Accrued related party advance		0	101,137
Deferred rent		0	44,623
Accrued computer equipment		0	8,752
Accrued other	1,389	13,406	11,007
Total accrued expenses	$ 1,071,214	$ 1,111,109	$ 689,280

Accrued Expenses (Narrative) (F

Accrued Expenses (Narrative) (FY) (Details)	Oct. 10, 2018USD ($)	Dec. 31, 2019USD ($)Payment	Dec. 31, 2014USD ($)Payment	Jun. 30, 2020USD ($)	Dec. 31, 2018USD ($)
Related Party Transactions [Abstract]
Number of bonus payments achieved \| Payment			3
Accrued severance executive payment			$ 300,000
Notes payable, related party principal		$ 5,372,743		$ 5,372,743	$ 5,372,743
Former Executive \| Severance Agreement
Related Party Transactions [Abstract]
Base salary payable period		6 months
Accrued bonus payable upon each bonus payment event		$ 100,000
Number of bonus payments \| Payment		4
President
Related Party Transactions [Abstract]
Notes payable, related party principal	$ 100,000
Related party interest rate	5.00%

Contract Liabilities (FY) (Deta

Contract Liabilities (FY) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Total contract liabilities	$ 639,801	$ 178,533
Non-current contract liabilities	(573,224)	(46,736)
Current contract liabilities	66,577	131,797
Service agreement
Total contract liabilities	133,510	57,365
Deposit on product
Total contract liabilities	0	92,950
License fees
Total contract liabilities	500,000	0
Other
Total contract liabilities	$ 6,291	$ 28,218

Contract Liabilities (Narrative

Contract Liabilities (Narrative) (FY) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Remaining performance obligations	$ 551,755	$ 66,577

Advances From Related Parties_2

Advances From Related Parties (Narrative) (FY) (Details)	Jan. 10, 2018USD ($)Note	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Payables and Accruals [Abstract]
Advances from related parties		$ 2,055,414	$ 0
Advances from related parties to equity		1,827,316
Advances from related parties to short term notes		210,000
Advances from related parties		18,098
Advances payable converted to convertible promissory notes	$ 310,000	$ 0	$ 310,000
Number of conversion of 10% convertible promissory notes \| Note	2
Percentage of advance payable converted into convertible promissory notes	10.00%

Line of Credit, Related Parti_2

Line of Credit, Related Parties (Narrative) (FY) (Details) - USD ($)	Nov. 12, 2018	Dec. 29, 2017	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2020
Debt Disclosure [Abstract]
Line of credit	$ 1,000,000	$ 370,000
Interest rate	6.00%	6.00%
Line of credit facility, increase (decrease) amount			$ (680,000)
Conversion of common stock			7,020,455
Payment on purchase from related party			$ 121,000
Deposit from future purchases from related party			90,000
Line of credit, related parties			212,388	$ 883,224	$ 222,164
Line of credit facility, remaining borrowing capacity			861,500
Interest expense on line of credit			$ 40,164	$ 33,724

Short Term Notes Payable (Narra

Short Term Notes Payable (Narrative) (FY) (Details) - USD ($)	Dec. 13, 2019	Apr. 17, 2019	Apr. 10, 2019	Jan. 30, 2019	Jun. 26, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2020
Notes Payable [Abstract]
Short term notes payable	$ 210,000		$ 1,215,000	$ 1,215,000	$ 1,870,525	$ 587,233	$ 1,883,163	$ 210,000
Issuance of common stock	2,250,000
Interest rate			5.00%	5.00%	5.00%		5.00%
Conversion of short term notes payable to equity						$ 3,559,542	$ 0
Short term notes payable, interest rate, as a result of default						10.00%
Interest expense, short term notes payable		$ 629,963				$ 838,613	$ 12,638
Officer and Director
Notes Payable [Abstract]
Principal and accrued interest are due and payable						$ 233,028
Class L and Class N Warrant
Notes Payable [Abstract]
Percentage of issuance of bonus		10.00%
Class N Warrant and Series A Warrant
Notes Payable [Abstract]
Cost basis of exercise price		10.00%

Convertible Promissory Notes _3

Convertible Promissory Notes (FY) (Details) - Class N Warrants	12 Months Ended
	Dec. 31, 2018
Forfeiture rate	0.00%
Expected dividend yield	0.00%
Minimum
Weighted average contractual term in years	1 year 1 month 17 days
Weighted average risk free interest rate	1.98%
Weighted average volatility	94.00%
Maximum
Weighted average contractual term in years	1 year 2 months 8 days
Weighted average risk free interest rate	2.15%
Weighted average volatility	99.00%

Convertible Promissory Notes _4

Convertible Promissory Notes (FY) (1) (Details)	6 Months Ended	12 Months Ended
Convertible Promissory Notes (FY) (1) (Details)	Jun. 30, 2020	Dec. 31, 2018
Debt Instruments [Abstract]
Weighted average contractual term in years	2 years 6 months
Weighted average volatility	107.12%
10% Convertible Promissory Note [Member]
Debt Instruments [Abstract]
Weighted average contractual term in years		1 year 1 month 20 days
Weighted average risk free interest rate		1.96%
Weighted average volatility		98.20%
Forfeiture rate		0.00%
Expected dividend yield		0.00%

Convertible Promissory Notes (N

Convertible Promissory Notes (Narrative) (FY) (Details) - USD ($)	Oct. 04, 2018	Aug. 02, 2018	Jun. 29, 2018	Jan. 29, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Instruments [Abstract]
Interest expense, convertible promissory notes					$ 168,941	$ 790,178	$ 187,673	$ 938,439	$ 1,147,986	$ 3,708,562
Convertible promissory notes									0	$ 2,652,377
Debt discount									$ 0
Class N Warrants
Debt Instruments [Abstract]
Warrant exercise price										$ 0.11	$ 0.11
Issuance of warrants	1,242,954		1,242,955							10,599,999
Interest expense, convertible promissory notes	$ 91,233		$ 417,633
Debt discount										$ 36,104
Class N Warrants \| Accredited Investor
Debt Instruments [Abstract]
Issuance of warrants				650,000
Class N Warrants \| Kevin A. Richardson II
Debt Instruments [Abstract]
Issuance of warrants										2,363,636
Class N Warrants \| A. Michael Stolarski
Debt Instruments [Abstract]
Issuance of warrants										1,545,455
10% Convertible Promissory Note
Debt Instruments [Abstract]
Interest rate											10.00%
Debt instrument term									6 months
Interest expense, convertible promissory notes									$ 280,936	$ 3,565,198
Default interest rate		18.00%
Convertible promissory notes beneficial conversion feature									$ 0	0
Debt discount										35,396
10% Convertible Promissory Note \| Accredited Investor
Debt Instruments [Abstract]
Convertible promissory notes				$ 71,500
10% Convertible Promissory Note \| Kevin A. Richardson II
Debt Instruments [Abstract]
Convertible promissory notes										260,000
10% Convertible Promissory Note \| A. Michael Stolarski
Debt Instruments [Abstract]
Convertible promissory notes										$ 170,000

Notes Payable, Related Partie_2

Notes Payable, Related Parties (Narrative) (FY) (Details) - USD ($)	Apr. 10, 2019	Jan. 30, 2019	Jun. 26, 2018	Jan. 02, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Notes Payable [Abstract]
Increase in related party interest rate in event of default occurs	5.00%	5.00%	5.00%							5.00%
Notes payable, related party principal					$ 5,372,743		$ 5,372,743		$ 5,372,743	$ 5,372,743
Notes payable, related party debt discount									0
Notes payable, related party accrued interest					2,229,713		2,229,713		1,859,977	1,171,782
Notes payable, related party interest expense					$ 187,172	$ 112,984	$ 369,736	$ 332,671	$ 688,195	$ 787,586
Notes Payable \| HealthTronics, Inc.
Notes Payable [Abstract]
Notes payable, related party interest rate									8.00%
Increase in related party interest rate in event of default occurs									2.00%
Related party, accrued interest rate				10.00%
Proceeds from related parties through issuance or sale of equity securities									20.00%

Preferred Stock (Narrative) (FY

Preferred Stock (Narrative) (FY) (Details) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 12, 2016	Mar. 14, 2014
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Number preferred stock, shares designated to convert into convertible stock				293	6,175
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Maximum
Beneficial ownership percentage of common stock outstanding				9.99%
Series A Convertible Preferred Stock
Preferred stock, shares authorized		6,175	6,175
Preferred stock, par value		$ 0.001	$ 0.001		$ 1,000
Common stock, shares issued upon conversion of each convertible preferred stock				2,000
Series B Convertible Preferred Stock
Preferred stock, shares authorized		293	293
Preferred stock, par value		$ 0.001	$ 0.001	$ 1,000

Equity Transactions (Narrative)

Equity Transactions (Narrative) (FY) (Details)

Dec. 13, 2019shares

Dec. 11, 2019$ / sharesshares

Mar. 31, 2019

Feb. 28, 2019shares

Apr. 30, 2018USD ($)BusinessDay

Jun. 30, 2020USD ($)shares

Mar. 31, 2020USD ($)

Jun. 30, 2020USD ($)shares

Jun. 30, 2019USD ($)

Dec. 31, 2019USD ($)shares

Dec. 31, 2018USD ($)$ / sharesshares

Oct. 31, 2018shares

Jun. 30, 2018shares

Mar. 31, 2018shares

Dec. 31, 2017USD ($)

Warrant Exercises [Abstract]

Issuance of common stock

2,250,000

Proceeds from warrant exercise | $

$ 10,000

$ 1,403,257

$ 1,758,142

$ 40,728

Conversion of short term notes payable to equity | $

3,559,542

Conversion of convertible promissory notes to equity | $

2,933,313

Conversion of line of credit, related party to equity | $

$ 680,000

Convertible promissory notes value | $

$ 902,500

Consulting agreement period

3 months

Issuance of common stock

302,119,428

293,780,400

155,665,138

Shares issued for services | $

$ 517,500

$ 200,000

$ 28,500

$ 181,500

Private Placement

Warrant Exercises [Abstract]

Issuance of common stock

21,071,143

PIPE Offering

Warrant Exercises [Abstract]

Issuance of common stock

20,000,711

Cash proceeds | $

$ 2,800,100

PIPE Offering | Private Placement

Warrant Exercises [Abstract]

Common stock, purchase price | $ / shares

$ 0.14

PIPE Offering | Private Placement | Maximum

Warrant Exercises [Abstract]

Issuance of common stock

21,071,143

Consulting Agreement | Fee and Services

Warrant Exercises [Abstract]

Issuance of common stock

75,000

74,714

Additional common stock to be issued upon renewing agreement

75,000

Shares issued

150,000

Shares issued for services | $

$ 4,000

$ 28,500

20,000

Business stock price of each month, closing day | BusinessDay

Accrued expenses | $

$ 120,000

Consulting Agreement | Advisory and Consulting Services

Warrant Exercises [Abstract]

Issuance of common stock

426,176

15,000

533,450

Shares issued for services | $

$ 37,500

Conversion of Short Term Notes Payable

Warrant Exercises [Abstract]

Issuance of common stock

2,903,758

Conversion of Convertible Promissory Notes

Warrant Exercises [Abstract]

Issuance of common stock

26,666,487

Conversion of Line of Credit

Warrant Exercises [Abstract]

Issuance of common stock

225,000

Conversion of 10% Convertible Promissory Notes

Warrant Exercises [Abstract]

Issuance of common stock

8,497,238

Convertible instrument, interest rate

10.00%

Accrued interest | $

$ 32,197

Conversion price | $ / shares

$ 0.11

Warrant Exercises 1

Warrant Exercises [Abstract]

Issuance of common stock

19,116,934

Proceeds from warrant exercise | $

$ 1,758,142

Warrant Exercises 2

Warrant Exercises [Abstract]

Issuance of common stock

21,167,488

Warrant Exercises 3

Warrant Exercises [Abstract]

Issuance of common stock

422,939

Cashless Warrant Exercises 1

Warrant Exercises [Abstract]

Issuance of common stock

4,962,157

Cashless Warrant Exercises 2

Warrant Exercises [Abstract]

Issuance of common stock

450,000

Cashless Warrant Exercises 3

Warrant Exercises [Abstract]

Issuance of common stock

6,395,499

Class L, Class N and Series A Warrant Exercises

Warrant Exercises [Abstract]

Issuance of common stock

38,581,030

Exercise of warrants

35,677,272

Class L, Class N and Series A Warrant Exercises | Conversion of Short Term Notes Payable

Warrant Exercises [Abstract]

Conversion of short term notes payable to equity | $

$ 3,559,542

Class L and Class N Warrants Exercises

Warrant Exercises [Abstract]

Issuance of common stock

7,020,455

Exercise of warrants

6,795,455

Warrants to Purchase Common Stock | Warrant Exercises 1

Warrant Exercises [Abstract]

Exercise of warrants

19,116,934

Warrants to Purchase Common Stock | Warrant Exercises 2

Warrant Exercises [Abstract]

Exercise of warrants

21,167,488

Warrants to Purchase Common Stock | Warrant Exercises 3

Warrant Exercises [Abstract]

Exercise of warrants

422,939

Warrants to Purchase Common Stock | Cashless Warrant Exercises 1

Warrant Exercises [Abstract]

Exercise of warrants

10,423,886

Warrants to Purchase Common Stock | Cashless Warrant Exercises 2

Warrant Exercises [Abstract]

Exercise of warrants

450,000

Warrants to Purchase Common Stock | Cashless Warrant Exercises 3

Warrant Exercises [Abstract]

Exercise of warrants

7,878,925

Customer Deposits | Warrant Exercises 2

Warrant Exercises [Abstract]

Warrant, exchange price value | $

$ 1,827,315

Accounts Payable | Warrant Exercises 2

Warrant Exercises [Abstract]

Warrant, exchange price value | $

$ 36,500

Warrants (FY) (Details)

Warrants (FY) (Details) - shares	6 Months Ended	12 Months Ended
Warrants (FY) (Details) - shares	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Warrants outstanding, beginning	9,474,091	103,994,927	97,977,851
Warrants issued	1,000,000	1,365,000	19,154,090
Warrants exercised	(1,000,000)	(94,727,180)	(8,301,864)
Warrants expired	(100,000)	(1,158,656)	(4,835,150)
Warrants outstanding, ending	9,374,091	9,474,091	103,994,927
Class F Warrants
Warrants outstanding, beginning	0	0	300,000
Warrants issued			0
Warrants exercised			0
Warrants expired			(300,000)
Warrants outstanding, ending		0	0
Class G Warrants
Warrants outstanding, beginning	0	0	1,503,409
Warrants issued			0
Warrants exercised			0
Warrants expired			(1,503,409)
Warrants outstanding, ending		0	0
Class H Warrants
Warrants outstanding, beginning	0	0	1,988,095
Warrants issued			0
Warrants exercised			0
Warrants expired			(1,988,095)
Warrants outstanding, ending		0	0
Class I Warrants
Warrants outstanding, beginning	0	0	1,043,646
Warrants issued			0
Warrants exercised			0
Warrants expired			(1,043,646)
Warrants outstanding, ending		0	0
Class K Warrants
Warrants outstanding, beginning	7,200,000	7,200,000	7,200,000
Warrants issued	0	0	0
Warrants exercised	0	0	0
Warrants expired	0	0	0
Warrants outstanding, ending	7,200,000	7,200,000	7,200,000
Class L Warrants
Warrants outstanding, beginning	0	57,258,339	63,898,173
Warrants issued		0	0
Warrants exercised		(57,133,339)	(6,639,834)
Warrants expired		(125,000)	0
Warrants outstanding, ending		0	57,258,339
Class N Warrants
Warrants outstanding, beginning	0	30,451,815	13,943,180
Warrants issued		0	17,644,999
Warrants exercised		(29,951,815)	(1,136,364)
Warrants expired		(500,000)	0
Warrants outstanding, ending		0	30,451,815
Class O Warrants
Warrants outstanding, beginning	909,091	7,929,091	6,540,000
Warrants issued	0	0	1,509,091
Warrants exercised	0	(6,549,090)	(120,000)
Warrants expired	0	(470,910)	0
Warrants outstanding, ending	909,091	909,091	7,929,091
Series P Warrants
Warrants outstanding, beginning	1,365,000	0	0
Warrants issued		1,365,000	0
Warrants exercised		0	0
Warrants expired		0	0
Warrants outstanding, ending		1,365,000	0
Series A Warrants
Warrants outstanding, beginning	0	1,155,682	1,561,348
Warrants issued		0	0
Warrants exercised		(1,092,936)	(405,666)
Warrants expired		(62,746)	0
Warrants outstanding, ending		0	1,155,682

Warrants (Narrative) (FY) (Deta

Warrants (Narrative) (FY) (Details)

Jun. 24, 2019$ / sharesshares

Jun. 14, 2019USD ($)$ / sharesshares

Jun. 11, 2019USD ($)$ / sharesshares

May 31, 2019

Mar. 01, 2019

Jan. 23, 2019

Jan. 26, 2018USD ($)$ / sharesshares

Mar. 31, 2019USD ($)shares

Feb. 28, 2019

Jun. 30, 2020$ / shares

Dec. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Warrants issued to purchase shares of common stock

1,000,000

Estimated fair value of warrants | $

$ 150,800

Consulting agreement period

3 months

Warrant agreement issued period

Jun. 30,
2019

Warrants remaining life

1 month 1 day

Common stock, volatility rate

1.02

Common stock, risk free interest rate

0.0243

Minimum

Warrants remaining life

2 months 16 days

Common stock, volatility rate

1.12

Common stock, risk free interest rate

0.0243

Maximum

Warrants remaining life

8 years 7 months 6 days

Common stock, volatility rate

1.34

Common stock, risk free interest rate

0.0264

Convertible Promissory Notes

Estimated fair value of warrants | $

$ 47,974

Interest rate

18.00%

Class K Warrants

Warrant exercise price/share | $ / shares

$ 0.08

Warrant expiration date

June 2025

Estimated fair value of warrants | $

$ 36,989

Class K (2) Warrants

Warrant exercise price/share | $ / shares

$ 0.11

Warrant expiration date

August 2027

Class O Warrants

Warrant exercise price/share | $ / shares

$ 0.11

Warrant expiration date

January 2022

March 17, 2019

Warrant extended expiration date

Jun. 28,
2019

Warrants issued to purchase shares of common stock

600,000

Number of common stock can purchase for each of warrant right

Estimated fair value of warrants | $

$ 159,370

Class O Warrants | Related Party Vendor

Warrant exercise price/share | $ / shares

$ 0.11

Warrant expiration date

March 17, 2019

Warrant extended expiration date

Jun. 28,
2019

Warrants issued to purchase shares of common stock

909,091

Number of common stock can purchase for each of warrant right

Estimated fair value of warrants | $

$ 160,455

Class P Warrants

Warrant exercise price/share | $ / shares

$ 0.20

$ 0.01

$ 0.20

$ 0.01

Warrant expiration date

June 24, 2024

June 14, 2021

June 11, 2024

June 2024

June 2021

Warrants issued to purchase shares of common stock

100,000

1,000,000

265,000

Number of common stock can purchase for each of warrant right

Estimated fair value of warrants | $

$ 150,800

$ 36,067

Class P (2) Warrants

Warrant exercise price/share | $ / shares

$ 0.20

Warrant expiration date

June 2024

Series A Warrants, Class L Warrants and Class N Warrants

Warrant extended expiration date

May 1,
2019

Class N Warrants and Class O Warrants

Warrant extended expiration date

Jun. 28,
2019

Class N Warrants

Warrant extended expiration date

Sep. 3,
2019

Class L Warrants

Warrants exercised, stock not yet issued

1,033,334

Series A Warrants

Warrants exercised, stock not yet issued

62,811

Series A Warrants | 2014 Private Placement

Estimated fair value of warrants | $

$ 557,733

Series B Warrants | 2014 Private Placement

Estimated fair value of warrants | $

$ 557,733

Warrants (FY) (1) (Details)

Warrants (FY) (1) (Details) - USD ($)	12 Months Ended
Warrants (FY) (1) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Warrant liability, beginning	$ 1,769,669	$ 1,943,883
Issued	0	0
Redeemed	(195,310)	(118,838)
Change in fair value	$ (32,359)	$ (55,376)
Reclassification due to Adoption of ASU 2017-11 (see Note 2)	(1,542,000)	0
Warrant liability, ending	$ 0	$ 1,769,669
Class K Warrants
Warrant liability, beginning	1,542,000	1,616,000
Issued	0	0
Redeemed	0	0
Change in fair value	$ 0	$ (74,000)
Reclassification due to Adoption of ASU 2017-11 (see Note 2)	(1,542,000)	0
Warrant liability, ending	$ 0	$ 1,542,000
Series A Warrants
Warrant liability, beginning	227,669	327,883
Issued	0	0
Redeemed	(195,310)	(118,838)
Change in fair value	$ (32,359)	$ 18,624
Reclassification due to Adoption of ASU 2017-11 (see Note 2)	0	0
Warrant liability, ending	$ 0	$ 227,669

Commitments and Contingencies_3

Commitments and Contingencies (FY) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies [Abstract]
Operating lease - Right of use assets	$ 243,251	$ 323,661	$ 0
Operating Lease liability - right of use, current	179,524	173,270	0
Operating Lease liability - right of use, noncurrent	92,889	185,777	0
Operating Lease liability - right of use	272,413	359,047
Finance Lease, Right-of-Use Asset	515,551	418,088
Finance Lease liability - right of use, current	181,371	121,634	0
Finance Lease liability - right of use, noncurrent	333,771	271,240	$ 0
Lease liability - right of use	$ 515,141	$ 392,874

Commitments and Contingencies_4

Commitments and Contingencies (FY) (1) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies [Abstract]
2020	$ 197,462	$ 191,713
2021		197,462
Total lease payments	294,503	389,175
Less: imputed interest	(22,090)	(30,128)
Total operating lease liability	$ 272,413	$ 359,047

Commitments and Contingencies_5

Commitments and Contingencies (FY) (2) (Details)	Dec. 31, 2019USD ($)
Commitments and Contingencies [Abstract]
2020	$ 165,078
2021	165,078
2022	130,278
Total	$ 460,434

Commitments and Contingencies_6

Commitments and Contingencies (Narrative) (FY) (Details)	Jan. 02, 2019ft²	Feb. 01, 2018ft²	Aug. 31, 2016ft²	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Lessee, Lease, Description [Line Items]
Monthly rent payable								$ 14,651
Percentage of rent adjusted on annual basis								3.00%
Operating lease liability-right of use remaining lease term								1 year
Operating lease weighted average remaining lease term				1 year 6 months		1 year 6 months		2 years
Operating lease discount rate				7.00%		7.00%		7.00%
Rent expense				$ 52,346	$ 54,698	$ 117,876	$ 107,536	$ 225,274	$ 157,395
Percentage of lease payment in which the present value exceeds the sale price								90.00%
Financing lease liability-right of use remaining lease term								1 year
Financing lease weighted average remaining lease term				2 years 5 months 8 days		2 years 5 months 8 days		2 years 9 months 18 days
Financing lease discount rate				13.20%		13.20%		13.20%
Office Space
Lessee, Lease, Description [Line Items]
Area of property \| ft²	2,297	380	7,500
Lease expiration date	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2021

Revenue (Narrative) (FY) (Detai

Revenue (Narrative) (FY) (Details)	12 Months Ended
Revenue (Narrative) (FY) (Details)	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Initial warranty period of device product	1 year
Extended warranty period of device product	1 year

Revenue (FY) (Details)

Revenue (FY) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Revenue (FY) (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 83,301	$ 316,976	$ 231,893	$ 494,939	$ 1,028,730	$ 1,850,060
United States
Revenues	63,787	126,738	107,982	150,667	404,977	234,842
International
Revenues	19,514	190,238	123,911	344,272	623,753	1,615,218
Product
Revenues	69,341	220,667	143,900	285,232	645,169	949,601
Product \| United States
Revenues	63,076	120,488	96,730	138,167	277,527	209,842
Product \| International
Revenues	6,265	100,179	47,170	147,065	367,642	739,759
License fees
Revenues	0	66,808	10,000	173,058	315,557	819,696
License fees \| United States
Revenues	0	6,250	10,000	12,500	125,000	25,000
License fees \| International
Revenues	0	60,558	0	160,558	190,557	794,696
Other
Revenues	13,960	29,501	77,993	36,649	68,004	80,763
Other \| United States
Revenues	711	0	1,252	0	2,450	0
Other \| International
Revenues	$ 13,249	$ 29,501	$ 76,741	$ 36,649	$ 65,554	$ 80,763

Related Party Transactions (Nar

Related Party Transactions (Narrative) (FY) (Details)	12 Months Ended
Related Party Transactions (Narrative) (FY) (Details)	Dec. 31, 2019USD ($)PurchaseUnits	Dec. 31, 2018USD ($)	Jun. 30, 2020USD ($)
Related Party Transaction [Abstract]
Minimum number of units purchased by related party \| PurchaseUnits	100
Purchase of units over period by related party	3 years
Royalties earned		$ 0
Contract liabilities with related party	$ 639,801		$ 605,537
A. Michael Stolarski
Related Party Transaction [Abstract]
Revenue from this related party	253,013	207,457
Contract liabilities with related party	$ 117,152	$ 156,565

Stock-Based Compensation (FY)_2

Stock-Based Compensation (FY) (Details) - Stock Option	12 Months Ended
Stock-Based Compensation (FY) (Details) - Stock Option	Dec. 31, 2019	Dec. 31, 2018
Weighted average expected life in years	5 years	5 years
Forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%
Minimum
Weighted average risk free interest rate	1.54%	2.84%
Weighted average volatility	131.00%	134.00%
Maximum
Weighted average risk free interest rate	2.15%	3.21%
Weighted average volatility	189.00%	144.00%

Stock-Based Compensation (FY)_3

Stock-Based Compensation (FY) (1) (Details) - $ / shares	6 Months Ended	12 Months Ended
Stock-Based Compensation (FY) (1) (Details) - $ / shares	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Noncash Expense [Abstract]
Options outstanding, beginning	34,303,385	31,703,385	21,593,385
Options granted		2,700,000	10,110,000
Options exercised	225,000	0	0
Options forfeited or expired	(10,000)	(100,000)	0
Options outstanding, ending		34,303,385	31,703,385
Options exercisable		33,928,385
Weighted average exercise price, outstanding, beginning	$ 0.28	$ 0.29	$ 0.31
Weighted average exercise price, granted		0.15	0.25
Weighted average exercise price, exercised		0	0
Weighted average exercise price, forfeited or expired		0.11	0
Weighted average exercise price, outstanding, ending		0.28	$ 0.29
Weighted average exercise price, exercisable		$ 0.29

Stock-Based Compensation (FY)_4

Stock-Based Compensation (FY) (2) (Details) - $ / shares	12 Months Ended
Stock-Based Compensation (FY) (2) (Details) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Noncash Expense [Abstract]
Nonvested options outstanding, beginning	0	0
Nonvested options granted	2,700,000	10,110,000
Nonvested options vested	(2,350,000)	(10,110,000)
Nonvested options forfeited or expired	0	0
Nonvested options outstanding, ending	350,000	0
Weighted average exercise price, outstanding, beginning	$ 0	$ 0
Weighted average exercise price, granted	0.15	0.25
Weighted average exercise price, vested	0.15	0.25
Weighted average exercise price, forfeited or expired	0	0
Weighted average exercise price, outstanding, ending	$ 0.18	$ 0

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (FY) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Issuance of common stock		2,700,000	10,110,000
Compensation cost related to options granted		$ 333,422	$ 2,480,970
Range of exercise prices for options, lower range limit	$ 0.04	$ 0.04	$ 0.04
Range of exercise prices for options, upper range limit	$ 2	$ 2	$ 2
Aggregate intrinsic value for outstanding options	$ 3,034,841	$ 981,088	$ 2,085,866
Aggregate intrinsic value for vested and exercisable options	$ 3,034,841	$ 981,088	$ 2,085,866
Weighted average remaining contractual term for outstanding exercisable stock options	6 years 1 month 6 days	6 years 7 months 13 days	7 years 4 months 24 days
Stock Incentive Plan
Non-statutory options expiration period		10 years
Stock options term		10 years	10 years
Common stock shares reserved		35,000,000	35,000,000
Shares available for grant		2,028,281
Issuance of common stock		2,700,000	10,110,000
Range of exercise prices for options, lower range limit		$ 0.14	$ 0.11
Range of exercise prices for options, upper range limit		$ 0.18	$ 0.42
Aggregate intrinsic value for outstanding options		$ 333,422	$ 2,500,000
Aggregate intrinsic value for vested and exercisable options		$ 333,422	$ 2,500,000
Stock Incentive Plan \| Maximum
Non-statutory options vesting period		3 years

Joint Ventures (FY) (Details)

Joint Ventures (FY) (Details)	Aug. 31, 2018USD ($)	Jun. 22, 2018USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)Director	Dec. 13, 2019USD ($)	Sep. 06, 2019USD ($)	Nov. 09, 2018	Sep. 21, 2018USD ($)	Jan. 12, 2016
Maximum
Joint Venture Agreements [Abstract]
Ownership percentage									9.99%
JV Agreement
Joint Venture Agreements [Abstract]
Ownership percentage							50.00%
Number of board of directors \| Director				5
Number of board of directors designated by company \| Director				2
Agreement
Joint Venture Agreements [Abstract]
Partnership fee					$ 600,000
Partnership fee received				$ 500,000
Contingent amount				$ 100,000
Agreement \| Minimum
Joint Venture Agreements [Abstract]
Period for regulatory approval				12 months
Agreement \| Maximum
Joint Venture Agreements [Abstract]
Period for regulatory approval				18 months
FKS \| Taiwan
Joint Venture Agreements [Abstract]
Fee for initial distribution rights received		$ 500,000
FKS \| SEA Region
Joint Venture Agreements [Abstract]
Fee for initial distribution rights received			$ 500,000
FKS \| JV Agreement
Joint Venture Agreements [Abstract]
Number of board of directors \| Director				2
Outstanding amount for equipment delivered								$ 63,275
Penalty fee for early termination				$ 50,000
Outstanding amount credited after return of equipment						$ 63,275
MundiMed
Joint Venture Agreements [Abstract]
Period for upfront distribution fee payments				18 months
Aggregate amount of upfront distribution fee payments received	$ 372,222

Income Taxes (FY) (Details)

Income Taxes (FY) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (FY) (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Current:
Federal					$ 0	$ 0
State					0	0
Foreign					0	0
Total					0	0
Deferred:
Federal					(2,300,997)	(2,157,035)
State					(409,313)	(383,705)
Foreign					(3,676)	2,673
Change in valuation allowance					2,713,986	2,538,067
Total					0	0
Components of Net Loss Before Provision for Income Taxes [Abstract]
Domestic					(10,595,457)	(12,031,115)
Foreign					165,618	399,721
NET LOSS	$ (3,633,020)	$ (2,734,431)	$ (6,634,168)	$ (4,931,748)	(10,429,839)	(11,631,394)
Tax benefit at statutory rate					$ (2,071,322)	$ (2,442,593)

Income Taxes (FY) (1) (Details)

Income Taxes (FY) (1) (Details) - USD ($)	12 Months Ended
Income Taxes (FY) (1) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Percentage of federal statutory income tax rate	21.00%	21.00%
Tax benefit at statutory rate	$ (2,071,322)	$ (2,442,593)
Increase (reduction) in income taxes resulting from:
State income benefit, net of federal benefit	(291,082)	(343,257)
Non-deductible loss on warrant valuation adjustment	(47,810)	(11,629)
Income (loss) from foreign subsidiaries	(2,595)	6,699
Change in valuation allowance	2,713,986	2,538,067
Other	(301,177)	252,713
Income tax expense (benefit)	$ 0	$ 0

Income Taxes (FY) (2) (Details)

Income Taxes (FY) (2) (Details) - USD ($)	12 Months Ended
Income Taxes (FY) (2) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 23,727,093	$ 21,320,935
Net operating loss carryforwards - foreign	20,227	16,551
Excess of tax basis over book value of property and equipment	4,240	(2,229)
Excess of tax basis over book value of intangible assets	73,705	146,943
Stock-based compensation	1,607,841	1,520,209
Accrued employee compensation	357,869	83,393
Capitalized equity costs	49,471	49,471
Inventory reserve	38,323	29,510
Gross deferred tax assets	25,878,769	23,164,783
Valuation allowance	(25,878,769)	(23,164,783)
Net deferred tax assets	0	0
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 100,000
Foreign Tax Authority \| Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiry date	Dec. 31, 2024
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			$ 77,900,000
Amount of operating loss carryforwards limited with no expiration	$ 18,000,000	$ 18,000,000
State and Local Jurisdiction \| Latest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiry date	Dec. 31, 2025

Subsequent Events (FY) (Details

Subsequent Events (FY) (Details) - USD ($)

Sep. 20, 2020

Aug. 26, 2020

Aug. 15, 2020

Aug. 13, 2020

Mar. 31, 2019

Feb. 28, 2019

Jun. 30, 2020

Mar. 31, 2020

Mar. 25, 2020

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2020

Dec. 31, 2019

Dec. 31, 2018

Apr. 30, 2020

Dec. 13, 2019

Subsequent Event [Abstract]

Conversion of short term notes and convertible notes payable

$ 90,745

$ 263,984

$ 180,000

$ 266,667

$ 354,729

$ 0

Consulting agreement period

3 months

Subsequent Event [Member]

Subsequent Event [Abstract]

Proceeds from issuance of shares (in shares)

$ 1,125,000

$ 18,685,000

$ 4,900,000

Common stock issued upon conversion of short term notes payable, shares

17,499,958

1,080,322

Amount financed for purchase of equipment

$ 125,689

Number of shares granted (in shares)

100,000

Series C Convertible Preferred Stock [Member]

Subsequent Event [Abstract]

Shares issued (in shares)

Series C Convertible Preferred Stock [Member] | Subsequent Event [Member]

Subsequent Event [Abstract]

Proceeds from issuance of shares (in shares)

$ 2,250,000

Shares issued (in shares)

Common Stock [Member]

Subsequent Event [Abstract]

Exercise of warrants

1,000,000

17,051,769

620,000

Common stock issued upon conversion of short term notes payable, shares

759,328

1,820,461

2,475,000

3,333,334

35,550

6,395,499

Conversion of short term notes and convertible notes payable

$ 759

$ 1,820

$ 2,475

$ 3,334

$ 36,000

$ 6,396

Consulting Agreement [Member] | Subsequent Event [Member]

Subsequent Event [Abstract]

Shares issued (in shares)

1,000,000

Additional common stock to be issued upon signing agreement

1,000,000

Consulting agreement period

6 months

Consulting Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]

Subsequent Event [Abstract]

Shares issued (in shares)

1,000,000

Class P Warrants | Subsequent Event [Member]

Subsequent Event [Abstract]

Exercise of warrants

1,062,811

Class P Warrants | Common Stock [Member] | Subsequent Event [Member]

Subsequent Event [Abstract]

Shares issued (in shares)

1,062,811

Class L Warrants

Subsequent Event [Abstract]

Common stock issued upon conversion of short term notes payable, shares

2,579,789

Conversion of short term notes and convertible notes payable

$ 354,729

Class L Warrants | Subsequent Event [Member]

Subsequent Event [Abstract]

Exercise of warrants

416,667

Conversion of short term notes and convertible notes payable

$ 208,109

Class L Warrants | Common Stock [Member] | Subsequent Event [Member]

Subsequent Event [Abstract]

Shares issued (in shares)

1,496,989

Note 2 - Going Concern (Narrati

Note 2 - Going Concern (Narrative) (Q2) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Note 2 - Going Concern (Narrative) (Q2) (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Going Concern [Abstract]
Accumulated deficit	$ (132,386,958)		$ (132,386,958)		$ (125,752,956)	$ (116,602,778)
Cash and cash equivalents	430,606		430,606		1,760,455	364,549	$ 730,184
Net cash used in operating activities			(4,511,968)	$ (3,386,634)	(6,410,758)	(3,621,172)
Net loss	$ (3,633,020)	$ (2,734,431)	$ (6,634,168)	$ (4,931,748)	$ (10,429,839)	$ (11,631,394)

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Narrative) (Q2) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Inventory, goods	$ 367,988	$ 357,265	$ 188,116
Inventory, parts	283,356	185,690	169,704
Inventory, net	$ 651,344	$ 542,955	$ 357,820

Note 4 - Accrued Expenses (Q2_2

Note 4 - Accrued Expenses (Q2) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued board of directors' fees	$ 416,667	$ 400,000	$ 200,000
Accrued legal and professional fees	200,000	134,970	0
Accrued executive severance	163,000	154,000	136,000
Accrued travel	120,000	120,000	58,993
Accrued outside services	106,233	108,033	115,118
Accrued inventory	50,275	167,050	0
Accrued clinical study expenses	13,650	13,650	13,650
Accrued other	1,389	13,406	$ 11,007
Total accrued expenses	$ 1,071,214	$ 1,111,109

Note 5 - Contract Liabilities_3

Note 5 - Contract Liabilities (Q2) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Total contract liabilities	$ 605,537	$ 639,801
Non-current contract liabilities	(53,782)	(573,224)	$ (46,736)
Current contract liabilities	551,755	66,577	$ 131,797
Service Agreement
Total contract liabilities	91,746	133,510
License Fees
Total contract liabilities	500,000	500,000
Other
Total contract liabilities	$ 13,791	$ 6,291

Note 5 - Contract Liabilities_4

Note 5 - Contract Liabilities (Narrative) (Q2) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Contract with Customer, Liability [Abstract]
Remaining performance obligations	$ 551,755	$ 66,577

Note 6 - Short Term Notes Pay_2

Note 6 - Short Term Notes Payable (Narrative) (Q2) (Details) - USD ($)	3 Months Ended				6 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Dec. 31, 2018	Dec. 31, 2019
Notes Payable [Abstract]
Conversion of short term notes and convertible notes payable	$ 90,745	$ 263,984	$ 180,000	$ 266,667	$ 354,729	$ 0
Short term notes converted in to shares					2,579,789
Common stock, par value	$ 0.001				$ 0.001	$ 0.001	$ 0.001

Note 7 - Convertible Promisso_2

Note 7 - Convertible Promissory Note (Narrative) (Q2) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 05, 2020
Debt Instruments [Abstract]
Convertible promissory notes					$ 0	$ 2,652,377
Interest expense, convertible promissory notes	$ 168,941	$ 790,178	$ 187,673	$ 938,439	$ 1,147,986	$ 3,708,562
Convertible Promissory Note \| LGH Investments LLC
Debt Instruments [Abstract]
Original principal amount							$ 1,210,000
Common stock warrants entitled to acquire							1,000,000
Restricted common shares entitled to acquire							200,000
Reserve of shares for purposes of exercise of warrant or conversion of convertible promissory note							11,000,000
Maturity date			Feb. 5, 2021
One-time interest charge							8.00%
Unpaid principal balance and interest on common stock							$ 0.25
Warrant exercise price/share							$ 0.35
Debt instrument term			5 years
Debt discount and original issuance discount	670,682		$ 670,682
Convertible promissory notes	$ 705,980		705,980
Convertible promissory notes beneficial conversion feature			600,820
Interest expense, convertible promissory notes			$ 166,663

Note 8 - SBA Loans (Narrative)

Note 8 - SBA Loans (Narrative) (Q2) (Details) - PPP Loans - COVID-19 - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 10, 2020	May 28, 2020
Loans and Leases Receivable, Net of Deferred Income [Abstract]
Loans received			$ 460,000
Loans payable, classified as current	$ 132,514
Loans payable, classified as noncurrent	$ 321,821
Principal amount SBA loan		$ 150,000
Accrued interest rate		3.75%
Term of loan principal and interest payable	30 years
SBA loan classified as non-current	$ 150,000

Note 9 - Notes Payable, Relat_2

Note 9 - Notes Payable, Related Parties (Narrative) (Q2) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Notes Payable [Abstract]
Notes payable, interest rate	8.00%		8.00%
Notes payable, increase in interest rate in event of default			2.00%
Notes payable, accrued interest rate in event of default			10.00%
Notes payable, percentage of principal prepayment			20.00%
Notes payable principal	$ 5,372,743		$ 5,372,743		$ 5,372,743	$ 5,372,743
Interest payable, current	2,229,713		2,229,713		1,859,977	1,171,782
Interest expense, related party	$ 187,172	$ 112,984	$ 369,736	$ 332,671	$ 688,195	$ 787,586

Note 10 - Preferred Stock (Narr

Note 10 - Preferred Stock (Narrative) (Q2) (Details) - USD ($)	May 14, 2020	Feb. 06, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Jan. 31, 2020	Jan. 12, 2016	Mar. 14, 2014
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares issued			0		0	0
Preferred stock, par value			$ 0.001		$ 0.001	$ 0.001		$ 0.001	$ 0.001
Preferred stock issued, stated value			$ 0		$ 0	$ 0
Preferred stock, shares authorized			5,000,000		5,000,000	5,000,000
Anti-dilutive securities			68,519,676	126,545,367	46,027,476	159,810,830
Preferred Stock Conversion
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Anti-dilutive securities			17,500,000	0
Series C Preferred Stock
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares issued			90		90
Preferred stock, par value			$ 0.001		$ 0.001
Aggregate total purchase price			$ 2,250,000		$ 0
Preferred stock, shares authorized			90		90		90
Shares conversion price		$ 0.14
Number of days following such amendment to Articles of Incorporation, shares converted to common stock			5 days
Series C Preferred Stock \| Maximum [Member]
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Shares redemption period			30 days
Shares redemption percentage on stated value			200.00%
Series C Preferred Stock \| Private Placement
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares issued		90
Preferred stock, par value		$ 0.001
Preferred stock issued, stated value		$ 25,000
Aggregate total purchase price		$ 2,250,000
Series D Preferred Stock
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares issued			8		8
Preferred stock, par value			$ 0.001		$ 0.001
Preferred stock, shares authorized	8		8		8
Shares conversion price	$ 0.14
Number of days following such amendment to Articles of Incorporation, shares converted to common stock			5 days
Series D Preferred Stock \| Maximum [Member]
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Shares redemption period			30 days
Shares redemption percentage on stated value			200.00%
Series D Preferred Stock \| Private Placement
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares issued	8
Preferred stock, par value	$ 0.001
Preferred stock issued, stated value	$ 25,000
Aggregate total purchase price	$ 200,000

Note 11 - Equity Transactions_2

Note 11 - Equity Transactions (Narrative) (Q2) (Details) - USD ($)	Dec. 13, 2019	Dec. 11, 2019	Jun. 30, 2020	Apr. 30, 2020	Mar. 31, 2020	Jan. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Jun. 24, 2019	Jun. 14, 2019	Jun. 11, 2019
Warrants Exercised											1,000,000		94,727,180	8,301,864
Common stock issued upon conversion of short term notes payable, amount							$ 90,745	$ 263,984	$ 180,000	$ 266,667	$ 354,729			$ 0
Common stock issued upon conversion of advances from related parties, amount							16,000	2,098			$ 18,098	$ 180,000
Fair value of shares issued for services							$ 517,500	$ 200,000					$ 28,500	$ 181,500
Common stock, shares issued, shares	2,250,000
Common stock, par value			$ 0.001				$ 0.001				$ 0.001		$ 0.001	$ 0.001
Proceeds from Common stock issued in conjunction with offering							$ 150,000
Stock option exercised, shares											225,000		0	0
Proceeds from stock option exercised											$ 44,250	$ 0
Litigation Settlement
Restricted common stock issued, shares											200,000
Fair value of restricted common stock issued											$ 50,000
Private Placement
Common stock, shares issued, shares		21,071,143
Common stock, par value		$ 0.14
Common stock issued in conjunction with offering, shares											1,071,428
Proceeds from Common stock issued in conjunction with offering											$ 150,000
Consulting Agreement
Term of consulting agreement											6 months
Shares to be issued for services, shares						1,000,000
Additional shares to be issued for services, shares						1,000,000
Shares issued for services, shares				1,000,000	1,000,000
Fair value of shares issued for services											$ 380,000
Consulting Agreement Extended
Shares to be issued for services, shares						2,000,000
Shares issued for services, shares			1,000,000
Fair value of shares issued for services											$ 287,500
Class P Warrant
Warrants Exercised											1,000,000
Warrant exercise price/share			$ 0.20				$ 0.20				$ 0.20		$ 0.01		$ 0.20	$ 0.01	$ 0.20
Class P Warrant \| Warrant Agreement
Common stock issued upon exercise of warrants							1,000,000				1,000,000
Warrants Exercised							1,000,000				1,000,000
Warrant exercise price/share			$ 0.01				$ 0.01				$ 0.01
Class L Warrant
Warrants Exercised													57,133,339	6,639,834
Common stock issued upon conversion of short term notes payable, shares											2,579,789
Common stock issued upon conversion of short term notes payable, amount											$ 354,729
Series A Warrant
Common stock issued upon conversion of advances from related parties, shares											262,811
Common stock issued upon conversion of advances from related parties, amount											$ 18,098

Note 12 - Warrants (Q2) (Detail

Note 12 - Warrants (Q2) (Details) - shares	6 Months Ended	12 Months Ended
Note 12 - Warrants (Q2) (Details) - shares	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Warrants outstanding, beginning	9,474,091	103,994,927	97,977,851
Warrants issued	1,000,000	1,365,000	19,154,090
Warrants exercised	(1,000,000)	(94,727,180)	(8,301,864)
Warrants expired	(100,000)	(1,158,656)	(4,835,150)
Warrants outstanding, ending	9,374,091	9,474,091	103,994,927
Class K Warrants
Warrants outstanding, beginning	7,200,000	7,200,000	7,200,000
Warrants issued	0	0	0
Warrants exercised	0	0	0
Warrants expired	0	0	0
Warrants outstanding, ending	7,200,000	7,200,000	7,200,000
Class O Warrants
Warrants outstanding, beginning	909,091	7,929,091	6,540,000
Warrants issued	0	0	1,509,091
Warrants exercised	0	(6,549,090)	(120,000)
Warrants expired	0	(470,910)	0
Warrants outstanding, ending	909,091	909,091	7,929,091
Class P Warrants
Warrants outstanding, beginning	1,365,000
Warrants issued	0
Warrants exercised	(1,000,000)
Warrants expired	(100,000)
Warrants outstanding, ending	265,000	1,365,000
Common Stock Purchase Warrants
Warrants outstanding, beginning	0
Warrants issued	1,000,000
Warrants exercised	0
Warrants expired	0
Warrants outstanding, ending	1,000,000	0

Note 12 - Warrants (Q2) (1) (De

Note 12 - Warrants (Q2) (1) (Details) - $ / shares	Jun. 24, 2019	Jun. 14, 2019	Jun. 11, 2019	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Class K Warrants
Warrant exercise price/share				$ 0.08	$ 0.08
Warrant expiration date				June 2025	June 2025
Class K2 Warrants
Warrant exercise price/share				$ 0.11	$ 0.11
Warrant expiration date				August 2027	August 2027
Class O Warrants
Warrant exercise price/share				$ 0.11	$ 0.11	$ 0.11
Warrant expiration date				January 2022	January 2022	March 17, 2019
Class P Warrants
Warrant exercise price/share	$ 0.20	$ 0.01	$ 0.20	$ 0.20	$ 0.01
Warrant expiration date	June 24, 2024	June 14, 2021	June 11, 2024	June 2024	June 2021
Common Stock Purchase Warrants
Warrant exercise price/share				$ 0.35
Warrant expiration date				June 2025

Note 12 - Warrants (Q2) (2) (De

Note 12 - Warrants (Q2) (2) (Details)	6 Months Ended
Note 12 - Warrants (Q2) (2) (Details)	Jun. 30, 2020
Warrants [Abstract]
Weighted average contractual term in years	2 years 6 months
Weighted average risk free interest rate	0.47%
Weighted average volatility	107.12%

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Q2) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies [Abstract]
Right of use assets	$ 243,251	$ 323,661	$ 0
Lease liability - right of use, current	179,524	173,270	0
Lease liability - right of use, noncurrent	92,889	185,777	$ 0
Lease liability - right of use	$ 272,413	$ 359,047

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies (Q2) (1) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies [Abstract]
2020 (remainder)	$ 97,041
2021	197,462	$ 191,713
Total lease payments	294,503	389,175
Less: imputed interest	(22,090)	(30,128)
Total operating lease liability	$ 272,413	$ 359,047

Note 13 - Commitments and Con_5

Note 13 - Commitments and Contingencies (Q2) (2) (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies [Abstract]
Right of use assets	$ 515,551	$ 418,088
Lease liability - right of use, current	181,371	121,634	$ 0
Lease liability - right of use, noncurrent	333,771	271,240	$ 0
Lease liability - right of use	$ 515,141	$ 392,874

Note 13 - Commitments and Con_6

Note 13 - Commitments and Contingencies (Q2) (3) (Details)	Jun. 30, 2020USD ($)
Commitments and Contingencies [Abstract]
2020 (remainder)	$ 117,297
2021	234,593
2022	199,793
2023	18,388
Total	$ 570,071

Note 13 - Commitments and Con_7

Note 13 - Commitments and Contingencies (Narrative) (Q2) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies [Abstract]
Monthly rent payable	$ 14,651		$ 14,651
Percentage of rent adjustment on annual basis			3.00%
Weighted average remaining lease term, operating lease	1 year 6 months		1 year 6 months		2 years
Weighted average discount rate, operating lease	7.00%		7.00%		7.00%
Rent expense	$ 52,346	$ 54,698	$ 117,876	$ 107,536	$ 225,274	$ 157,395
Weighted average remaining lease term, finance lease	2 years 5 months 8 days		2 years 5 months 8 days		2 years 9 months 18 days
Weighted average discount rate, finance lease	13.20%		13.20%		13.20%

Note 14 - Revenue (Q2) (Details

Note 14 - Revenue (Q2) (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Note 14 - Revenue (Q2) (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 83,301	$ 316,976	$ 231,893	$ 494,939	$ 1,028,730	$ 1,850,060
Product
Revenues	69,341	220,667	143,900	285,232	645,169	949,601
License Fees
Revenues	0	66,808	10,000	173,058	315,557	819,696
Other
Revenues	13,960	29,501	77,993	36,649	68,004	80,763
United States
Revenues	63,787	126,738	107,982	150,667	404,977	234,842
United States \| Product
Revenues	63,076	120,488	96,730	138,167	277,527	209,842
United States \| License Fees
Revenues	0	6,250	10,000	12,500	125,000	25,000
United States \| Other
Revenues	711	0	1,252	0	2,450	0
International
Revenues	19,514	190,238	123,911	344,272	623,753	1,615,218
International \| Product
Revenues	6,265	100,179	47,170	147,065	367,642	739,759
International \| License Fees
Revenues	0	60,558	0	160,558	190,557	794,696
International \| Other
Revenues	$ 13,249	$ 29,501	$ 76,741	$ 36,649	$ 65,554	$ 80,763

Note 14 - Revenue (Narrative) (

Note 14 - Revenue (Narrative) (Q2) (Details)	6 Months Ended		12 Months Ended
Note 14 - Revenue (Narrative) (Q2) (Details)	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Distributor 1 \| Revenue
Concentration risk	86.00%		18.00%	33.00%
Distributor 1 \| Accounts Receivable
Concentration risk	72.00%	49.00%	0.00%	24.00%
Distributor 2 \| Revenue
Concentration risk			15.00%	23.00%
Distributor 2 \| Accounts Receivable
Concentration risk		0.00%	0.00%	60.00%
Distributor 3 \| Revenue
Concentration risk			12.00%	11.00%
Distributor 3 \| Accounts Receivable
Concentration risk		25.00%	22.00%	7.70%
Three Distributors \| Revenue
Concentration risk		72.00%

Note 15 - Related Party Trans_2

Note 15 - Related Party Transactions (Narrative) (Q2) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Contract liabilities			$ 605,537		$ 639,801
A. Michael Stolarski
Revenues from related party	$ 13,105	$ 17,678	26,210	$ 138,167
Contract liabilities		$ 102,899	$ 90,943	$ 102,899

Note 16 - Stock-based Compens_2

Note 16 - Stock-based Compensation (Narrative) (Q2) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Shares Granted or Issued, Share-based Payment Arrangement [Abstract]
Stock option exercised, shares	225,000	0	0
Exercise price		$ 0	$ 0
Stock options forfeited	10,000	100,000	0
Exercise prices for options, lower range limit	$ 0.04	$ 0.04	$ 0.04
Exercise prices for options, upper range limit	$ 2	$ 2	$ 2
Aggregate intrinsic value for vested and exercisable options	$ 3,034,841	$ 981,088	$ 2,085,866
Weighted average remaining contractual term for outstanding exercisable stock options	6 years 1 month 6 days	6 years 7 months 13 days	7 years 4 months 24 days
Exercise Price $0.21
Shares Granted or Issued, Share-based Payment Arrangement [Abstract]
Stock option exercised, shares	175,000
Exercise price	$ 0.21
Exercise Price $0.15
Shares Granted or Issued, Share-based Payment Arrangement [Abstract]
Stock option exercised, shares	50,000
Exercise price	$ 0.15

Note 17 - Earnings (Loss) Per_3

Note 17 - Earnings (Loss) Per Share (Q2) (Details) - shares	6 Months Ended		12 Months Ended
Note 17 - Earnings (Loss) Per Share (Q2) (Details) - shares	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Anti-dilutive securities	68,519,676	126,545,367	46,027,476	159,810,830
Stock Options
Anti-dilutive securities	34,168,385	32,183,385	34,303,385	31,703,385
Preferred Stock Conversion
Anti-dilutive securities	17,500,000	0
Warrants
Anti-dilutive securities	9,374,091	68,357,635	9,474,091	103,994,927
Convertible Promissory Notes
Anti-dilutive securities	5,227,200	26,004,347
Short Term Notes Payable
Anti-dilutive securities	2,250,000	0

Note 18 - Subsequent Events (Na

Note 18 - Subsequent Events (Narrative) (Q2) (Details)

Sep. 28, 2020shares

Sep. 20, 2020shares

Sep. 11, 2020shares

Aug. 26, 2020USD ($)shares

Aug. 15, 2020USD ($)shares

Aug. 13, 2020USD ($)shares

Aug. 06, 2020USD ($)$ / sharesshares

Jul. 23, 2020shares

Dec. 13, 2019shares

Dec. 11, 2019shares

Mar. 25, 2020shares

Sep. 30, 2020$ / sharesshares

Jul. 22, 2020shares

Jun. 30, 2020$ / sharesshares

Dec. 31, 2019$ / sharesshares

Dec. 31, 2018shares

Nov. 12, 2018USD ($)

Dec. 29, 2017USD ($)

Subsequent Event [Abstract]

Common stock, shares authorized

350,000,000

Common stock, shares issued, shares

2,250,000

Warrants expiration period

1 month 1 day

Line of credit | $

$ 1,000,000

$ 370,000

Class K Warrants

Subsequent Event [Abstract]

Warrant exercise price | $ / shares

$ 0.08

Private Placement

Subsequent Event [Abstract]

Common stock, shares issued, shares

21,071,143

Maximum

Subsequent Event [Abstract]

Warrants expiration period

8 years 7 months 6 days

Minimum

Subsequent Event [Abstract]

Warrants expiration period

2 months 16 days

Subsequent Event

Subsequent Event [Abstract]

Common stock, shares authorized

605,000,000

355,000,000

Initial term of license agreement

5 years

License agreement automatic renewal term

1 year

Written notice required prior to expiration of current term

180 days

Common stock, shares issued, shares

5,625,000

93,425,000

Share price | $ / shares

$ 0.20

Warrant exercise price | $ / shares

$ 0.25

Warrants expiration period

3 years

Proceeds from issuance of common stock | $

$ 1,125,000

$ 18,685,000

$ 4,900,000

Common stock shares issued for services

5,000,000

Common stock shares issued for conversion of series c and d preferred stock

17,499,958

1,080,322

Subsequent Event | Short Term Notes Payable

Subsequent Event [Abstract]

Common stock, shares issued, shares

2,250,000

Subsequent Event | Class E Warrants

Subsequent Event [Abstract]

Warrants to purchase shares

123,550,000

Subsequent Event | Private Placement

Subsequent Event [Abstract]

Common stock, shares issued, shares

24,500,000

123,550,000

Subsequent Event | Wainwright & Co., LLC | Private Placement

Subsequent Event [Abstract]

Common stock, shares issued, shares

8,934,375

Subsequent Event | NH Expansion Credit Fund Holdings LP

Subsequent Event [Abstract]

Warrant exercise price | $ / shares

$ 0.01

Warrants expiration period

10 years

Percentage of diluted common stock

2.00%

Principal amount | $

$ 15,000,000

Subsequent Event | Health Tronics

Subsequent Event [Abstract]

Common stock, shares issued, shares

8,275,235

Warrant exercise price | $ / shares

$ 0.25

Warrants expiration period

3 years

Principal amount | $

$ 1,372,743

Repayment of debt | $

$ 4,000,000

Subsequent Event | Health Tronics | Class K Warrants

Subsequent Event [Abstract]

Common stock, shares issued, shares

7,200,000

Subsequent Event | LGH Investment LLC

Subsequent Event [Abstract]

Common stock, shares issued, shares

200,000

Warrants to purchase shares

1,750,000

Warrant exercise price | $ / shares

$ 0.20

Principal amount | $

$ 1,210,000

Subsequent Event | A. Michael Stolarski

Subsequent Event [Abstract]

Principal amount | $

223,511

Line of credit | $

$ 1,000,000

Maturity date

Aug. 6,
2021

Interest rate

12.00%

Common stock conversion price | $ / shares

$ 0.10

Subsequent Event | Celularity's UltraMIST Assets

Subsequent Event [Abstract]

Payment for assets | $

$ 24,000,000

Cash payment | $

18,890,000

Issuance of promissory notes | $

4,000,000

Credit of previous payment | $

$ 1,110,000

Subsequent Event | Maximum

Subsequent Event [Abstract]

Common stock reverse split ratio

Subsequent Event | Maximum | Health Tronics

Subsequent Event [Abstract]

Warrants to purchase shares

8,275,235

Subsequent Event | Minimum

Subsequent Event [Abstract]

Common stock reverse split ratio